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Abstract  
 
Nanoparticle based targeted drug delivery systems hold great promise for cancer therapy 
because of their targeting functions, sustained drug release profiles, reduced side-effects 
and ability to overcome multidrug resistance (MDR). Nevertheless, inadequate specificity 
and stability, insufficient intratumor drug concentration, and high toxicity related to 
carriers are still not well solved and thus restrict clinical translation of such systems. To 
overcome these shortcomings, hollow mesoporous silica nanoparticles (HMSNs) were 
chosen as carriers for engineering a novel drug delivery system with specifically targeting, 
high drug loading, sustained release behaviour, and negligible toxicity.  
 
HMSNs are one of the most promising carriers for effective drug delivery due to their 
large surface area, high volume for drug loading and excellent biocompatibility. However 
the non-ionic surfactant templated HMSNs often have a broad size distribution, a 
defective mesoporous framework or a missed hollow structure because of the difficulties 
involved in controlling the formation and organization of micelles for the growth of silica 
framework. In this study, a novel “Eudragit assisted” strategy has been developed to 
fabricate HMSNs by utilising the Eudrgit nanoparticles as cores and to assist the self-
assembly of micelle organisation. Highly dispersed mesoporous silica spheres with intact 
hollow interiors and through pores on the shell were achieved after the removal of 
Eudragit core and surfactant micelles. The HMSNs have shown a high surface area (670 
m2/g), small diameter (120 nm) and uniform pore diameter (2.5 nm). Eudragit S100 was 
proven to assist in the spontaneous organization of the Triton X-100 (TX100) micelles 
into structurally ordered nanoscale architecture via hydrogen bonding. The HMSNs have 
demonstrated non-cytotoxicity to colorectal cancer cells SW480. The high quality of 
HMSNs and their excellent biocompatibility demonstrate that the Eudragit assisted 
HMSNs can be potential intracellular vehicles for targeted drug delivery. 
 
Besides biocompatibility, targeting functions are essential for drug delivery systems as 
they have the potential to precisely target and kill cancerous cells while leaving normal 
cells unharmed. Given that human epidermal growth-factor receptor (EGFR) is over 
expressed by tumour cells and their natural ligand, epidermal growth factor (EGF) has 
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emerged as an attractive targeting molecule labelled onto nanoparticles for cancer therapy. 
To generate targeting function of the synthesized HMSNs, EGF was grafted to HMSNs. 
HMSNs with and without EGF bio-ligands were covalently linked to a fluorescent dye 
(FITC), making them detectable by fluorescence microscopy and flow cytometry. In vitro 
studies with colorectal cancer cells SW 480 overexpressing EGFR demonstrated that 
HMSNs with EGF bioconjugates (HMSN-EGF) achieved nearly 25 times higher cellular 
internalization than the unfunctionalised control at a concentration of 10 μg/mL and an 
incubation time of 30 mins. In addition, this superior cellular uptake of HMSN-EGF was 
inhibited when EGFR in cancer cells was knocked down by free EGF. Similarly, the 
targeting function of HMSN-EGF was very limited when they were applied to cells 
without EGFR expression (SW 620), revealing the very high specificity of HMSN-EGF 
to EGFR positive cells and the contribution of EGF-EGFR interaction. 
 
On the other hand, the properties of grafted targeting ligands, in terms of effective 
immobilization, stability and binding efficiency, significantly affect the subsequent 
cellular interactions of HMSNs because the performance of biomaterials in a biological 
environment is largely influenced by their surface properties. Although the utilization of 
EGF for targeting delivery is well established, a precise control of the density of EGF 
attachments on nanoparticles is limited. It is found that a small change in the quantity of 
EGF labels on HMSNs may make a significant difference in the subsequent cell activities 
of HMSN-EGF. To address this issue, hollow mesoporous silica nanoparticles 
functionalized with amine group were conjugated with EGF using carbodiimide 
chemistry. The time of flight secondary ion mass spectrometry (ToF-SIMS), a very 
surface specific technique (penetration depth < 1.5 nm), was employed to study the 
binding efficiency of the EGF to the nanoparticles. Principal component analysis (PCA) 
was employed to track the relative surface concentrations of EGF on the surface of 
HMSNs. Effective control of the quality and density of the resulting grafted EGF on 
nanoparticles was achieved which would provide opportunities for engineering targeted 
drug delivery systems with tailored targeting efficacy in the future. 
 
Furthermore, the capacity to encapsulate drugs and perform a sustained release is one of 
the most important requirements for a drug delivery system. To evaluate the drug loading 
and releasing effectiveness of the HMSNs, the model drug, 5-fluorouracil (5-FU), was 
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loaded in the resultant HMSNs and achieved a sustained release profile. However, for 
drug delivery systems, an adequate intratumor concentration of targeted drug is essential 
for effective cancer therapy, which requires a high drug loading capacity of drug carriers. 
Moreover, it was reported that, in addition to sustained release, specific drug release rates 
are always pursued for personal treatment as different stages of disease evolution need 
different drug release rates. In this regard, smart delivery systems with a higher drug 
encapsulation and more effective control of drug release rate were of great importance. 
To meet these requirements, ways to enhance the loading capacity of HMSNs specifically 
to 5-FU were investigated and the results showed that 5-FU loading capacity of HMSNs 
can be tuned by introducing chemical groups onto HMSNs, varying pH values for loading 
process and generating electrostatic attractions between 5-FU and HMSNs. The highest 
5-FU encapsulation ability of HMSNs was achieved when these nanocariers conjugated 
with amine groups (-NH2). The highest loading capacity of 288.9 mg(5-FU)/g(HMSNs) was 
observed at pH 8.0 which is 2 times of that reported in a similar study. On the other hand, 
the release rate of 5-FU from HMSNs was controlled by changing the structure parameter 
of HMSNs in terms of pore size, shell thickness and particle diameter. Experimental 
results revealed that a larger pore size resulted in a quicker release rate while a thicker 
shell decreased the amount of drug released from HMSNs. Moreover, particle diameter 
is not as important as pore size and shell thickness in determining the release profile of 
HMSNs.  
 
In addition to excellent loading and release, overcoming multidrug resistance (MDR) is 
a new requirement set for modern drug delivery systems. MDR referring to the ability of 
cancer cells to adapt and survive from chemotherapy is one of the most complex and 
challenging problems in cancer treatments. Although nanopariticle based drug delivery 
systems are often used to prevent MDR in cancer treatment by sidestepping drug 
resistance mechanisms, the development of drug resistant genes by cancer cells ultimately 
leads to unsatisfied outcomes. To overcome the 5-FU resistance, HMSNs were modified 
to deliver siRNA to silence the gene expression involved in MDR. It is found that rather 
than surface charge, pore size is a key parameter of HMSNs for effective siRNA 
encapsulation. In particular, when the pore size of HMSNs was expanded form 2.5 nm to 
4.3 nm, an obvious increase in siRNA loading was found. Almost all siRNA can be 
encapsulated into HMSNs when HMSNs have a pore size larger than 4.3 nm and the 
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particle to siRNA ratio is 100. 
 
In summary, high quality HMSNs were synthesized via a newly developed strategy 
assisted by Eudragit. These HMSNs were proven to be non-cytotoxic to colorectal cancer 
cells SW480. The HMSNs have a high drug and siRNA loading capacity, sustained and 
controlled release, and efficient and selective cell internalization when bioconjugated 
with Epidermal Growth Factor (EGF). The promising in vitro cell tests have revealed the 
great potential of the HMSNs to be used for colorectal cancer therapy. 
  
IX 
 
Contents 
 
Chapter 1 Introduction ................................................................................................... 1 
1.1. Research aims and objects ................................................................................... 1 
1.2. Outline of the thesis ............................................................................................. 3 
Chapter 2   Literature review ........................................................................................ 5 
2.1. Background ................................................................................................................. 5 
2.2. Controlled and slowed drug delivery systems .......................................................... 7 
2.2.1. Controlled and slowed drug delivery ..................................................................... 7 
2.2.2. Nanoparticle based drug delivery systems ............................................................. 9 
2.2.3. Active targeting drug delivery ............................................................................. 10 
2.2.4. Platforms for nanoparticles based drug delivery systems .................................... 12 
2.3. Preparation and modification of HMSNs ............................................................... 19 
2.3.1. Architectural features of MSNs ........................................................................... 19 
2.3.2. Fabrication of HMSNs ......................................................................................... 20 
2.3.3. Modification of MSNs ......................................................................................... 24 
2.3.4. Qualitative characterization of HMSNs ............................................................... 28 
2.3.5. MSNs’ pharmacokinetics ..................................................................................... 33 
2.4. Drug loading and release .......................................................................................... 34 
2.5. Drug resistant phenomenon ..................................................................................... 37 
Chapter 3   Materials and methodology ...................................................................... 41 
3.1 Introduction ............................................................................................................... 41 
3.2 Materials .................................................................................................................... 41 
3.3 Preparation of  versatile HMSNs ............................................................................. 42 
3.3.1 Formation of Eudragit S-100 nanoparticles ......................................................... 42 
3.3.2 Fabrication of HMSNs ......................................................................................... 42 
3.3.3 Control of particle size ......................................................................................... 43 
3.3.4 Control of shell thickness .................................................................................... 43 
3.3.5 Pore expansion of HMSNs .................................................................................. 44 
3.4 Modifications of HMSNs .......................................................................................... 44 
3.4.1 Amine-, methyl- and cyano-functionalization ..................................................... 44 
3.4.2 Carboxyl-modification (HMSN-COOH) ............................................................. 45 
3.4.3 FITC-modification (FITC-HMSNs) .................................................................... 45 
3.4.4 EGF labelling (HMSN-EGF) ............................................................................... 45 
3.5 5-FU loading and release study ................................................................................ 46 
3.5.1 Measurement of 5-FU oil : water partition coefficients ....................................... 46 
X 
 
3.5.2 5-FU loading ........................................................................................................ 46 
3.5.3 5-FU release ......................................................................................................... 47 
3.6 Cell experiments ........................................................................................................ 48 
3.6.1 Cell culture ........................................................................................................... 48 
3.6.2 Cellular uptake of HMSNs and EGF-HMSNs in colorectal cancer cells ............ 48 
3.7 Characterizations ...................................................................................................... 49 
3.7.1 Electron microscopy ............................................................................................ 49 
3.7.2 Nitrogen absorption and desorption experiments ................................................ 49 
3.7.3 Small angle X-Ray diffraction (SAXRD) ............................................................ 49 
3.7.4 Thermo-gravimetric analysis (TGA) ................................................................... 49 
3.7.5 Fourier transform infrared spectrometer (FTIR) .................................................. 50 
3.7.6 Time of flight secondary ion mass spectrometry (ToF-SIMS) ............................ 50 
3.7.7 Nuclear magnetic resonance (NMR) ................................................................... 51 
3.7.8 Dynamic light scattering (DLS) ........................................................................... 51 
3.7.9 Confocal microscopy ........................................................................................... 51 
Chapter 4 Synthesis of tailored HMSNs for nanotheranostics ................................. 52 
4.1 Introduction ............................................................................................................... 52 
4.2 Synthesis of HMSNs with designed properties for drug delivery systems ........... 54 
4.2.1 Preparation and characterization of HMSNs ....................................................... 54 
4.2.2 Innovations of Eudragit-assisted HMSNs fabrication ......................................... 60 
4.2.3 Mechanism of Eudragit-assisted HMSNs fabrication .......................................... 63 
4.2.4 5-FU encapsulation and the in vitro release ......................................................... 69 
4.3 Pore size tuning for controlled release .................................................................... 71 
4.3.1 BET analysis of pore size .................................................................................... 73 
4.3.2 PALS  analysis of pore size ................................................................................. 74 
4.3.3 Controlled  and sustained release of HMSNs with different pore size ................ 76 
4.4 Cytotoxicity and non-specific cellular uptake of HMSNs ..................................... 80 
4.5 Conclusions ................................................................................................................ 83 
Chapter 5   Modification of HMSNs for targeting delivery ...................................... 84 
5.1 Introduction ............................................................................................................... 84 
5.2 A facile, one step strategy for EGF labelling .......................................................... 85 
5.2.1 Synthesis of amine functionalized HMSNs  (HMSNs-NH2) ............................... 86 
5.2.2 Preparation of EGF grafted HMSNs and characterization of EGF labelling ........... 
 ............................................................................................................................. 92 
5.2.3 The effect of EGF concentration on surface chemistries of the HMSNs ............. 95 
5.2.4 Analysis on immonium ions distinguishing samples with different surface 
chemistry .............................................................................................................. 99 
XI 
 
5.3 Comparison of newly developed grafting method with other methods.............. 101 
5.3.1 Superior EGF grafting efficiency by the new grafting method ......................... 101 
5.3.2 Increase EGF labels on HMSNs for enhanced targeting efficiency .................. 103 
5.4 Effectively target colorectal cancer cells by EGF grafted HMSNs ..................... 106 
5.4.1 Effective targeting effect of HMSN-EGF to EGFR positive CRC cells ............ 106 
5.4.2 Reduced targeting effect of HMSN-EGF by pretreating SW480 cells with free 
EGF .................................................................................................................... 109 
5.4.3 Non-targeting effect of HMSN-EGF to EGFR negative cell line SW620 ......... 110 
5.5 Conclusions .............................................................................................................. 111 
Chapter 6   Functionalization of HMSNs for favourite 5-FU loading and siRNA 
encapsulation .......................................................................................... 113 
6.1 Introduction ............................................................................................................. 113 
6.2 Enhanced 5-FU loading capacity of HMSNs by precise functionalization ........ 114 
6.2.1 Study of 5-FU partition coefficient .................................................................... 114 
6.2.2 Preparation and characterization of functionalized HMSNs .............................. 117 
6.2.3 Regulate 5-FU loading capacity of HMSNs by modifications .......................... 123 
6.3 Control of 5-FU loading and release ..................................................................... 124 
6.3.1 The effect of pH on drug loading and release .................................................... 124 
6.3.2 The effect of particle size and shell thickness on drug loading and release ...... 126 
6.3.3 The effect of EGF on HMSNs’ drug loading and release behaviours ............... 129 
6.4 SiRNA encapsulation based on HMSNs ................................................................ 131 
6.4.1 Increased surface charge of HMSNs for SiRNA loading .................................. 131 
6.4.2 Pore size expansion of HMSNs for efficient SiRNA encapsulation .................. 135 
6.5 Conclusions .............................................................................................................. 142 
Chapter 7 Conclusions and future works ................................................................. 144 
7.1 Overview of current work ...................................................................................... 144 
7.2 Limitations and future work .................................................................................. 148 
7.2.1 Targeting efficiency of EGF-HMSNs ................................................................ 148 
7.2.2 siRNA release and knockdown efficiency ......................................................... 149 
7.2.3 Preparation multi-anticancer drug loaded HMSNs ............................................ 149 
7.2.4 Animal experiences............................................................................................ 151 
Bibliography ................................................................................................................. 152 
Publication List ............................................................................................................. 175 
 
XII 
 
List of Table 
 
 
Table 2. 1 Methods employed to introduce functional groups ....................................... 25 
 
Table 4. 1 Proton diffusion coefficients (D) of Eudragit and Eudragit/TX100 mixture . 67 
Table 4. 2 Physicochemical Properties of HMSNs ......................................................... 74 
Table 4. 3 PALS data for HMSNs .................................................................................. 75 
Table 4. 4 Loading capacity and other physical parameters of HMSNs ......................... 77 
Table 4. 5 Values of diffusional exponent and corresponding drug release mechanism 79 
 
Table 5. 1 Positive fragment ions (immonium ions) used in PCA ................................. 97 
 
Table 6. 1 Partition coefficient of 5-FU and relevant parameters ................................. 115 
Table 6. 2 Structure parameters of functionalized and non-functionalized HMSNs .... 120 
Table 6. 3 Loading capacity of functionalized and non-functionalized HMSNs .......... 123 
Table 6. 4 Parameters of HMSNs and HMSN-NH2 ...................................................... 132 
Table 6. 5 siRNA encapsulation efficiency................................................................... 135 
Table 6. 6 Structure parameter of HMSNs-S, HMSN-M and HMSNs-L ..................... 138 
  
XIII 
 
List of Figure 
 
Figure 2. 1 Tine line showing advancements made in CRC treatment ............................. 5 
Figure 2. 2 History of adjuvant therapy of colon cancer................................................... 6 
Figure 2. 3 Drug’s pharmacokinetic fates of different administration modes .................. 7 
Figure 2. 4 Schematic structure of EGFR ....................................................................... 10 
Figure 2. 5 EGFR signalling pathway ............................................................................. 11 
Figure 2. 6  Multifunctional carbon nanotubes in cancer therapy................................... 14 
Figure 2. 7  Preparation of modified SWCNTs............................................................... 15 
Figure 2. 8 Mesoporous silica nanoparticles as a platform for drug delivery ................. 16 
Figure 2. 9 Transmission electron microscopy of mesoporous silica nanoparticles ....... 16 
Figure 2. 10 Schematic representation of the drug delivery system by using mesoporous 
silica nanoparticles .......................................................................................................... 18 
Figure 2. 11 Different particle morphologies of MSN. ................................................... 19 
Figure 2. 12 The synthesis process of HMSNs ............................................................... 21 
Figure 2. 13 Schematic illustration of the formation process of HMSs .......................... 22 
Figure 2. 14 Scheme of the synthetic procedure of HMSs ............................................. 23 
Figure 2. 15 Formation (left) and microscopic structure (right) of hollow/rattle-type 
MSNs .............................................................................................................................. 23 
Figure 2. 16 Introduction of functional groups in different regions of MSN. ................ 24 
Figure 2. 17 Functionalized hollow mesoporous silica nanoparticles ............................ 26 
Figure 2. 18 TEM morphology of HMSNs ..................................................................... 28 
Figure 2. 19 XRD patterns of mesoporous silica nanoparticles synthesized at different 
pH .................................................................................................................................... 29 
XIV 
 
Figure 2. 20 Six categories of gas adsorption isotherms for porous materials with 
different pore size. ........................................................................................................... 30 
Figure 2. 21 Adsorption isotherms of nitrogen in mesoporous silica nanoparticles of 
different pore sizes.. ........................................................................................................ 31 
Figure 2. 22 Pore geometry ............................................................................................. 32 
Figure 2. 23 Effect of pore geometry on shapes of hysteresis loop ................................ 32 
Figure 2. 24 TEM images of MSNs (black dots) endocytosed by human cervical cancer 
cells ................................................................................................................................. 34 
Figure 2. 25 HMSNs based drug delivery system for simultaneous joint lubrication and 
treatment .......................................................................................................................... 35 
Figure 2. 26 HMSNs based drug delivery system for high-intensity focused ultrasound 
(HIFU)-mediated intravenous drug delivery. .................................................................. 36 
Figure 2. 27 Rational design of a multifunctional micellar nanomedicine for targeted co-
delivery of siRNA and DOX to overcome multidrug resistance .................................... 38 
Figure 2. 28 System for delivery of doxorubicin (DOX)/siRNA combination based on 
quantum dots (QDs) modified with β-cyclodextrin ........................................................ 40 
 
Figure 4. 1 Fabrication possess of HMSNs ..................................................................... 54 
Figure 4. 2 a, b & c) SEM images of HMSNs and d, e & f) TEM image of HMSNs 
displaying hollow interior ............................................................................................... 56 
Figure 4. 3 DLS curve of HMSNs .................................................................................. 57 
Figure 4. 4 Small angle XRD pattern of HMSNs ........................................................... 58 
Figure 4. 5 Nitrogen adsorption-desorption isotherm (A) and the BJH pore size 
distribution of HMSNs (B) ............................................................................................. 59 
XV 
 
Figure 4. 6 TEM images (a) and SEM images (b & c) of HMSNs-S and TEM images 
(d) of HMSNs-C and SEM images (e & f) ..................................................................... 61 
Figure 4. 7 Zeta potential of HMSNs-S and HMSNs-N ................................................. 62 
Figure 4. 8 Stability study of HMSNs-C and HMSNs-S ................................................ 62 
Figure 4. 9 Formation schematics and of TX100/Eudragit S100 composite micelles (a) 
and proposed reactions between TX100 and Eudragit S100 .......................................... 64 
Figure 4. 10 DLS of Eudragit S100 nanoparticles, TX100 and their mixture ................ 65 
Figure 4. 11 FTIR spectra of Eudragit S100 nanoparticles, TX100 and the mixture of 
Eudragit and TX100 ........................................................................................................ 66 
Figure 4. 12 1H NMR spectra of Eudragit S100 nanoparticles (upper) and 
Eudragit/TX100 mixture (bottom); Inserts are TX100 molecular structure. .................. 67 
Figure 4. 13 SEM images (a) and TEM image (b) of non-Eudragit assisted MSNs....... 68 
Figure 4. 14 (a):5-FU loading profile and (b): 5-FU release profile of HMSNs ............ 70 
Figure 4. 15 Three stages of the slow release kinetic model .......................................... 71 
Figure 4. 16 Representative schematic illustration of controlling drug release rate by 
tuning the pore size of HMSNs ....................................................................................... 72 
Figure 4. 17 Adsorption-desorption isotherms (A) and corresponding pore size 
distribution (B) of HMSNs ............................................................................................. 73 
Figure 4. 18 The relationship between porosity and τn ................................................... 75 
Figure 4. 19 In vitro release profiles of HMSNs with different pore size in PBS with a 
pH of 5.0 ......................................................................................................................... 77 
Figure 4. 20 In vitro release kinetics of HMSNs with different pore size in PBS with a 
pH of 5.0 ......................................................................................................................... 79 
Figure 4. 21  Cytotoxicity of HMSNs on SW 480 cells at different concentrations....... 80 
XVI 
 
Figure 4. 22 Cell uptake of FITC-HMSNs with varying time and concentration by 
SW480 cells. ................................................................................................................... 82 
 
Figure 5. 1. a, b & c) SEM images of HMSNs and d, e & f) TEM image of HMSNs 
displaying hollow interior ............................................................................................... 88 
Figure 5. 2 A) Nitrogen adsorption-desorption isotherm; B) Small angle XRD pattern of 
HMSNs; C) BJH pore size distribution. .......................................................................... 89 
Figure 5. 3 FTIR spectra of HMSNs-NH2 and HMSNs ................................................. 90 
Figure 5. 4 TGA thermograms of HMSNs & HMSNs-NH2 (a) and 29Si single pulse 
excitation (SPE) spectrum of HMSNs-NH2 .................................................................... 91 
Figure 5. 5 Schematic diagram showing the process of EGF grafting onto HMSNs ..... 92 
Figure 5. 6 Positive survey mass spectra for: (A) HMSNs surface; (B) HMSNs-NH2 
surfaces; (C) EGF; (D) HMSNs-NH2-EGF..................................................................... 94 
Figure 5. 7 Positive survey mass spectra of HMSN-NH2-EGF surface using different 
EGF concentration .......................................................................................................... 95 
Figure 5. 8 Plot of ratios of the intensities of the 28 m/z (from HMSNs) to 59 m/z, 70 
m/z and 58 m/z (from EGF) ............................................................................................ 96 
Figure 5. 9 Scores on PC1 and PC2 (a) and corresponding loading plots on PC1 (b) and 
PC2 (c) of immonium ions from static positive spectra of HMSNs-NH2-EGF prepared 
with EGF concentration .................................................................................................. 98 
Figure 5. 10 Comparison of characteristic immonium ions intensities between samples
 ....................................................................................................................................... 100 
Figure 5. 11 Routes of EGF lebelling based on carbodiimide chemistry ..................... 102 
Figure 5. 12 SEM images of HMSN-COOH-EGF (a) and HMSN-NH2-EGF (b)........ 103 
Figure 5. 13 Positive survey mass spectra   .................................................................. 105 
XVII 
 
Figure 5. 14 Cellular uptake of EGF grafted and plain HMSNs in SW480 cells ......... 106 
Figure 5. 15 Confocal microscopic images of SW480 cells after incubating with FITC 
labelled HMSN-EGF (a & b) or HMSNs (c & d) with a concentration of 5mg/ml and an 
incubation time of 2 hours ............................................................................................ 108 
Figure 5. 16.  The cellular uptake rate of HMSN-EGF and HMSNs in SW 480 cells with 
or without 5 μM of free EGF pretreatment ................................................................... 109 
Figure 5. 17. Confocal microscope images of EGF-HMSNs and HMSNs in SW 480 
cells. .............................................................................................................................. 110 
Figure 5. 18. The mean fluorescence intensity in the SW 620 cells treated with different 
concentrations of HMSNs or EGF-HMSNs for 2 hours. .............................................. 111 
 
Figure 6. 1 percentages of 5-FU dissolved in each phase with varying octanol to water 
ratio ............................................................................................................................... 116 
Figure 6. 2 TEM images of HMSNs (a), HMSN-NH2 (b), HMSN-COOH (c), HMSN-
CN (d) and HMSN-CH3 (e)........................................................................................... 117 
Figure 6. 3 N2 adsorption-desorption isotherms (a) and the corresponding pore size 
distributions (b) of plain and functionalized HMSNs ................................................... 119 
Figure 6. 4 FTIR spectra of plain and functionalized HMSNs and plain HMSNs ....... 120 
Figure 6. 5 TGA curves of functionalized HMSNs and plain HMSNs ........................ 122 
Figure 6. 6  5-FU loading capacity of HMSNs and HMSN-NH2 at different pH values 
(a) and UV spectra of remaining 5-FU after 24 hours loading by HMSN-NH2 at 
different pH values (b) .................................................................................................. 125 
Figure 6. 7 Two possible 5-FU anions (AN1 and AN3) and dianion ........................... 126 
Figure 6. 8 SEM images of HMSNs with different particle size: 100 nm (a & d); 200 nm 
(b & e) and 300 nm (c & f) ........................................................................................... 127 
XVIII 
 
Figure 6. 9 Loading capacities (a) and release profiles (b) at pH 5.5 of HMSNs with 
varying particle size ...................................................................................................... 127 
Figure 6. 10 SEM images of HMSNs with different shell thickness: 10 nm (a & d); 15 
nm (b & e) and 30 nm (c & f) ....................................................................................... 128 
Figure 6. 11 Loading capacities (a) and release profiles (b) at pH 5.5 of HMSNs with 
varying shell thickness .................................................................................................. 129 
Figure 6. 12 SEM images (a & b) and TEM image (c) of HMSN-EGF ....................... 130 
Figure 6. 13 Loading (a, at pH 8.0) and release (b, at pH 5.5) profiles of HMSNs with 
and without EGF attachments ....................................................................................... 130 
Figure 6. 14 SEM image (a) and zeta potential (b) of HMSN-NH2 .............................. 132 
Figure 6. 15 siRNA encapsulation efficiency of HMSN-NH2. Various weight ratio of 
particles/siRNA from 5 to 200 were applied. ............................................................... 133 
Figure 6. 16 Zeta potential of HMSNs, HMSN-NH2-1, HMSN-NH2-2 ....................... 134 
Figure 6. 17 siRNA encapsulation efficiency of HMSN-NH2-2 (a) and HMSN-NH2-3 
(b). Various weight ratio of particles/siRNA from 5 to 200 were applied. ................... 134 
Figure 6. 18 SEM and TEM images of HMSNs-S (a & b), HMSNs-M (c & d) and 
HMSNs-L (e & f) .......................................................................................................... 137 
Figure 6. 19 Zeta potential (a) and TGA (b) of aminated HMSNs, HMSNs-S, ........... 139 
Figure 6. 20 siRNA encapsulation efficiency of HMSNs-S, HMSNs-M and HMSNs-L. 
Various weight ratio of particles/siRNA from 5 to 200 were applied. ......................... 141 
Figure 6. 21 Proposed siRNA encapsulation of HMSNs with different pore sizes ...... 142 
 
 
1 
 
Chapter 1 Introduction  
 
 
1.1. Research aims and objects 
 
Colorectal cancer (CRC) remains a significant health burden in the world. For its 
treatment, the anticancer drug of fluorinated pyrimidine 5-fluorouracil (5-FU) as the 
backbone stands alone in CRC therapy [1]. Nearly every chemotherapy regimen for CRC 
includes 5-FU. However, owing to its inadequate intratumor concentrations and severe 
side effects, CRC patients pay great prices when receive the treatments. Obviously, the 
therapeutic utility of 5-FU on CRC treatment has been hindered by lacking a safe delivery 
system. The challenge is to extend its circulating half-life and to control its distribution 
in tissues.  
 
One way to address this challenge is to engineer a system where a constant dose of 5-FU 
is delivered directly to colorectal cancer cells over an extended period [2, 3]. After 
reviewing the relationship between drug’s pharmacokinetic fates and administration 
modes, an optimally efficacious approach toward achieving the goal of continuous, 
nontoxic bioactivity would involve controlled and sustained drug delivery systems based 
on nanocarriers labelled with cell targeted molecules.  
 
When compared to polymer and carbon nanotubes which have been widely investigated 
as carriers in drug delivery systems, hollow mesoporous silica nanoparticles (HMSNs) 
have the potential to serve as a versatile drug nanocarrier for smart drug delivery. For 
example, HMSNs can level off the drug concentration at the targeted area as the drug 
molecules released from the ordered pores by a tunable diffusion. This will reduce drug 
dosage and side effects. Zero premature release before reaching the targeted sites can be 
attained when using functionalized HMSNs as carriers. Furthermore, HMSNs have large 
pore volume and surface area and are an ideal platform for cancer treatment because of 
their higher drug loading [4].  
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However, owning to the lack of structure and morphology controlling, applications of 
HMSNs for drug delivery are still limited. Thus, technology to fabricate, functionalize 
and modify HMSNs with expected shapes, sizes and defined properties is vitally essential. 
Additionally, as pointed out by Argyo [5] in a very recent review, cell type specificity is 
a challenge that still needs to be overcome by using these types of materials as 
nanoplatforms for drug delivery systems. This is because extensive studies on 
nanoparticle based targeted drug delivery systems were relied on the enhanced-
permeation end-retention effect (EPR) [6, 7] of cancer cells. However, this effect is 
limited just to vascularized tumours and is usually not sufficient for a complete 
eradication of the cancer [8].  Base on the comprehensive literature review, we 
hypothesized that active targeting of cancer cells by epidermal growth factor (EGF) on 
the surface of the nanoparticles [9-11] could be an efficient strategy to provide an 
enhanced accumulation of the nanoparticles in targeted cell population (CRC cells) and 
thus represent a powerful tool to improve the efficacy of the cancer treatment. 
 
Therefore the main objectives of this project are: 
 
1.  Engineering new ways to prepare HMSNs with designed properties and tailored 
structure for targeted drug delivery and investigating the biosafety of these 
synthesized HMSNs. 
 
2. Detail studies on chemical modifications of HMSNs to achieve high 5-FU loading 
and sustained release and the fabrication of HMSNs with controllable drug release 
rate. On the other hand, the 5-FU behaviours at different pHs were different, which 
is another factor that needs to be investigated to obtain a high 5-FU encapsulation 
rate by HMSNs.   
 
3. Grafting of targeting ligands on HMSNs to attain a high specificity of HMSNs for 
further application. The relationship between grafted biological attachments and 
properties as well as biological behaviours need to be fully studied.  
 
4. In vitro studies with colorectal cancer cells to assess the biological activities of 
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HMSNs in biological environment are require to demonstrate HMSNs as an effective 
vehicle for successful intracellular delivery of 5-FU for colorectal cancer therapy.  
 
1.2. Outline of the thesis 
 
This thesis consists of 7 chapters as follows: 
 
Chapter 2 provides a comprehensive review of the challenges existing in colorectal cancer 
treatments, the background information and recent studies in the areas of nanoparticle 
based drug delivery systems, nanoplatforms used for sustained release, and biomarkers 
identified for targeted drug delivery. Throughout this chapter, gaps in 5-FU delivery 
specifically for colorectal cancer therapy are identified. In addition, feasible methods 
proposed to fill these gaps are introduced and discussed.   
 
Chapter 3 outlines all the materials and experimental procedures used in this thesis. 
Techniques for the fabrication and modification of HMSNs as well as the strategies 
applied for testing the drug loading and release properties, for introducing biological 
targeting labels and for in vitro experiments are illustrated. Methods for the 
characterization of HMSNs such as SEM, TEM, XRD, FTIR and TGA etc. are described 
in details.  
 
Chapter 4 focuses on the synthesis of HMSNs and the fabrication mechanism.  
Characterizations of structure, morphology and biocompatibility are also studied in this 
chapter.  
 
Chapter 5 aims at the study of the targeting function of current drug delivery systems. 
Extremely high specificity of HMSNs for targeting delivery is generated by introducing 
a bio-ligand, EGF, onto HMSNs. Especially, the characterization of EGF attachments and 
EGF concentration on the surface of nanoplatforms were fully investigated in this chapter.  
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Chapter 6 explores ways to effectively increase 5-FU and siRNA loading capacity of 
HMSNs. In addition, strategies regarding better control of drug release kinetics from 
HMSNs are investigated.  
 
Chapter 7 summarizes the major findings and contributions of this project and identifies 
some limitations in the current study. Future research directions in this area are also 
proposed in this chapter.   
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Chapter 2   Literature review 
 
 
2.1. Background 
 
Colorectal cancer (CRC) manifesting as cancerous growths in the colon and rectum, is 
the fourth most commonly diagnosed malignancy in the world. Over the past 25 years, 
significant advances have been made in the treatment of CRC (Figure 2.1), leading to a 
steady improvement of the treatment of this illness [12]. However, it still remains a 
significant health burden in the world with over 1,000,000 cases and a disease-specific 
mortality of nearly 33% even in developed countries [1]. Obviously, the treatment of CRC 
is still full of challenges and many of them are still unsolved, such as toxic effects of 
chemotherapy [13] and tumours developing resistance to drugs [14].  
 
 
 
Figure 2. 1 Tine line showing advancements made in CRC treatment [12]  
 
Among drugs for CRC treatment, the fluorinated pyrimidine 5-fluorouracil (5-FU) as the 
backbone stands alone in CRC therapy (Figure 2.2). Fluorouracil inhibits thymidylate 
synthase which is the rate-limiting enzyme for pyrimidine nucleotide synthesis [15]. 
Nearly all chemotherapy regimens shown to be effective for CRC treatments incorporate 
5-FU [1, 16], highlighting its crucial and first-line role in treating colorectal cancer.  
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Figure 2. 2 History of adjuvant therapy of colon cancer [17] 
 
Many 5-FU intravenous administration schedules are in clinical use, but the efficacy is 
limited, because intravenous 5-FU injection is hard to reach optimal dose effectiveness at 
targeted sites due to 5-FU’s very short half-life and quick metabolism in plasma 
circulation [18]. Moreover, intravenous administration of 5-FU has been shown to cause 
severe side effects [19] because it induces high drug concentration above the maximum 
tolerable drug concentration in the plasma [20, 21]. Obviously, the therapeutic effect of 
5-FU on cancer treatment has been hindered by the lack of a safe delivery system.  
 
In summary, 5-FU plays an important role in CRC chemotherapy. However, the more 
extensive use of 5-FU is limited by its inadequate intratumor concentrations and severe 
side effects which may result from its short half-life and non-specific systemic organ 
distribution. Therefore, new strategies for effective and safe 5-FU delivery is urgently 
needed for colorectal cancer therapy [22]. 
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2.2. Controlled and slowed drug delivery systems 
 
 
2.2.1. Controlled and slowed drug delivery  
 
One way to overcome the limitations associated with 5-FU for CRC chemotherapy is to 
engineer a systems where a constant dose of 5-FU is delivered directly to colorectal 
cancer cells over an extended period. With the development of pharmaceutics, a 
medicinal agent’s therapeutic effect regarding its pharmacokinetic fate in vitro and in vivo 
can be optimized by the utility of precise drug administrations [23]. Figure 2.3 depicts the 
relationship between drug’s serum concentration and administration modes. Obviously, 
an optimally efficacious approach toward achieving the goal of continuous, nontoxic 
bioactivity would involve controlled and sustained administrations which provide a 
considerably extended therapeutic delivery of the drugs.  
 
 
 
Figure 2. 3 Drug’s pharmacokinetic fates of different administration modes [23]  
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Engineering sequential release dosage forms is beneficial for optimal therapy in terms of 
safety, efficacy and patient compliance. Ideally, a controlled release dosage form will 
maintain a therapeutic concentration of the drug in the blood throughout the dosing 
interval [24, 25]. With this aim, techniques for the preparation of sustained release 
formulations were investigated including preparation of prodrug [26, 27], incorporation 
of drugs into carriers and coating with special materials [28, 29]. In addition, liquisolid 
technique, referring to the control of the dissolution rate of drugs, is one of the best and 
most successful methods because of its simplicity and low cost [30]. Particularly, a 
“liquisolid system” involved in blending drug solutions with selected coating materials 
or carriers before drying to form compactible powder mixtures [31]. It has been used to 
produce sustained release formulations of water-soluble drugs such as propranolol 
hydrochloride [24] and the release of drug from these formulations had been proven to 
follow zero-order release kinetics [30-32]. 
 
At present, 5-FU sequential release pellets have been prepared [22, 33, 34] and evidenced 
to exhibit inhibition for tumour growth and proliferation to some extent [35]. This 
augmentative therapeutic efficiency is due to the extension of 5-FU plasma half-life by 
the sequential release [34]. However, when compared to free drug, these pellets showed 
limited advantages in minimising side effects of 5-FU because only limited control over 
the release kinetics is possible [36], where an initially rapid release is presented and 
followed by an inability to maintain a sufficient drug concentration for an extended period 
of time [37]. This limitation is due, in part, to the poor water-soluble nature of 5-FU and 
its low molecular weight (130.08). An alternative approach has been reported to control 
the release of 5-FU by attaching the drug covalently to the network of selected materials 
or carriers [38] via degradable linkages. Nevertheless, the dependence on temperature, 
pressure or pH [39] and susceptibility to degradation by esterases [40] often present a 
challenge, which finally leads to deviations from predicted release kinetics.  
 
While sustain release formulations offer promising opportunities to enhance anti-tumour 
efficacy of 5-FU with low systemic toxicity, the unpredictable tumour environment and 
susceptibility of drugs to collapse on the way to tumour site make it difficult to precisely 
control the drug release kinetics. Therefore, an alternative or complementary strategy is 
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required to be developed to overcome these shortcomings, where a biomaterial platform 
is applied to enable sustainable, predictable, and tunable 5-FU release. 
 
2.2.2. Nanoparticle based drug delivery systems 
 
Recently, nanomedicine has been demonstrated to significantly enhance the efficacy of 
cancer therapy because nanoparticles maintain a prolonged effective drug concentration 
which renders cancer cells expose sustainedly to the drug [20]. The feasibility of 
nanoparticle-based anticancer therapy has been proven in clinical use [6]. Owning to their 
small size and the characteristic features of tumour biology, like the leaky vasculature 
and the impair lymphatic system, nanoparticles can reach certain solid tumours and 
release biologically active cargos by diffusion into the tumour tissues. This method is 
called passive targeting approach [6]. Previously, passive targeting nanoparticles had 
been used as platforms to successfully control and sustain drug release for therapy. For 
example, it was shown that selective anticancer effect had been enhanced by passive 
targeting self-assembled nanoparticles [41]. Similarly, silica nanoparticles as drug 
carriers have effectively demonstrated heart-targeting profile by passive targeting 
approach [42].  
 
These inspired studies could help to engineer a 5-FU delivery system to the colon basing 
on nanoparticles with small enough size to improve the transportation efficiency of 5-FU 
to cancer cells. Although there have been some preliminary reports [43], the application 
of this passive targeting approach in colon targeted drug delivery systems is still hindered.  
Because of the random nature of this approach, it is hard to control the drug release 
kinetics and this in turn decreases the efficacy of localizing nanomedicines at cancer cells 
in vivo. As we know, our body is so perfectly structured that some physiological drug 
barriers in our body are existing to protect organs from external toxins, like the 
gastrointestinal barrier [44]. Moreover, cancer cells are smart enough that their survival 
is achieved by presenting barriers to fight with anti-cancer drugs, such as drug resistant 
genes and transport proteins for expelling drugs out of cancer cells. Unfortunately, as 
colon is the distal segment of the gastrointestinal tract, when delivering 5-FU to the colon, 
nanocarriers will encounter barriers motioned above on their route to the targeted site.  
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Therefore, it would be desirable to combine the rational design of nanocarriers with novel 
nanoscale targeting molecules.    
 
2.2.3. Active targeting drug delivery  
 
To address this challenge, rather than passive delivery, it is essential to find an actively 
targeting region on the surface of colorectal cancer cells with higher specificity and 
binding affinity. Therefore, understanding the pathology of colorectal cancer becomes 
imperative.  
 
In recent years, overexpression of growth factors and receptors has been implicated in 
tumorigenesis and tumour progression of CRC [45, 46]. Dysfunctions in signalling 
pathways have also been demonstrated to lead to proliferation, survival and migration of 
cancers [47, 48]. The overexpression of epidermal growth factor receptor (EGFR) has 
been documented in 30 – 90% of cases of advanced CRC, which has shown to involve in 
numerous cellular responses including proliferation and metastatic spread [49]. It thus 
becomes vital to understand the EGFR signalling pathway in CRC during neoplastic 
transformation as it may enable us to programme the nanocarriers so they can actively 
bind to colorectal cancer cells. 
 
 
Figure 2. 4 Schematic structure of EGFR 
 
EGFR is an endogenous cell surface glycoprotein with a molecular weight of 170 KDa 
[11]. It comprises three domains that include a 622 amino acid extracellular domain, a 23 
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amino acid hydrophobic transmembrane domain, and an intracellular tyrosine Kinase 
domain with several phosphorylation sites (Figure 2.4) [49].  
 
The EGFR signalling pathway consists of 4 sub-pathways: PI3K-mTOR pathway, JAK-
STAT pathway, PLC signalling pathway and RAS-ERK signalling pathway. On ligand 
binding (signal activation), EGFR homo-dimerizes activate the intracellular kinase 
domain. Then, importins (adopter proteins, like PI3K, JAK and PLC) bind with 
transcription factors (like STAT and ERK), leading to the nucleus accumulation of EGFR. 
As a result, tumour proliferation, metastasis and survival happen (Figure 2.5) [1].  
 
 
Figure 2. 5 EGFR signalling pathway  
(JAK, Janus kinase; PLC, phospholipase C; STAT, signal transducer and activator of transcription.) 
 
With its association with tumour survival and proliferation, EGFR has the potential to 
serve as an actively targeting region of colon targeted drug delivery system. Epidermal 
growth factor (EGF), hepatin-binding EGF (HB-EGF), betacellulin, transforming 
growth-factor-a (TGF-a), epiregulin and amphiregulin are six known endogenous ligands 
of EGFR. Although any of these ligands can be used as a targeting agent for EGFR, EGF 
with a good compromise between the binding affinity and the size of the molecule (EGF, 
6.1 kDa) is one of the most commonly detected factors in humans [8]. It is hypothesized 
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that introducing EGF as a ligand to EGFR on the surface of nanocarriers will exhibit 
specific delivery of 5-FU into colorectal cancer cells, and thus enhance the resultant anti-
cancer activity. To the best of our knowledge, at present there is not EGFR targeting 5-
FU delivery system being exploited specifically for colorectal cancer. 
 
2.2.4. Platforms for nanoparticles based drug delivery systems 
 
Before designing a colon targeted drug delivery system, several questions should be 
addressed. How to achieve a tight association between the targeting molecules and the 
surface of nanocarrier is one of key questions. Also, as for colon targeted drug delivery 
system, biodegradability and toxicological harmlessness is another point that should be 
considered beforehand because the materials to be used for drug delivery may accumulate 
in the human body on prolonged use. As we mentioned above, nanoparticles exhibit slow-
release profile, but different functions can be observed even for the same drug delivery 
system when using different nanocarriers. In this regard, it would therefore be desirable 
to study materials used for drug delivery and find out the one that can achieve the expected 
functions greatly. 
 
In order to achieve an ideal colon targeted drug delivery system, a variety of materials 
have been exploited to meet different therapeutic needs, many with great potential for 
topical delivery. Reports on materials with controlled release properties for topical 
delivery include: cellobiose-derived monomer [50], carbon nanotubes [51], metals [52, 
53], chitosan [54, 55], pectins [54, 56], guar gum [57, 58], inulin, and dextran. These 
materials can be divided into steroids, e.g. polymer, carbon nanotubes and inorganic 
nanoparticles.  
 
2.2.4.1.Polymer 
 
Polymers are a kind of widely used materials for colon targeted drug delivery system due 
to their inherent properties. For example, excellent stability and safety, less toxicity and 
gel forming make the utilisation of polymers for colon specific delivery wide and 
intensive. Moreover they are more cost-effective, as they are abundant in various 
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structures and exhibit diversified properties.   
 
A large number of studies have been done in exploiting polymers as potential carriers for 
colon specific delivery including chitosan [59], pectin [60, 61], sugar gum [58] and 
dendrimer [62]. The effects of formulation parameters on drug release pattern are studied 
by Das, Chaudhury et al. [54]. Elkhodairy, Barakat et al. [63] used low molecular weight 
chitosan to prepare a new guar-based colon delivery formulation.  Hiorth, Skoien et al. 
[64] revealed that a high degree of swelling of chitosan-containing pellets may boost the 
drug release. pH-responsive fluorinated dendrimer-based particulates were prepared by 
Criscione, Le et al. [65] which exhibit controlled release of agents. Moreover, these dense 
particulates are self-assembled and possess a high density of fluorine spins that can be 
easily detected in vivo.  
 
However, the issue associated with the utilisation of polymers is their high water 
solubility. Polymers are easily assimilated by microorganisms or degraded by enzymes 
on its way to the targeting site such as the human colon, resulting in breaking down of the 
molecules back bone [66]. As a consequence, the molecular weight reduces as the 
polymer undergoes a further degradation leading to the loss of mechanical strength, 
unable to hold the targeting molecules (such as EGF) and drug (like 5-FU) any longer. 
This is how the burst release and premature release happen.  
 
2.2.4.2.Carbon nanotube 
 
Carbon nanotubes (CNTs), regarded as one of the most promising nanomaterials, possess 
the ability to deliver drug into living systems [67]. Owning to their unique 
physicochemical properties like their inherent stability, novel structure, high aspect ratio 
as well as high electrical and thermal conductivity, CNTs can not only detect the 
cancerous cell, but also transport biologically active cargo into these living cells [68]. 
During the last several years, CNTs have been widely investigated in the field of cancer 
treatment modality [69], containing gene [70] and photodynamic therapy [71], lymphatic 
targeted chemotherapy [72], drug delivery [73] and thermal therapy [74] (Figure 2.6). 
Research has found that CNTs present great potential to meet future drug delivery 
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challenges [75]. For instance, when the titanium alloys were implanted, the self-organized 
TiO2 nanotubes are found to be a promising drug delivery system [76].  Again, 
molecularly imprinted nanotubes are found to possess the potential of controlled drug 
release [77]. 
 
 
 
Figure 2. 6  Multifunctional carbon nanotubes in cancer therapy [51] 
 
Novel SWNT-based tumor-targeted drug delivery systems which are mainly made up of 
functionalized SWNTs, tumor-targeting ligands, and anticancer drugs have gained 
considerable interests [51].  By linking precise peptides or ligands on their surface, 
functionalized CNTs can recognize cancer-specific receptors on the cell surface and cross 
the mammalian cell membrane by endocytosis or other mechanisms to recognize cancer-
specific receptors on the cell surfaces. Finally, therapeutic drugs are released more safely 
and effectively than untargeted ones for the purpose of targeted killing of cancer cells 
[78]. A pH-triggered targeted drug delivery system based on modified single wall carbon 
nanotubes is prepared by Zhang, Meng et al. (Figure 2.7). The loading efficiency and 
release rate of the anticancer drug doxorubicin (DOX) can be controlled [79]. 
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Figure 2. 7  Preparation of modified SWCNTs [79]  
(SWCNTs: single wall carbon nanotubes; ALG: sodium alginate; CHI: chitosan; DOX: doxorubicin) 
 
Inspired by these studies, it seems that CNTs could serve as a nanoplatform with specific 
colon targeting function. However, the application of CNTs in biomedicine has been 
concerned over their side effects and toxicity. Studies performed has found that the CNTs 
toxicity not rely on the presence of metal impurities and their length [80] but the CNTs 
themselves like physical form, concentration and functionalization degrees. In addition, 
multi-walled carbon nanotubes could result in oxidative stress and cell death as they may 
cause incomplete phagocytosis [81]. What is more, in the research performed by Ji, Liu 
et al., correlation between toxicity of CNTs and the route of administration is suggested 
[51]. Therefore, CNTs is not the most suitable nanoplatform due to its high toxicity. 
 
2.2.4.3.Mesoporous silica nanoparticles 
 
The synthesis and application of mesoporous silica nanoparticles (MSN) has attracted 
great attention in the last two decades since the first ordered mesoporous silica molecular 
sieves (the type of MCM-41) was synthesized by Kresge, Leonowicz et al. in 1992 [82]. 
The tunability of the structure, morphology, modification, functionalization, surface 
properties, particle size and pore diameter are drawing increasing attention for the purpose 
of their applications in the sectors of pharmaceutical [83], optics [84], environmental 
protection [85] and catalysis [86]. Particularly, owning to their unique properties, MSNs 
possess great potential to be applied in controlled release (Figure 2.8). In addition, in 
order to develop the application of MSNs in biomedicine, research on the 
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biocompatibility [87], cellular uptake [88] and cytotoxicity [89] of MSNs has been 
performed [90]. 
 
 
 
Figure 2. 8 Mesoporous silica nanoparticles as a platform for drug delivery 
A=gatekeepers B=drugs C=stimuli-responsive linkers K=functional groups G=complexation with 
plasmid DNA  [88] 
 
 
 
 
 
Figure 2. 9 Transmission electron microscopy of mesoporous silica nanoparticles 
The honeycomb-like structure of the nanoparticles is visualized with the parallel stripes (black arrow) and 
the hexagonally packed light dots (red arrow) [88] 
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MSNs are synthesized inorganic nanoparticles with a honeycomb-like porous structure 
(Figure 2.9), which is originated from the idea of extending the application of zeolites 
[89]. When compared to most general organic materials like polysaccharides, liposomes 
and micelles, MSNs possess many unique properties such as high surface area and pore 
volume, ordered pores and sizes, tunable morphology [90]. Firstly, MSNs are widely used 
in molecular sieving, ion exchange, adsorption [91] and separation. Soon, the well-
ordered sizes and pores extend their application to new fields. Specifically, MSNs were 
used in sewage circulation purification by functionalization with mercaptopropyl groups. 
Moreover MSNs are also used as templates for conductive polymers, or for controlled 
polymerization processes [92]. There is also potential for MSNs to be applied for 
macromolecule and micromolecule immobilization.   
 
In particular, as there are mesopores (channels) on MSNs which are able to encapsulate 
pharmaceutical cargoes, they are exploited to be used as carriers in order to attain the 
controlled release in recent years. More importantly, more and more research proves that 
MSNs with the diameter range of 100nm to 200nm can be taken by cells through the 
endocytosis [93]. In addition, MSNs have significant advantages to be used in targeting 
drug delivery systems [90]. For example, MSNs possess the capacity to level off the drug 
concentration at the targeted area as the drug molecules are released from the ordered 
pores or channels of MSNs by a tuneable diffusion. This gives rise to a reduction in 
dosage and the preventions of side effects. Zero premature release before reaching the 
targeted sites can be attained when using functioned MSNs as carriers in targeting drug 
delivery systems. Furthermore, the large pore volume and large surface areas lead to a 
higher drug loading [4]. Choi, Jaworski et al. functionalized MSNs for the purpose of 
controlling drug release, and developed a drug delivery system using MSNs as carriers 
based on the host-guest concept (Figure 2.10) [83] . Mamaeva and co-workers [94] 
proposed MSNs as a platform for cancer treatments. In their study, MSNs based drug 
delivery system can block the Notch signalling in cancer by controlling the delivery of γ-
secretase inhibitors to cancer cells. 
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Figure 2. 10 Schematic representation of the drug delivery system by using mesoporous 
silica nanoparticles: (a) preparation of mesoporous silica nanoparticle, (b) immobilization 
of 1 as gate molecule, (c) encapsulation of curcumin (2), (d) complex formation of 18-
crown-6 moiety with Cs+ ion and (e) release of curcumin (2) upon addition of K+ ion. 
[83] 
 
Most importantly, recent studies pointed out that MSNs are biocompatible, and particles 
are degraded and excreted mainly through urine and faeces without being retained within 
the organs [94]. Lu and co-workers [87] find that 95% degraded products of MSNs could 
be safely eliminated out of body by renal excretion. 
 
To  summarize, great advancements are made in the synthesis of versatile drug 
nanocarriers to date, including polymers, carbon nanotubes and MSNs [66]. However, 
due to high toxicity of the nanotubes and premature leakages of the polymeric carriers 
[61], the development of colon targeted drug delivery systems that can reduce the toxic 
effect while augment therapeutic efficacy of 5-FU remains a significant challenge. From 
the literature review, it can be found that MSN have been highlighted as compelling 
carriers for anticancer drugs owning to their unique properties, such as high surface area, 
ordered porous structure, and easily functionalized surface. More importantly, its 
biocompatibility and physical and chemical stability make MSNs the potential drug 
delivery vehicles that target colon cancer cells.  
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2.3. Preparation and modification of HMSNs 
 
2.3.1.  Architectural features of MSNs 
 
During the MSN synthesis process, the silicate polymerization directed by templates can 
be controlled in order to achieve different designed architectural features [95]. The 
morphology of MSNs can be controlled in different ways, including varying templates, 
controlling the synthesis pH and choosing additives to control the magnitude of the 
interactions between the growing silica polymer and the assembled templates. Moreover, 
the control of the rates of the silica source hydrolysis and condensation is important to 
attain certain architectural features of MSNs. Sphere, rod, shuttle and lamel are the main 
structures of MSNs (Figure 2.11).  
 
 
Figure 2. 11 Different particle morphologies of MSN: (a) rod, (b) sphere, (c) lamel, (d) 
shuttles, (e) core-shell and (d) hollow particles [4, 96]. 
 
Among the different MSNs, it is important to choose the right one that can achieve the 
expected functions. For drug delivery, it was reported that the nanospheres exhibit a 
higher efficiency of cell internalization of when compared with nanorods. This is based 
on the positive relationship between the particle surface areas and the speed of cell 
membrane enclosing a particle [88, 97]. Moreover, with the development of 
nanomedicine, demands for nanoplatforms with specific performance such as large drug 
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loading gradually increase. To meet such new requirements, more and more new methods 
are under investigation for developing new drug carriers. Recently, hollow MSNs 
(HMSNs) have been studied as a new-generation drug platform for delivery systems 
owning to their extraordinarily high loading capacity. Li and co-workers [98] exploited 
HMSNs as drug carriers to increase the capacity of storing aspirin.  
 
Based on these studies, it is proposed that hollow mesoporous silica nanospheres is an 
ideal nanocarrier for colon targeting 5-FU delivery system as it exhibits spherical 
morphology to enhance cell internalization and hollow cave in the middle to increase drug 
loading. However, up to date, fabricating hollow MSNs with good stability and 
dispersibility remains a main challenge owning to the complex effects of physicochemical 
parameters on synthesis reactions. Thereby, developing new methods to fabricate hollow 
MSNs is important for the further development of efficient drug delivery systems.  
 
2.3.2. Fabrication of HMSNs 
 
The formation of meso-structure materials is usually attained by the synthesis of liquid-
crystal-like arrays at low-temperature. The liquid-crystal-like arrays consist of precursors 
and templating agents, typically an amphiphilic organic surfactant [99]. For hollow MSN, 
the synthesis is usually achieved by using a dual template method. More specifically, a 
hard or soft template (cave template) which is used for the generation of the interior cave 
is dispersed in a neutral or charged surfactant (pore template). Then pore template 
micelles are formed around the surface of cave templating agents. After that, silica matrix 
coating on the core template is generated by adding silica source agents. Finally, both 
core and cave templates are removed by thermal calcination or solvent extraction to obtain 
hollow MSNs with hollow interiors and mesoporous shells [100] (Figure 2.12). Now, 
soft-templating, hard-templating and select-etching approaches are investigated for 
successfully fabricating hollow MSNs. 
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Figure 2. 12 The synthesis process of HMSNs 
 
 
2.3.2.1.Soft-templating method 
 
Soft-templating method refers to using surfactants as cave templates to build a hollow 
interior cave after the removal of surfactants. For example, Feng and co-workers [101] 
synthesized hollow MSNs through the aggregation of micelles. In their work, (-)-N-
dodecyl-N-methylephedrinium bromide (DMEB) was employed as a cave and pore 
template and carboxyethylsilanetriol sodium salt (CSS) was used to stabilize the DMEB 
micelles. Importantly, the particles size and mesoporous shell thickness could be changed 
by altering the pH values during the synthesis possess (Figure 2.13). It has been suggested 
that DMEB, CSS and pH values determine the morphology of hollow MSNs. Other 
surfactants using for hollow MSNs fabrication through soft-templating route include 
tetrapropylammonium hydroxide [98], hexadecane [102], Pluronic F127 [103] and 
polystyrene latex [104].  
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Figure 2. 13 Schematic illustration of the formation process of HMSs [101] 
 
Soft-templating method has been proved to be a simple and effective synthesis approach 
of hollow MSNs. However, hollow MSNs obtain through this method tend to collapse in 
the surfactant removing process. Moreover, it is hard to completely remove the cave 
template through solvent extraction and this in turn will lead to severe side effects when 
hollow MSNs are used to deliver drugs to human [100]. 
 
2.3.2.2.Hard-templating approach 
 
Another strategy for the synthesising of HMSNs relies on employing some solid particles 
like silica and hematite as hard templates to build a hollow interior cave after template 
removal process (Figure 2.14). This fabrication route is made up of four steps: (a) the 
formation of solid cave templates; (b) core template dispersion, sometimes 
functionalization is needed to ensure core surfactants coat the cave templates favourably; 
(c) silica mesoporous shell generation; and (d) the removal of solid cave. The diameter of 
the spheres and the caves can be easily tuned by changing the solid core size. Zhang and 
co-workers [105] prepared hollow MSNs with tunable shell porosity by the 
transformation of solid silica particles to hollow structure in NaBH4 solution. Other hard 
templates being used to create hollow structures are nanospheres of carbon, metals and 
metal oxides [106]. In general, the challenge of this approach is to fabricate hollow MSNs 
with small diameters (under 100nm). 
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Figure 2. 14 Scheme of the synthetic procedure of HMSs [107] 
 
2.3.2.3.Select-etching technique 
 
 
 
 
Figure 2. 15 Formation (left) and microscopic structure (right) of hollow/rattle-type 
MSNs [108] 
 
Recently, the fabrication of hollow MSNs through select-etching method was developed. 
Hollow interiors are generated by making use of etching agents to etch the inner cores. 
This strategy is based on the structural differences or compositional differences between 
the core and shell structures [108]. Chen and co-workers [96, 108] prepared hollow/rattle-
type MSNs by using sodium carbonate solution to etch solid silica nanoparticles, resulting 
in the building of a hollow cave in the middle (Figure 2.15). Gao and co-workers [109] 
synthesized hollow MSNs with three different pore sizes by a structural difference based 
selective etching methods. In their work, hollow MSNs exhibited the function of 
controlling drug release rate which is achieved by changing the pore sizes. Similarly, 
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Zhang and co-workers [110] described a surface protected approach to prepare hollow 
MSNs. The interior of solid silica spheres is selectively etched by NaOH when their near 
surface layer is protected by poly (vinyl pyrrolidone).  
 
2.3.3. Modification of MSNs 
 
 
Figure 2. 16 Introduction of functional groups in different regions of MSN (a) at the 
external surface, (b) at the pore entrances, or (c) within the walls [4]. 
 
After the preparation of MSNs, it is essential that these as synthesized nanocarriers 
possess designed properties for specific drug delivery systems, such as high cellular 
uptake, effective cell internalization, higher binding affinity with targeting molecules. In 
this regard, modification of MSNs is always needed to make hollow MSNs smart carriers 
for targeting.  
 
As there are many hydroxyl groups existing on the surfaces, MSNs can be modified very 
easily in different regions including pore walls, the interior/exterior surfaces and the pore 
entrance (Figure 2.16). The introduction of functional groups results in more versatile 
MSNs. For example, creating hydrophobic and hydrophilic surfaces, positively and 
negatively charged surfaces, improving biocompatibility and targeting functions, 
regulating drug release rates can be attained by the functionalization of MSNs. He and 
co-worker [111] changed the surface charge of SBA-15-structured mesoporous silica 
nanoparticles from -31.1 mV to 29.6 mV by grafting rhodamine B onto the surfaces. The 
resulting MSNs showed an outstanding sustained-release property when used for drug 
delivery. Again, Lu and co-workers [112] improved the dispersion of MSNs by modifying 
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the surfaces with trihydroxysilylpropyl methylphosphonate.  
 
Methods used for the surface modification of MSNs include post synthesis grafting, 
molecular imprinting, and organosiloxane/siloxane co-condensation. Some functional 
groups have been widely introduced onto the surface of MSNs through one or more of 
these methods (Table 2.1).  
 
Table 2. 1 Methods employed to introduce functional groups onto  
the MSNs surface [89] 
Functional group Method 
Ureidoalkyl Co-condensation 
Mercaptoalkyl Co-condensation, grafting 
Cyanoalkyl Co-condensation, grafting 
Aminoalkyl Co-condensation, grafting 
Allyl Co-condensation, grafting 
Isicyanatoalkyl Grafting 
Epoxyalkyl Grafting 
Phosphonatoalkyl Grafting 
Metal-aminoalkyl Molecular imprinting 
 
2.3.3.1.Co-condensation 
 
Inorganic–organic hybrid networks of MSNs are usually attained using co-condensation 
of a tetraalkoxysilane and one or more organo-substituted trialkoxysilanes. This method 
has the advantages of the homogeneous coverage of functional groups. However, the 
selective functionalization of the external or internal surfaces of MSN is hard to achieve 
through this method. The degree of organic functionalization can be controlled through 
studying the electrostatic matching effects between substituent groups and the surfactant 
[113, 114].  It is found that the anions which are less hydrated than Br- can displace it 
from the cetyltrimethylammonium bromide (CTAB) micelle and bind tightly to the 
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cationic CTAB. The anionic lyotropic series reported by Larsen for interactions with 
CTAB is: citrate < CO32- < SO42- < CH3CO2- < F- < OH- < HCO2- < Cl- < NO3- < Br- < 
CH3C6H4SO3- [113] . 
 
2.3.3.2.Grafting 
 
Grafting is a method commonly used for the post-synthesis modification of MSNs. 
Introduction of some functional groups on the external or the internal surfaces of MSNs 
is usually achieved by silylation on free silanol groups (įSi–OH) and germinal silanol 
groups (-Si(OH)2). When compared to the co-condensed method, grafted materials 
exhibit better hydrothermal stability. However, the problem that this method encountered 
is the inhomogeneous surface coverage of functional groups. More specifically, 
functional groups grafted onto the surfaces of MSN are mainly located on the external 
surface and in close proximity to the pore entrances [84]. 
 
2.3.3.3.HMSNs modified with chemical groups for certain applications 
 
 
 
Figure 2. 17 Functionalized hollow mesoporous silica nanoparticles [115] 
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HMSNs with a large cavity inside each original MSN, have recently been highlighted to 
have great potential for biomedical applications due to their greatly enhanced drug 
loading ability [115]. Additionally, with the availability of well-established techniques 
for surface functionalization as illustrated above, HMSNs possessing biocompatibility 
can be selectively modified for various applications, such as specific targeting and 
imaging (Figure 2.17).  
 
Recently, HMSNs have been modified and successively employed as highly attractive 
multifunctional nanoplatforms for increasing surface hydrophobicity [116], enhancing 
cellular uptake [117], cell targeting [106], bioimaging [115], and controlled drug release 
[109]. For example, by integrating different types of chemical groups on the internal or 
external surface, HMSNs can be used as a stationary phase in HPLC to separate both 
biomolecules and small aromatic molecules, such as proteins [118]. By changing the type 
(and length) of the employed alkyl chains, the accessible pore sizes of HMSNs can be 
tailored for controlling the release kinetics of loaded cargos [119, 120]. Gao [109] and Jia 
et al. [121] progressively increased the pore dimensions of HMSNs by extending the 
etching time of HMSNs with the Na2CO3 and NaBH4 solutions, respectively and showed 
sustained and controlled release of these modified HMSNs. 
 
Nevertheless, although modifications have made HMSNs more versatile for applications, 
they also have disadvantages that negatively affect HMSNs when they are exploited as 
drug carriers. Firstly, if not well controlled, modifications would cause structure collapse 
[102] of HMSNs. Further, the introduction of chemical groups on the surface of HMSNs 
may bring additional toxicity which makes HMSNs unsuitable as carriers for drug 
delivery systems. Moreover, in many cases, it is difficult to couple several functional 
groups in sufficient concentration, since the number of attachment sites on the particle 
surface is limited. In addition, each functionalization step might negatively affect the 
suspension stability of the particulate system, depending on the physicochemical 
properties of the added function. Therefore, all these issues should be considered when a 
drug delivery system is engineered based on modified HMSNs and the development of 
effective methods to deal with these problems are of great importance.  
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2.3.4. Qualitative characterization of HMSNs 
 
2.3.4.1. Morphology  
 
HMSNs as a kind of mesoporuous materials possess a porous shell with well-defined 
cylindrical/hexagonal mesopores and a spherical hollow cavity. The characterization of 
HMSNs is similar to other mesoporous materials. In general, a variety of techniques 
including transmission electron microscopy (TEM), scanning electron microscopy (SEM), 
electron diffraction (ED), X-ray diffraction (XRD), small-angle X-ray/neutron scattering 
(SAXS/SANS), gas adsorption measurements and nuclear magnetic resonance (NMR) 
were applied to study the morphology and microstructure of HMSNs [122]. Particularly, 
the hollow structure can be clearly seen under TEM, where a contrast in colour between 
the cavity and the shell was observed due the reduced density in the cavity (Figure 2.18). 
Moreover, the existence of mesoporous shell of HMSNs is often confirmed by the 
presence of low angel peaks (2θ < 5˚) in HMSNs’ XRD or SAXS patterns (Figure 2.19) 
[123-125].  
 
 
 
 
Figure 2. 18 TEM morphology of HMSNs [104, 126] 
 
Conventionally, sorption isotherms represent the most widely used method to provide 
detailed information for determining porous structure, pore geometry and size as well as 
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pore distribution of HMSNs [127, 128]. According to the IUPAC classification, there are 
six categories of gas adsorption isotherms, Types I-V and IVc (Figure 2.20) [129], which 
is a source to study structural information of porous materials due to their different 
characteristic shapes.  
 
 
 
Figure 2. 19 XRD patterns of mesoporous silica nanoparticles synthesized at different 
pH [125] 
 
On the basis of the diameter, pores are classified as micropores (< 2 nm), mesopores (2 - 
50 nm), and macropores (> 50 nm).  In detail, Type I isotherm exhibiting prominent 
adsorption at low relative pressures and then levelling off, is usually related to adsorption 
in micropores. However, it may also be considered to be indicative of mesoporous 
materials with pore sizes close to the micropore range. Type II and III isotherms are often 
observed for macroporous materials while Type IV in general, and IVc in particular, is 
typical for many materials with accessible mesopores.  
 
Adsorption on mesoporous solids is a multilayer adsorption process followed by capillary 
condensation in mesopores, which give rise to Type IV isotherms [129]. It should be 
noted that some porous materials may exhibit a combination of the six types of isotherms 
as a result of the presence of several different types of pores in the structure.  
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Figure 2. 20 Six categories of gas adsorption isotherms for porous materials with different 
pore size [129]. 
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Based on the above illustration, nitrogen adsorption-desorption isotherm of HMSNs 
should follow the type IV as illustrated in Figure 2.21, with a high pore volume and a 
large surface area.  
 
 
 
Figure 2. 21 Adsorption isotherms of nitrogen in mesoporous silica nanoparticles of 
different pore sizes. Closed symbols, adsorption; open symbols, desorption [122]. 
 
2.3.4.1.  Pore geometry and pore size 
 
Pore geometry is an essential part of investigating HMSNs as pore types and shapes play 
important roles in the applications of HMSNs. According to the types of pores that define 
the networks (Figure 2.22), MSN are divided into several types, such as MCM-41, SBA-
15 and FDU-1 [130].  
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Figure 2. 22 Pore geometry [129] 
 
Nitrogen Absorption and Desorption (BET/BJH) is commonly used to characterize the 
pore geometry and pore size of MSNs. Isotherm linear plots (Figure 2.23, type H1-H4) 
obtained from BET/BJH adsorption and desorption equipment provide information of 
pore geometry [128, 129, 131]. Owning to different pore structure, the way of gas 
evaporation differs from one another, which results in the change in shape of the 
hysteresis loops on nitrogen adsorption-desorption isotherms (Figure 2.23). Therefore the 
shape of a gas adsorption and desorption isotherm is one of the sources that provide 
important qualitative structural information. By studying shapes of the corresponding 
isotherms, the information about pore geometry can be obtained.     
 
 
 
Figure 2. 23 Effect of pore geometry on shapes of hysteresis loop  
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For an ideal 5-FU delivery system, it is essential to make sure that the drug is easily loaded 
and released in a designed profile. The pore connection would therefore be a vital element 
that should be taken into consideration, as it plays a key role in assessing the feasibility 
of hollow MSNs nanocarriers for 5-FU delivery. The accessibility of mesopores as well 
as the pore size can be acquired through this method. However, this characterization 
method is limited to pores with a size of 2-50 nm.  
 
Positron annihilation lifetime spectroscopy (PALS) is another technique used to identify 
the porosity of mesoporous materials. PALS is a powerful characterization giving useful 
information on hierarchical porosity, especially on micropores and molecular scale free 
volume elements that is information hardly available from other characterisation methods, 
such as BET and XRD.  
 
2.3.5. MSNs’ pharmacokinetics 
 
The pharmacokinetics of MSNs is fundamentally significant to understand, interpret and 
assess the effectiveness of particles as it is closely connected to the toxicity and 
biocompatibility of MSNs as drug carriers. Thus, the study of MSNs’ pharmacokinetics 
is vitally essential before the utilization of MSNs for delivery systems. The current 
investigations on MSNs’ pharmacokinetics include blood circulation [132], retention, 
biodegradation, excretion and bio-distribution.  
 
MSNs have found to be biocompatible and well tolerated when injected in mice with a 
dosage of 50 mg kg-1. This dosage is proved to be an adequate concentration to provide 
effective cancer therapy. On the other hand, higher dosage of MSNs (1.5 g kg-1) would 
cause death to mice. The biocompatibility of MSNs can be improved by coating 
biocompatible polymers.  
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Figure 2. 24 TEM images of MSNs (black dots) endocytosed by human cervical cancer 
cells [88] 
 
The pathways of HMSNs for entry into cells are endocytosis but the surface 
functionalization and change in structural properties of HMSNs can lead to different 
pathways (Figure 2.24) [88]. Lu [87] found that MSNs were rapidly and completely 
cleared from animal bodies through urine and feces. The biodegradation of HMSNs 
follows a three-stage degradation, involving a fast bulk degradation stage in the first hour, 
a decelerated degradation stage hindered by calcium/magnesium silicate layer and finally, 
a slow diffusion stage on day-scale [133, 134]. The bio-distribution of HMSNs is mainly 
in the liver and spleen [87, 135]. Moreover, the influence of surface potential on the 
pharmacokinetics of HMSNs is significant. Studies conducted by Mou and co-workers 
[136] reveal that HMSNs with positive charge on the surface undergo faster transportation 
and excretion. 
 
2.4. Drug loading and release 
 
As for drug delivery system, high drug loading and controlled or sustained drug release 
are highly desired. In this case, hollow MSNs possessing both nano-scaled particle size 
and large pore and cave diameter are one of the promising candidates being pursued 
(Figure 2.25). Size, surface potential and hydrophilicity are factors to be controlled to 
make MSNs as ideal drug carriers with extraordinarily high load capacity as well as 
controlled release profile [137]. 
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Figure 2. 25 HMSNs based drug delivery system for simultaneous joint lubrication and 
treatment [138] 
 
Hollow MSNs have open pores for drug molecules to be encapsulated and have hollow 
interiors for a high drug storage (Figure 2.26) which makes drug loading and release quite 
different from polymeric carriers [139, 140]. The hollow cave and pore size would have 
significant effect on drug loading and release capacity. It is reported that selective 
adsorption of drug greatly depends on the pore size diameter [100]. Moreover, surface 
potential and hydrophilicity also play important roles on drug loading capacity. In general, 
hollow MSNs with both the opposite potential and similar hydrophilicity of drug 
molecules are more likely to achieve higher drug adsorption. Therefore, such parameters 
should be taken into account while designing nanocarriers for a given drug molecule. He, 
Zhang et al. [111, 141] developed a drug delivery system by fabricating MSNs with 
positive charge on their surface to load a negative charged drug for anti- hepatic fibrosis. 
It is found that the positively charged MSNs present better drug loading capacity and 
controlled release profiles than negatively charged ones. Gao and co-workers [109] 
regulated the release rate of doxorubicin by tuning the pore diameter of hollow MSNs. 
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Figure 2. 26 HMSNs based drug delivery system for high-intensity focused ultrasound 
(HIFU)-mediated intravenous drug delivery [142].(a) The schematic illustration of the 
synthesis route of HMSN-LM and its applications in multi-drug co-delivery, temperature-
responsive release and HIFU treatment enhancement; TEM images of HMSNs (b) and 
drug loaded HMSNs (c), and the insets are their corresponding schematic illustration. 
 
Transmembrane transport of hollow MSNs is another element that affects drug release 
kinetics in vivo. It is well established that the internalization of nanocarriers via 
endocytosis are size and cell dependent. MSNs can be prepared with a wide range of 
particle size (30-300nm) and tailored shapes (spheres, plates and rods). However, only 
particular size and shape can exhibit good transmerbrane transport. Lu and co-workers 
[143] found out MSNs with 50 nm in diameter exhibit the best cellular uptake efficiency. 
This is also proved by Tang et al [100] who pointed out that the order of cellular uptake 
efficacy of MSNs is 50 nm > 30 nm > 110 nm > 280 nm > 170 nm. Importantly, it is 
suggested that the most effective size range of MSN in drug delivery is 50-150 nm from 
this standing point of cellular uptake efficacy. In addition, for transmembrane transport, 
the feature of the net negative surface charge of cell membrane attracts attention from 
researchers [88, 144]. Nanocarriers are modified to possess positive charge on their 
surfaces leading to high efficiency in the endocytic trafficking in mammalian cells [136, 
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145]. He et al [146] pointed out that the higher surface hydrophobicity and larger particle 
size will prohibit the transmembrane delivery. 
 
Inspired by these studies, as for 5-FU, in order to attain high adsorption, it is essential to 
fabricate hollow MSNs with a particle size within the range of 50-150 nm.  Also, hollow 
MSN carriers possessing hydrophilic and positively charged groups on its mesopore walls 
and surfaces would enhance their 5-FU loading capacity.  
 
2.5. Drug resistant phenomenon  
 
Systemic toxicity of anti-cancer drugs as well as the emergence of multidrug resistance 
(MDR) by cancer cells have greatly limited the success of chemotherapy, making cancer 
remains one of the major causes of mortality and morbidity in the world [147-150]. 
 
The systemic toxicity of 5-FU mainly resulted from its nonspecific distribution in a 
biological system, leading to the death of normal cells [35, 151]. Nanocarriers such as 
HMSNs have been developed that can offer targeting delivery of chemotherapy drugs to 
cancer cells by taking the advantage of enhanced permeation and retention (EPR) eơect 
[152, 153] in the tumour site. Further functionalization of the surface of HMSNs allows 
for enhanced recognition and internalization of drug loaded HMSNs by target cell 
population, thereby protecting normal tissues from exposing to the toxic effects of anti-
cancer drugs [154-157].  
 
However, even though the toxicity of 5-FU would be overcome by a well-designed 
HMSNs based targeted drug delivery system, the effective cancer treatment of 5-FU 
cannot be maintained for a relative long period for a complete killing of the cancel cells. 
Instead, the therapeutic effect of 5-FU decreased along the time, leading to treatment 
failure and recurrence or relapse of tumours [158, 159]. This is mainly due to the cancer 
cells developing resistance to the drug 5-FU, which is another obstacle to the successful 
cancer treatment [160, 161].  
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Figure 2. 27 Rational design of a multifunctional micellar nanomedicine for targeted co-
delivery of siRNA and DOX to overcome multidrug resistance [162]  
(a) Chemical structure of functionalized copolymers with ligands at the end of the PEO block and 
conjugated moieties on the PCL block. (b) Assembly of multifunctional micelles with DOX and siRNA in 
the micellar core and RGD and/or TAT on the micellar shell. (c) Schematic diagram showing the proposed 
model for the intracellular processing of targeted micelles in MDR cancer cells after receptor-mediated 
endocytosis, leading to cytoplasmic siRNA delivery followed by P-gp down-regulation on the cellular and 
nuclear membrane and endosomal DOX release, followed by DOX nuclear accumulation 
 
Multidrug resistance (MDR) involves cancer cells overexpressing drug transporter 
proteins, like P-glycoprotein (P-gp) to pump the drugs out of the cells [163, 164]. To 
overcome this problem, combination delivery of chemotherapy drugs [165, 166] is 
emerged as a strategy and is proved to be effective for some short-term treatments. 
However, in many case, long-terms therapy is required for a full cure of cancers, where 
co-delivery of chemotherapy drugs shows inability [167]. This is mainly due to the fact 
that after a particular type of cancer has developed resistance to a given drug, the cancer 
cells develop resistance to other drugs as well. Fortunately, the mechanism and genes 
behind MDR are well explored and the inhabitation of P-gp functions was achieved by 
specific small biological molecules [162]. Despite this effort, because of their nonspecific 
action that caused intolerable toxicity, no P-gp inhibitor has been approved for clinic use. 
Therefore, new strategies to inhibit the expression (rather than the function) of P-gp is of 
great importance. 
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In this regard, the use of small interfering RNA (siRNA) for a potent post-transcriptional 
gene silencing was developed [163]. However, the delivery of siRNA through systemic 
administration is often obsessed with poor stability, low cellular uptake, and rapid 
clearance of siRNA from the circulation [162]. Similarly, nanoplatforms can provide 
efficient delivery of siRNA with high specificity and low off-target effect. A better 
therapeutic effect in MDR tumours was observed by co-delivery of drugs and siRNA to 
the same cancer cells [162, 167]. For example, as shown in Figure 2.27, siRNA was 
successfully delivered by a multifunctional micellar system to overcome multidrug 
resistance. Mao et al. [168] used functionalized quantum dots for simultaneous delivery 
of siRNA and anticancer drug DOX, which showed effectively induced apoptosis and 
suppressed tumour growth (Figure 2.28). 
 
Inspired by the research illustrated above, we hypothesised that co-delivery of 5-FU and 
siRNA using HMSNs as nanocarriers would simultaneously deal with the problems 
regarding systemic toxicity and drug resistance. Nevertheless, co-delivery of drug and 
siRNA is a challenging task due to their huge different properties [169]. Thus, when 
engineering a co-delivery system, multiple factors need to be considered beforehand. 
Firstly, mutual chemical compatibility should be ensured.  The capacity to load and 
release drug-siRNA combination then needs to be determined [170]. More importantly, 
the differences in hydrophobicity, metabolic stability and molecular weight between 
drugs and siRNA are very critical for nanocarriers [167, 171].  
 
Based on this literature review, we propose to develop a co-delivery system through a 
more feasible option. HMSNs will be loaded with 5-FU and siRNA separately. Then by 
combining 5-FU loaded HMSNs and si-RNA loaded HMSNs with different ratio will be 
delivered to colorectal cancer cells. This proposed strategy take the advantage of avoiding 
co-encapsulation of 5-FU and si-RNA, which will provide a more-potent, independent 
control and less-toxic means for cancer treatment.  
40 
 
 
 
Figure 2. 28 System for delivery of doxorubicin (DOX)/siRNA combination based on quantum dots (QDs) modified with β-cyclodextrin [168]
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Chapter 3   Materials and methodology 
 
 
3.1 Introduction  
 
This chapter outlines the chemical reagents, HMSNs fabrication and modification 
techniques, in vitro experimental methods as well as characterization technologies 
applied in this thesis. Firstly, all the materials including chemicals and auxiliary reagents 
are specified, followed by a full illustration of preparation and chemical functionalization 
technologies for HMSNs. Additionally, strategies used for 5-FU loading and release study 
are described. Furthermore, detailed in vitro experimental methods for assessing the 
biological activity of HMSNs as drug carriers for targeted drug delivery system are 
discussed. Finally, technologies utilised to characterize the morphology and properties of 
samples in terms of particle size, pore size, surface area, modification efficiency, drug 
loading capacity, release profile, biocompatibility and targeting ability are fully 
introduced.  
 
3.2 Materials 
 
Tetraethyl orthosilicate (TEOS, Si(OCH2CH3)4), Triton X-100 (TX100), Poly(ethylene 
glycol)20-block-poly(propylene glycol)70-block-poly(ethylene glycol)20 (P123), 
Poly(ethylene glycol)106-block-poly(propylene glycol)70-block-poly(ethylene glycol)106 
(F127), Tweens 20, ammonia solution (28-30%), Sulphuric acid, Sodium carbonate 
(Na2CO3), Octadecyltrimethoxysilane (OTMS), N-Hydroxysuccinimide (NHS), 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC), (3-Aminopropyl)triethoxysilane 
(APTES), 3-Cyanopropyltriethoxysilane (CPTES), Fluorescein isothiocyanate (FITC), 
fluorinated pyrimidine 5-fluorouracil (5-FU), deuterium oxide, Epidermal growth factor  
(EGF, human), 100× penicillin/streptomycin solution, Trypsin−EDTA Solution (0.25% 
trypsin, 0.1% EDTA),   paraformaldehyde (PFA), 4',6-Diamidino-2-Phenylindole (DAPI) 
were all purchased from Sigma Aldrich (Sydney, Australia). Dulbecco's Modified Eagle 
Medium (DMEM), Fetal Bovine Serum (FBS), Phosphate-Buffered Saline (PBS) and 
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GlutaMAX™ were from life technologies. Eudragit S100 which is made in Germany was 
purchased from Shenzhen Youpuhui Pharmaceutical Co. Ltd (Shenzhen, China). 
 
3.3 Preparation of  versatile HMSNs 
 
3.3.1 Formation of Eudragit S-100 nanoparticles  
 
The synthesis of the Eudragit core particles were achieved by nanoprecipitation [172]. 
Specifically, 20 mL acetone solution of Eudragit S-100 (4 mg/mL) was added dropwise 
to 100 mL deionised water under stirring. The suspension was left to proceed for 5 h 
under agitation at room temperature before being used for HMSNs fabrication. 
 
3.3.2 Fabrication of HMSNs 
 
For the formation of the mesoporous silica shell, 120 mL Eudragit S-100 nanoparticle 
solution (0.75 mg/mL) was ultrasonically dispersed for 3 min (100W), followed by 
addition of 1.0 g TX100 under stirring. After TX100 was completely dissolved, 2.3 mL 
TEOS was added and this solution was left to proceed for 24 h before being transferred 
into a sealed container and hydrothermally treated overnight under 100 qC. The resulting 
nanoparticles (as-synthesized HMSNs) were collected by centrifugation (10000 rpm for 
20 mins) and redispersed in Acetone for the removal of Eudragit core and TX100 
templates. The particles were then washed 3 times with ethanol and deionized water 
respectively before finally freeze-dried (deionized water was used as the solvent for all 
freeze-drying procedures). 
 
For stability study, paralleled samples were prepared using the same method illustrated 
above to obtain as-synthesized HMSNs. Then these as-synthesized HMSNs were freeze-
dried before undergoing a calcination process, where 550 ˚C was applied for 6 h to 
remove the Eudragit core and TX100 templates. 
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3.3.3 Control of particle size  
 
The particle size of HMSNs was controlled by synchronously changing the amount of 
TEOS and the concentration of Eudragit S-100 solution applied in HMSNs fabrication. 
In detail, 20 mL acetone solution of Eudragit S-100 (4 mg/ml, 8 mg/ml and 16 mg/ml) 
was added dropwise to 100 ml deionised water under stirring. The suspension was left to 
proceed for 5 h under agitation at room temperature. Then the resulting Eudragit S-100 
nanoparticles suspensions were ultrasonically dispersed for 3 min, followed by addition 
of 1.0 g TX100 under stirring. After completely dissolving TX100, 2.3 mL, 3.5 mL and 
8.0 mL TEOS were added, respectively and these solutions were left to proceed for 24 h 
before transferred into sealed containers and hydrothermally treated overnight under 100 
˚C. The resulting HMSNs with different size were collected by centrifugation and 
redispersed in Acetone to remove Eudragit core and TX100 templates. Finally all the 
particles were collected and freeze-dried. 
 
3.3.4 Control of shell thickness 
 
HMSNs with varying shell thickness (10 nm, 15 nm and 30 nm) were fabricated by using 
different types of nanoparticles as cores. Typically, HMSNs with 10 nm shell thickness 
was fabricated according to the method illustrated in 3.3.2 while those with 15 nm and 30 
nm shell thickness were synthesised with the following procedures. 
 
Six milliliter TEOS was added dropwise to a mixture containing 100 mL ethanol and 6 
mL ammonia solution, which was hydrolysed and condensed for 0.5 and 1 h at 30 ˚C to 
obtain silica nanoparticles with different diameters as cores for further HMSNs 
fabrications. After that, 2 mL OTMS and 5 mL TEOS were firstly mixed and then added 
to the above solutions, which was left to react for another 1 and 4 h at 30 ˚C under 
magnetic stirring. Finally, the yield particles were collected by centrifugations and 
redispersed in Na2CO3 solutions (0.6 M) for 1 h at 80 ˚C before calcinations and freeze-
drying. 
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3.3.5 Pore expansion of HMSNs 
 
The control of the pore size of then HMSNs were achieved by varying the molecular 
weight of non-ionic surfactants used for HMSNs fabrications. Larger pores were 
developed by surfactants with longer molecular chain which forms bigger micelles that 
finally evolved to pores of HMSNs. F127, P123 and Tweens 20 were used instead of 
TX100 for HMSNs synthesis described in 3.3.2.  
 
Another method for pore expansion is to apply different calcination time to HMSNs, 
where small pores were collapsed and merged into larger pores. In detail, 6 mL TEOS 
was added dropwise to a mixture containing 100 mL ethanol and 6 mL ammonia solution, 
which was hydrolysed and condensed for 1 h at 30 ˚C. Then, 2 mL OTMS and 5 mL 
TEOS were mixed first and added to the above solutions, which was left to react for 
another 1 h at 30 ˚C under magnetic stirring. After that, the yield particles were collected 
by centrifugations and redispersed in Na2CO3 solutions (0.6 M) for 1 h at 80 ˚C. The 
resultant particles were divided into 3 groups which underwent calcinations for 3, 6 and 
12 h at 550 ˚C before freeze-drying. HMSNs with pore size of 2.5, 4.3 and 20.1 nm were 
acquired. 
 
3.4 Modifications of HMSNs 
 
3.4.1 Amine-, methyl- and cyano-functionalization   
 
For amine-functionalization (HMSN-NH2), 50 mg HMSNs were ultrasonically dispersed 
in 50 mL ethanol, 25 μL APTES were added and stirred for 24 h before centrifugations 
and washed 3 times with ethanol then deionized water respectively. Finally these yielded 
HMSN-NH2 were collected and freeze dried.  
 
The experimental procedure for methyl- and cyano-functionalization (HMSN-CH3 and 
HMSN-CN) is similar to amine-functionalization. The only difference is to use OTMS 
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and CPTES instead of APTES for chemical modification. 
 
3.4.2 Carboxyl-modification (HMSN-COOH) 
 
Fifty milligrams of HMSNs were ultrasonically dispersed in 50 mL ethanol, 25 μL 
APTES were added and stirred for 24 h. The resulting nanoparticles were collected by 
centrifugations and redispersed in sulphuric acid (50% v/v), heated at 150 ˚C for 4 h. The 
final products were re-collected, washed and freeze dried. 
 
3.4.3 FITC-modification (FITC-HMSNs) 
 
Twenty milligrams of HMSNs were suspended in 20 mL ethanol, followed by addition 
of 10 mL APTES, then this mixture was stirred for 24 h at room temperature. The 
resulting amino functionalized HMSNs were collected by centrifugation and then 
redispersed in 10 mL FITC ethanol solution (1 mg/mL) and stirred for another 24h. The 
final FITC modified HMSNs (FITC-HMSNs) were collected for freeze-drying. 
 
3.4.4 EGF labelling (HMSN-EGF) 
 
Sixteen milligrams of NH2-HMSNs were ultrasonically dispersed in 1 mL deionised 
water, to which 2.1 mg NHS and 17.3 mg EDC were added.  After that, 0.4mL of EGF 
solution (0.2 mg/mL in PBS solution) and 0.8 μL of triethyl amine were added. The 
mixture was left to proceed for 1 h under stirring at room temperature. The EGF grafted 
hollow mesoporous silica nanoparticles (EGF-HMSNs) were collected by centrifugation 
and washed in deionised water. These EGF-HMSNs were redispersed in 8 mL FITC 
ethanol solution (1 mg/mL) and stirred for 24h. The final FITC modified EGF-HMSNs 
(EGF-HMSN-FITC) were collected by centrifugation and washed with ethanol then 
deionized water. Finally, the product was freeze-dried.  
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3.5 5-FU loading and release study  
 
3.5.1 Measurement of 5-FU oil : water partition coefficients 
 
Measurement of 5-FU oil : water partition coefficients was conducted via shake flash 
method according to OECD guideline 107 [173]. Firstly, n-octanol and Milli-Q water 
were saturated, respectively prior to the experiments and herein their saturated solutions 
were referred to as octanol and water. Then, 5-FU was dissolved in water to obtain a 
concentration of 266.7 μg/mL. A combination of octanol and water with an octanol:water 
ratio of 1:1, 1:2 and 2:1 were added to centrifuge tubes and a total volume of 40 mL was 
maintained. Each ratio was carried out in triplicate. 1mL 5-FU was added to the centrifuge 
tubes and the phases were mixed by vortex for 10 min before centrifuging at 1000 rpm 
for a further 10 min. Both 5-FU concentrations in water and octanol phases were 
determined via UV-Vis spectroscopy (Ocean Optics system, USA).  
 
The partition coefficient Pow is calculated from the data of each run using the following 
equation (Equ. 3.1): 
 
ைܲௐ ൌ ׋೙ష೚೎೟೚೙ೌ೗׋ೢೌ೟೐ೝ                                                         3.1 
 
3.5.2 5-FU loading  
 
The loading of 5-FU was carried out by soaking HMSNs in a concentrated drug solution 
at room temperature for 24 h while stirring to ensure the diffusion of the drug molecules 
through the mesopores. Firstly, 5-FU was dissolved in deionized water to a concentration 
of 3 mg/ml. 150 mg of HMSNs was ultrasonically dispersed in 50 mL of the 5-FU solution. 
The mixture was stirred at room temperature. At timed intervals of 0, 2, 4, 6, 8, 12 and 
24 h, 0.5 mL of the solution was extracted, centrifuged to collect the supernatant for UV-
Vis analysis at a wavelength of 266 nm while the 5-FU -loaded HMSNs precipitate was 
placed back into the drug solution. At intervals of 0, 2, 4, 6, 8 and 12h, the HMSNs only 
loaded a certain amount of 5-FU and they still have the capacity for further encapsulation 
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of the drug. Therefore, the 5-FU loaded HMSNs precipitate collected at intervals were 
placed back to the mixture for further loading. After the loading, the 5-FU loaded HMSNs 
were washed with deionized water before freezer-drying. The loading amount of 5-FU in 
the HMSNs was calculated by subtracting the amount of 5-FU in the supernatant from 
the amount in the original drug loading solution.  
 
The drug loading capacity was calculated using the following equation:  
 
ሺΨሻ ൌ ୑ୟୱୱ୭୤ୢ୰୳୥ୱ୧୬୲୦ୣୌ୑ୗ୒୍୬୧୲୧ୟ୪୑ୟୱୱ୭୤ୌ୑ୗ୒                           
 
3.5.3 5-FU release 
 
To measure the drug release profile from 5-Fu loaded HMSNs, 30 mg of 5-FU-loaded 
HMSNs were dispersed in 150 mL of phosphate buffer saline (PBS) solutions at pH 5.5 
or pH 8.0 and the mixtures were gently stirred at 37 qC. At timed intervals, 1 mL of the 
solution was removed and centrifuged (13000 rpm for 5 mins) for UV-Vis analysis and 1 
mL of fresh PBS was added to the drug release solution to keep the volume constant. For 
drug release, it is important to make sure that a certain amount of the drug is released into 
a constant volume. A changing volume can affect the release rate and release kinetics to 
some extent. The method used in this work for measuring the drug release behavior of 
HMSNs is a standard method which has been widely used [174-177].   
 
The release percentage at each time point was analysed by UV-Vis at a wavelength of 
266 nm and calculated using the following equation:  
 
ܴ௧ ൌ ஼೟௏భା௏మሺ஼೟షభା஼೟షమାڮା஼బሻௐభ௅  ×100% 
 
where Ct is the drug concentration at a time t, Ct-1, Ct-2 are the drug concentrations detected 
at different time points previous to t (C0 =0). V1 is the total volume for drug release (150 
mL), V2 is the volume that is taken for UV measurement (1 mL), W1 is the weight of drug 
loaded HMSNs (0.03 g) and L is the drug loading capacity of HMSNs (194.5 mg(5-
FU)/g(HMSNs)). The 5-Fu release experiment was conducted in triplicate and the mean 
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results were reported.  
 
 
3.6 Cell experiments 
 
3.6.1 Cell culture 
 
The colorectal cancer cell line, SW 480 and SW 620, with and without EGFR 
overexpression, were cultured in DMEM containing 10% foetal bovine serum and 1% 
penicillin/streptomycin supplemented with 1% GlutaMAX™. The culture was 
maintained at 37 qC in a humidified atmosphere containing 5% CO2.  
 
3.6.2 Cellular uptake of HMSNs and EGF-HMSNs in colorectal cancer cells 
 
SW480 and SW 620 were seeded into 24-well plates with 1×105 cells per well in 0.5 mL 
of complete growth medium. After 24 hours of cell attachment at 37 q& in 5% CO2, the 
cells were treated with 2, 5 or 10 μg/mL of EGF-HMSN-FITC or FITC-HMSNs for 30 
min, 2 hours or 4 hours. The cells were washed with PBS three times and harvested by 
trypsinization. Then the cells were resuspended in PBS containing 10% of FBS for flow 
cytometric analysis. The green fluorescently-labelled live cells were counted as positive 
cells which are associated with nanoparticles and the mean fluorescence intensity (MFI) 
was calculated. The cells incubated with DMEM only were used as a negative control. 
To visualize the uptake of HMSNs via confocal microscope, SW 480 and SW 620 cells 
were seeded into 8-well chamber slides at 5 ×104 per well for 24 hours before incubation 
with 10 μg/mL of EGF-HMSN-FITC or FITC-HMSNs for 30 min, 2 hours or 4 hours. 
Cells were fixed with 4% paraformaldehyde and stained with DAPI for confocal 
microscopy imaging. Confocal imaging of the cells was carried out on a laser scanning 
confocal microscope. 
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3.7 Characterizations 
 
3.7.1 Electron microscopy  
 
The morphology of HMSNs was studied using scanning electron microscopy (SEM, Carl 
Zeiss AG SEM Supra 55VP) and transmission electron microscopy (TEM, LaB6 JEOL 
JEM-2100). Before imaging under SEM, all the samples were coated with carbon through 
a BAL-TEC SCD 050 sputter coater (Leica Microsystems, Australia). TEM imaging were 
conducted under 200 kV. 
 
3.7.2 Nitrogen absorption and desorption experiments 
 
Nitrogen absorption and desorption isotherms of HMSNs were conducted on a 
Micromeritics Tristar 3000 (Particle & Surface Science, UK) equipment at 77K. Before 
measurements, samples were degassed at 523 K for 1 h under nitrogen. The specific 
surface areas of HMSNs were calculated using the Brunauer-Emmett-Teller (BET) 
method. The Barrett-Joyner-Halenda (BJH) model was utilized to obtain the pore size 
distributions from the desorption branch of isotherms.  
 
3.7.3 Small angle X-Ray diffraction (SAXRD) 
 
The mesoscopic ordering of the nanoparticles was confirmed by small angle X-ray 
diffraction (SAXRD) using a Bruker D8 Advance (Bruker, Germany) X-ray 
diffractometer with Cu-Kα radiation (λ=0.1542 nm). The instruments were operated at 40 
kV and 40 mA current.  
 
3.7.4 Thermo-gravimetric analysis (TGA) 
 
TGA of HMSNs were conducted using a TG Simultaneous Thermal Analyser (STA 449C, 
ZETZSCH, Germany). Samples with a weight of ~5 mg were placed into aluminium 
oxide crucibles and heated under nitrogen condition at a heating rate of 10 ˚C/min from 
room temperature to 600 ˚C.  
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3.7.5 Fourier transform infrared spectrometer (FTIR) 
 
Fourier transform infrared (FTIR) spectra were measured with a Vertex 70 spectrometer 
(Bruker, Germany). All the samples were compressed into KBr pellets and recorded at 64 
scans from 4000cm-1 to 400cm-1 with a resolution of 4 cm-1.  
 
3.7.6 Time of flight secondary ion mass spectrometry (ToF-SIMS) 
 
ToF-SIMS experiments were performed using a Physical Electronics Inc. PHI TRIFT V 
nanoTOF instrument (Physical Electronics Inc., Chanhassen, MN, USA) equipped with 
a pulsed liquid metal 79+Au primary ion gun (LMIG), operating at 30 kV energy. Dual 
charge neutralisation was provided by an electron flood gun (10 eV electrons) and 10 eV 
Ar+ ions. Experiments were performed under a vacuum of 5x10-6Pa or better. “Bunched” 
Au1 instrumental settings were used to optimise mass resolution for the collection of 
spectra.  Positive SIMS spectra were collected from areas of 100×100 micron, with an 
acquisition time of 2 minutes.  
 
In order to meet the static SIMS regime, the corresponding total primary ion dose of less 
than 1 × 1012 ions cm-2 was typically achieved [178]. A mass resolution at nominal m/z 
= 27 amu (C2H3+) was m/'m of > 5000. Ten positive ion mass spectra were collected 
from areas that did not overlap for each sample. Sample spectra were processed and 
interrogated using WincadenceN software (Physical Electronics Inc., Chanhassen, MN, 
USA). Integrations were performed on all recognisable and unobscured immonium ions 
in the 2-160 amu mass range. The peaks were normalised to the total intensity of all 
selected peaks [179].  
 
PCA was performed using Statistica software (StatSoft Pacific Pty Ltd, North Melbourne, 
VIC, Australia).  
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3.7.7 Nuclear magnetic resonance (NMR) 
 
The pulse-field gradient NMR (PFG-NMR) diffusion experiments were carried out on a 
Bruker Avance III 500 MHz wide bore spectrometer (with proton Larmor frequency of 
500.07 MHz) equipped with a 5 mm diff50 pulse-field gradient probe. Each sample was 
packed in a 5 mm Schott E NMR tube to a height of 50 mm. The pulse-field gradient 
stimulated echo (PFG-STE) pulse sequence [180] was used to obtain diffusion 
coefficients and the 1H NMR signal was used for the determination of diffusion 
coefficients of different molecules. The maximum gradient strength of the amplifier is 
29.454 T/m. 
 
3.7.8 Dynamic light scattering (DLS) 
 
The particle size of Eudragit and micelle sizes of TX100 were investigated by dynamic 
light scattering (Malvern ZetaSizer Nano). Each sample was tested in triplicate and the 
mean result was reported.  
 
Zeta potential of HMSNs were analysed on this instrument as well. Samples were 
dispersed in ethanol with a concentration of 1 mg/ml. Measurements of each sample were 
conducted in triplicate and the average value was considered. 
 
3.7.9 Confocal microscopy 
 
Confocal laser scanning microscope (CLSM) images of cells were took via a confocal 
microscopy (Leica TCS SP5, Germany) using 40× objective, 488 nm/405 excitation. 
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Chapter 4 Synthesis of tailored HMSNs for 
nanotheranostics 
 
 
 
4.1 Introduction 
 
Hollow mesoporous silica nanoparticles (HMSNs) with large hollow interiors and 
penetrating pores in the shell are exceptionally promising platforms in many current and 
emerging fields such as pharmaceutics [1], optics [2], environmental protection [3] and 
catalysis [4]. In particular, they were exploited as nanocarriers for drug delivery [5] 
because their huge cavities provide large drug loading capacities [6] and the open 
mesopores allows transportation of drugs [7]. In addition, owing to their hollow structure, 
HMSNs also possess other characteristics such as a decreased particle density and 
increased active area for drug loading. In this regard, HMSNs are superior to non-hollow 
mesoporous silica nanoparticles (MSNs) and other corresponding mesoporous silica 
nanoparticle composites [8]. However, owing to the complex effects of physicochemical 
parameters on synthesis reactions, fabricating HMSNs with good stability and dispersion 
remains a main challenge [5] which limits their further application in drug delivery. 
Thereby, developing new, reliable and facile methodologies for synthesising discrete and 
dispersible HMSNs is important and could contribute to the further development of drug 
delivery systems. 
 
One of the typical methods to produce mesoporous silica materials is self-assembly which 
is a well-known synthesis strategy and occurs when molecules interact with one another 
through a balance of attractive and repulsive interactions [9, 10]. For mesoporous silica 
materials, self-assembly is achieved via a surfactant templating route which involves the 
spontaneous organization of templates into structurally ordered micelles through van der 
Waals and Coulomb interactions [11] or hydrogen bonding. As shown in previous studies, 
non-ionic surfactants such as tri-block copolymers with certain hydrophilic/hydrophobic 
ratios and neutral surfactants like Triton X-100 (TX100) have been demonstrated to be 
extremely suitable for assembling ordered mesoporous silicates [12, 13]. However, due 
to the difficulty in adjusting micelle structure and the poor understanding of the 
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mechanisms behind the self-assembly formation of mesoporous structure in sol–gel 
chemistry,  the controllable tailored design of non-ionic surfactant templated HMSNs is 
still far from satisfactory. Therefore, there is immense value in the development of new 
methodologies for regulating the structure of non-ionic surfactant micelles in order to 
tailor HMSNs for certain applications. 
 
Current efforts are ongoing to optimize the parameters and yield of mesoporous structures 
by changing material ratios or fabrication parameters, such pH [14, 15] and synthesis 
temperature [16].  From a technical point of view, an insight into the micelle organization 
mechanism can contribute to the improvement of the silica structure including stability, 
pore size and volume. In addition, customisation of the silica structure will allow 
facilitation of the host-guest specific interaction for the intended purpose. 
 
In this chapter Eudragit S100 was introduced as a core particle to bind and facilitate the 
self-assembly of the non-ionic surfactant into stable composite micelles. The reactions 
between surfactant molecules and Eudragit S100 was investigated by Fourier Transform 
Infrared (FTIR), Dynamic Light Scattering (DLS) and Pulse Field Gradient NMR (PFG-
NMR) analyses. The addition of Eudragit S100 were inferred to result in the redistribution 
of surfactant micelles by hydrogen-bonding. Uniform and highly ordered HMSNs were 
achieved, demonstrating the efficiency of using Eudragit to assist in the morphological 
formation of surfactant micelles and consequently, the silica shell structure.  
 
The efficacy of Eudragit-assisted HMSNs as drug carriers was ascertained by examining 
the loading and release behaviour of the first line anticancer drug, 5-FU. Additionally, in 
vitro cytotoxicity and cellular uptake of these HMSNs by colorectal cancer cells SW480 
were investigated.  
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4.2 Synthesis of HMSNs with designed properties for drug delivery    
systems 
 
4.2.1 Preparation and characterization of HMSNs 
 
 
For HMSNs preparation, typically a hard or soft sphere is used to create the hollow cavity 
in HMSNs while surfactants are employed to develop pores in the shell and this in turn, 
involves a template-eliminated process [106, 107, 116, 181] . One of the typical methods 
to remove the core template and the pore template is calcination, where the as-synthesized 
HMSNs (with templates) subject to a very high temperature (>500 ˚C). However, during 
high-temperature, irreversible particle aggregation occurs, leading to the formation of 
nondispersible and conglutinated materials. Current efforts have been made in creating 
the intrinsic space in HMSNs, but little attention has been paid to solve the problem of 
particle dispersibility in solvents [182].  
 
To obtain dispersible HMSNs, a new method was developed to synthesise hollow 
mesoporous silica nanoparticles (HMSNs) by employing Eudragit S100 nanoparticles as 
the dissolvable core templates. Both the Eudragit S100 core and the structure-directing 
surfactant can be easily and synchronously removed through solvent extraction in acetone 
rather than calcination.  
 
 
 
Figure 4. 1 Fabrication possess of HMSNs 
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As a working model, the designed protocol as shown in Figure 4.1 depicts the fabrication 
possess where Eudragit S 100 nanoparticles were employed as a core template and the 
non-ionic surfactant Triton X-100 (TX100) was used as the pore template. Firstly, TX100 
micelles were assembled on the surface of Eudragit S 100 nanoparticles. Subsequently, 
TEOS was added as a silica source to form the mesoporous silica shell with embedded 
TX100 micelles. TX100 micelles and Eudragit S 100 nanoparticles can be easily removed 
by solvent extraction at the same time resulting in HMSNs with open mesopores and a 
hollow cavity.  
 
The microstructure of synthesized nanoparticles which are made up of a huge hollow 
cavity and a mesopourous shell are proved by SEM and TEM images (Figure 4.2). The 
spherical hollow interior can clearly be seen from the TEM images in Figure 4.2c-f, with 
a shell thickness of 10 nm (Figure 4.2e). The synthesized particles were spherical in shape 
with a mean diameter of 100nm. The rough surface of these hollow mesoporous silica 
nanoparticles shown in Figure 4.2b further suggested their porous structures [183, 184].  
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Figure 4. 2 a, b & c) SEM images of HMSNs and d, e & f) TEM image of HMSNs displaying hollow interior 
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Figure 4. 3 DLS curve of HMSNs 
 
 
The particle distribution collected by dynamic light scattering (DLS) in Figure 4.3 
definitely displays a narrow size distribution centred at 164 nm. The polydispersity index 
(PDI) of these HMSNs is approximately 0.048, suggesting a high size uniformity in these 
products [185]. It is found that the diameters showed here are slightly bigger than the size 
was measured by TEM (~100nm). This is presumably due to the fact that the DLS 
technique measured the particle size in solution where a hydrate layer exists on the 
HMSNs, thereby producing a larger diameter than that in its dried form observed from 
TEM or SEM. 
 
The small angle X-ray diffraction (SAXRD) pattern of the synthesized HMSNs was 
presented in Figure 4.4. Only one distinct broad Bragg diffraction peak was presented at 
2θ=2-3q, which was the characteristic XRD pattern of a mesophase pore system [146, 
186, 187]. The characteristic peak of mesoporous materials was centred at 2θ=2.1˚. This 
result was in good agreement with other mesoporous silica nanoparticles synthesized by 
nonionic surfactant templating [101, 118, 135, 188].   
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Figure 4. 4 Small angle XRD pattern of HMSNs 
 
 
According to IUPAC classification, HMSNs exhibited a classical IV type N2 adsorption- 
desorption isotherm with well-defined steps at relative pressures (P/P0) of 0.1-0.3 and 0.9-
1.0 corresponding to capillary condensation and desorption in open mesopores and 
interstitial pores respectively [189]. The N2 adsorption-desorption isotherm for HMSNs 
(Figure 4.5a) displayed two hysteresis loops at P/P0=0.3-0.5 and P/P0=0.9-0.96, 
respectively, which further supports the XRD results that suggested HMSNs have a 
mesoporous structure.  The HMSNs were calculated to have a narrow pore size 
distribution centred at 2.5 nm (Figure 4.5b). The specific surface area and pore volume 
of HMSNs were 760m2/g and 0.45cm3/g, respectively. 
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Figure 4. 5 Nitrogen adsorption-desorption isotherm (A) and the BJH pore size 
distribution of HMSNs (B) 
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4.2.2 Innovations of Eudragit-assisted HMSNs fabrication 
 
 
When compared to other conventional synthesis strategies of HMSNs, the use of Eudragit 
as template is novel. Eudragit S100 is a co-polymer of methacrylic acid and methyl 
methacrylate with the ratio of 1:2. It is stable under acidic pH (< 7) but becomes 
dissolvable in base condition (pH >7) or in Acetone [190, 191]. Because of this property, 
Eudragit S100 is often used as an enteric polymers for drug delivery [192-194]. By 
applying Eudragit S 100 nanoparticles as a core template, the yield products HMSNs 
don’t have to undergo the calcination process for the removal of the core template to 
create a hollow cavity in HMSNs. Instead, Eudragit core can be easily removed by 
soaking the as-synthesized HMSNs (HMSNs with Eudragit cores) in base solution or in 
Acetone under room temperature. This solvent extraction process to clean the Eudragit 
cores is facile and gentle, which can remarkably prevent the HMSNs from further damage 
or aggregation caused by subjecting to a very high temperate.  To our knowledge, this is 
the first time to report the use of Eudragit S100 nanoparticles as a core template for 
HMSNs synthesis. More importantly, Eudragit S100 is non-toxic, which is also superbly 
useful for the fabrication of HMSNs as drug carriers. 
 
To further demonstrate the above illustration, as-synthesized HMSNs (with Eudragit 
cores) underwent solvent extraction in Acetone and calcination at 550 ˚C for 6 h 
separately. Both treatments achieved the same goal, to remove the Eudragit cores, and the 
yield products were named as HMSNs-S and HMSNs-C, respectively.  The EM images 
in Figure 4.6 definitely displayed the superiority of solvent extraction. It can be seen that 
HMSNs-C were aggregated and some of them were damaged due to the high temperature. 
In contrast, HMSNs-S exhibited an excellent dispersion revealing that the solvent 
extraction method plays a crucial role in preparation of discrete HMSNs. 
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Figure 4. 6 TEM images (a) and SEM images (b & c) of HMSNs-S and TEM images (d) of HMSNs-C and SEM images (e & f)
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Figure 4. 7 Zeta potential of HMSNs-S and HMSNs-C 
 
In addition, the aqueous stability of HMSNs was thoroughly studied. The zeta potential 
of HMSNs-S and HMSNs-C were -25.6 mV and -4.8 mV at pH 7.4, respectively (Figure 
4.7). The higher surface charge of HMSNs-S was due to the abundant Si–OH groups on 
the surface [195]. In comparison, when HMSNs-C were subject to calcination at 550 ˚C 
for 6 h, some of the Si–OH groups condense with one another resulting in decreased  Si–
OH groups on the surface and thus a decreased surface charge (-5.89  mV) was observed.  
 
 
 
Figure 4. 8 Stability study of HMSNs-C and HMSNs-S 
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As shown in Figure 4.8, no obvious precipitation tendency of HMSNs-S was observed 
over one week indicating its excellent stable dispersion in water. On the other hand, 
HMSNs-C with a low surface charge exhibited decreased stability in aqueous solution, 
which was proved by the presence of sediment at the bottom of the sample vial after 2 
days of storage. 
 
As such, it is demonstrated that the new Eudragit-assisted strategies for the fabrication of 
HMSNs is superior to conventional methods used to fabricate HMSNs in preparation of 
highly uniform, discrete and stable HMSNs, given that particle stability is one of the 
critical considerations in the biomedical use of mesoporous silica nanoparticles. 
Therefore, the aggregation state of HMSNs beginning at the synthesis process should be 
taken into account before administration.  
 
4.2.3 Mechanism of Eudragit-assisted HMSNs fabrication  
 
Considering the successful results observed for Eudragit-assisted HMSNs fabrication, it 
is important to further elucidate the fabrication mechanism. Generally, Eudragit S100 
nanoparticles could be readily synthesized by nanoprecipitation [172] and TX 100 
micelles are formed in water at a given concentration and temperature [196]. Hydrogen 
bonds may be formed between Eudragit S100 nanoparticles and TX100 micelles due to 
the existence of carboxyl groups in Eudragit molecules and hydroxyl groups in TX100 
molecules.   
 
If Eudragit S100 nanoparticles and TX 100 micelles are combined to form a core/shell 
structure, hydrogen-bonding may be significantly complementary to the Coulombic 
interaction between Eudragit S 100 nanoparticles and TX100 micelles. The interactions 
between TX100 micelles and Eudragit S100 nanoparticles are proposed in Figure 4.9, 
demonstrating the formation of TX100/Eudragit composite micelles. The hydroxyl 
groups of surfactant micelles react with the carboxyl groups of Eudragit S100 particles to 
form hydrogen bonds. These are critical properties for the formation of TX100 micelles 
on the surface of Eudragit nanoparticles which finally form mesopores of HMSNs.  
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Figure 4. 9 Formation schematics and of TX100/Eudragit S100 composite micelles (a) 
and proposed reactions between TX100 and Eudragit S100 (equations 1-3) 
 
 
To demonstrate this hypothesis, Eudragit S100 nanoparticles and TX 100 micelles were 
prepared and their reactions were characterized by dynamic light scattering (DLS), FTIR 
and PFG-NMR techniques. As shown in Figure 4.10, the formation of composite micelles 
was tracked by DLS. Firstly, TX100 micelles with a diameter of approximately 8.7 nm 
were formed in water. Subsequently, after adding Eudragit nanoparticles (diameter ~ 68 
nm), the TX100/Eudragit composite micelles were formed with a diameter of ~ 92 nm 
indicating the coupling between Eudragit nanoparticles and TX100 micelles.  
 
From the FTIR results in Figure 4.11, the investigated composite micelles 
(TX100/Eudragit S100) were found to display a broad and intense absorption (continuum) 
in the 1500 – 800 cm-1 region, typical for short hydrogen bonds [197-201]. Broad 
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absorption arise from the bending and stretching vibrations of the O-H group involved in 
the short OH….O hydrogen bonds.  In addition, the red shift of the O-H stretch, which 
varies from 3545 to 3500 cm-1, provides unambiguous information about the formation 
of hydrogen bond [202, 203].  Thus, the extrinsic interaction between surfactant and 
Eudragit led to the nanocoating of surfactant micelles around Eudragit nanoparticles 
through self-assembly.  
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Figure 4. 10 DLS of Eudragit S100 nanoparticles, TX100 and their mixture 
 
To provide more direct evidence of the interactions between Eudragit S100 nanoparticles 
and TX100 micelles, 1H NMR spectra of Eudragit S100 nanoparticles and the mixture of 
TX100/ Eudragit S100 were recorded in Figure 4.12 and the diffusion coefficients of 
different species in both samples were listed in Table 4.1 
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Figure 4. 11 FTIR spectra of Eudragit S100 nanoparticles, TX100 and the mixture of 
Eudragit and TX100 
 
 
As shown in Figure 4.12, the 1H NMR spectra of Eudragit S100 nanoparticles presented 
two obvious peaks at 4.81 ppm (peak I) and 2.25ppm (peak II), which are assigned to the 
residual water and acetone in the D2O solution, respectively. The three peaks labelled as 
‘III’ are attributed to the Eudragit S100 molecules. The low intensity of the Eudragit peaks 
is due to its poor solubility in D2O at room temperature. In Eudragit S100 nanoparticle 
samples, the Eudragit S100 and the acetone molecules show similar diffusion coefficients, 
which are largely different from the diffusion coefficient of H2O molecules. This result 
suggests that the Eudragit molecules exist in the acetone phase, which is separated from 
the bulk water phase. Remarkably, upon the addition of the TX100, the diffusion 
coefficient of Eudragit S100 dropped by 75%, from 6.5×10-10 m2/s to 1.635×10-10 m2/s, 
whereas the acetone molecules maintain a similar diffusion coefficient to that in the 
system of pure Eudragit S100 nanoparticles. This is a strong indication of interactions 
between the Eudragit and the TX100 molecules which have a much lower diffusion 
coefficient (4.51 ×10-11 m2/s).   
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Figure 4. 12 1H NMR spectra of Eudragit S100 nanoparticles (upper) and 
Eudragit/TX100 mixture (bottom); Inserts are TX100 molecular structure. 
 
Table 4. 1 Proton diffusion coefficients (D) of Eudragit and Eudragit/TX100 mixture 
a The detailed assignment of each peak is shown in the inset of Figure 4.12. 
b The diffusion coefficient of TX100 molecules was obtained by fitting the sum of 
the integrals of all the corresponding peaks to the diffusion equation. 
Samples Peaks Assignment D (m2/s) SDb 
Eudragit I H2O (in D2O) 1.22×10-9 1.22×10-3 
II Acetone (in D2O) 7.25×10-10 4.65×10-3 
III  Eudragit 6.5×10-10 4.25×10-3 
Eudragit/TX100 I' H2O (in D2O) 1.25×10-9 1.017×10-3 
II'  Acetone (in D2O) 7.74×10-10 5.32×10-3 
III' Eudragit 1.635×10-10 7.4×10-3 
1,2,3,4,5,6a TX100 4.51×10-11 b 6.1×10-3 
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The measured NMR diffusion coefficient of the Eudgragit in Eudragit/TX100 samples is 
lower than that of the free Eudragit molecules (in the pure Eudragit sample), yet higher 
than that of the TX100 molecules. This can be explained by the fast exchange process 
between the free and associated Eudragit molecules. In the time scale of NMR 
measurements (10 ms), the Eudragit molecules exhibit a very fast exchange between the 
free and associated states. The measured diffusion coefficient (also termed as apparent 
diffusion coefficient) is then a population-weighted value between the free and associated 
values. Assuming that the associated Eudragit molecules are of the same diffusion 
coefficient as the TX100 molecules (4.51 ×10-11 m2/s), it can be easily calculated that 
about 19% of the Eudragit molecules are free and 81% of the Eudragit molecules are 
associated with TX100 molecules in the equilibrium state.  
 
 
 
Figure 4. 13 SEM images (a) and TEM image (b) of non-Eudragit assisted MSNs 
 
 
To further confirm the effect of the coordination between Eudragit S-100 nanoparticles 
and TX-100 micelles on the formation of the hollow mesoporous silica nanoparticles, 
Eudragit S-100 was omitted during HMSNs fabrication while keeping other experimental 
conditions the same. As seen from the SEM and TEM results (Figure 4.13), without 
Eudragit S-100 nanoparticles, the mesoporous silica nanoparticles obtained did not 
contain a hollow cavity. More importantly, the dispersibility, yield, size distribution and 
overall quality of the structure of these nanopartilces were significantly inferior to the 
HMSNs fabricated with the assistance from Eudragit. Thus, the role of Eudragit S-100 is 
crucial in the formation of high quality mesoporous nanoparticles. More than being a 
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solid core particle to develop the hollow cavity, Eudragit S100 nanoparticles also assisted 
in the cooperative assembly of TX100 micelles, which contributed to the excellent 
morphology of the HMSNs.  
 
 
4.2.4 5-FU encapsulation and the in vitro release 
 
 
To assess the potential application of HMSNs in drug delivery, the drug loading and 
release behaviour of HMSNs were investigated. 5-fluorouracil (5-FU) standing alone in 
colorectal cancer therapy was chosen as a model drug for this study. The 5-FU loading 
process predominantly relied on a physical adsorption mechanism in mesopores. The 
results shown in Figure 4.14a indicated that HMSNs have a loading capacity of 194.5 
mg(5-FU)/g(HMSNs) at 3 mg/mL of 5-FU loading solution. It has been found that a maximum 
loading content can be obtained after 8 h.  
 
Figure 4.14b presents the release of 5-FU from HMSNs in pH 5.5 and 8.0 PBS solutions. 
The results demonstrated that the release pattern of 5-FU in both pHs is similar. There 
were two stages during the release of 5-FU from HMSNs. The first stage of release was 
initially rapid, and within this stage, nearly 23.38% and 26.58% of the 5-FU was released 
into the aqueous media at pH 8.0 and 5.5, respectively. This may be due to the rapid 
diffusion of the 5-FU molecules which were adsorbed on the surface and in pore entrances 
of the HMSNs. When 5-FU loaded HMSNs were initially immersed into the PBS solution, 
there is a concentration gradient of 5-FU between the PBS buffer and the HMSNs. Thus, 
5-FU diffuses more quickly from the pores to the outside media driven by the diffusion 
effect. After 1h, the second stage of release was relatively slow and the drug concentration 
levelled off in 25 h which is an excellent release profile for cancer treatments.  
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Figure 4. 14 (a):5-FU loading profile and (b): 5-FU release profile of HMSNs 
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On the other hand, when the pH was decreased from 8.0 to 5.5, the release rate was 
accelerated and the total amount of 5-FU released increased. Near the isoelectric point of 
5-FU (pKa = 8.0), the net charge of this drug molecule was decreased. Thus, electrostatic 
attractions between the inorganic carrier and drug molecules were minimal [204]. 
However, at lower pH (pH =5.5) the elevated electrostatic repulsion would lead to a 
higher transport of 5-FU through the mesoporous silica shell and thus a greater release 
capacity [205]. The amount of 5-FU released from HMSNs in pH 8.0 and 5.5 PBS 
solutions was ~37.98% and ~43.99% at 25h, respectively.  These results illustrated that 
these novel HMSNs exhibited great sustained release due to their mesoporous structure.   
 
4.3 Pore size tuning for controlled release 
 
An ideal delivery system is the one that can provide a considerably extended period of 
effective drug delivery. The ideal slow release kinetic model [23] has three stages (Figure 
4.15). The release rate in stage I is initially rapid and as a results, the drug concentration 
in plasma can reach its therapeutic concentration rapidly. In stage II, the therapeutic 
concentration is maintained for a period of time then drop off gradually to the minimum 
effective concentration in stage III.  The HMSNs based drug delivery system can exhibit 
such a sustained release profile as demonstrated above.  
 
 
Figure 4. 15 Three stages of the slow release kinetic model 
 
I II III 
therapeutic zone 
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However, with the further development of the cancer treatments, more requirements were 
introduced to drug delivery systems. It was reported that, in addition to sustained release, 
specific drug release rates are always pursued for personal treatment as different stages 
of disease evolution need different drug release rates [206-208]. In this regard, smart 
delivery systems with more effective control of drug release rate were of great importance. 
Fortunately, the release rate of HMSNs based drug delivery system can be further 
controlled and adjusted by changing the pore diameter (Figure 4.16). By varying the pore 
size in the shell, the release rate of drug would be tuned to a specific rate for personal 
treatments. It is anticipated that the release rate will increase along with the increase of 
pore size because the space provided by small pores is limited for the diffusion of drug 
molecules while large ones can supply bigger room for more drug molecules to go 
through at the same time, which results in a quicker release speed.  
 
 
 
Figure 4. 16 Representative schematic illustration of controlling drug release rate by 
tuning the pore size of HMSNs 
 
Three HMSNs with different pore size were synthesized using the same fabrication 
system. The pore size of HMSNs was successfully tuned by using different surfactants 
with different molecular weight (poly ethylene oxide block copolymers F127, P123 and 
low molecular weight nonionic surfactant Tweens 20).  The higher the molecular weight 
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of surfactant, the bigger the micelles would be form which were finally evolved to 
mesopores of HMSNs.  
 
The pore size of HMSNs can be investigated by a suite of characterisation techniques, 
such as BET, XRD and PALS. These techniques provide different information whilst are 
complementary to each other. BET and PALS were used to study the pore size distribution 
of these three HMSNs (HMSN-1, HMSN-2 and HMSN-3). Combining these methods 
would allow a complementary pore size analysis of materials. 
 
4.3.1 BET analysis of pore size 
 
0.0 0.2 0.4 0.6 0.8 1.0
 
 
V
ad
s/c
m
3  g
-1
P/P0
HMSNs-2
HMSNs-3
HMSNs-1
(a)
0 10 20 30 40 50 60
0
1
2
 
 
P
or
e 
vo
lu
m
e/
(c
m
3  g
-1
)
Pore size/nm
 HMSNs-2
 HMSNs-1
 HMSNs-3
9.0nm
5.6nm
(b)
 
Figure 4. 17 Adsorption-desorption isotherms (A) and corresponding pore size 
distribution (B) of HMSNs 
 
Adsorption-desorption isotherms of HMSNs-1, HMSNs-2 and HMSNs-3 were recorded 
in Figure 4.17a and the corresponding pore size distribution was shown in Figure 4.17b. 
In addition, some physicochemical properties of HMSNs were listed in Table 4.2.  The 
adsorption-desorption isotherms (Figure 4.17a) of all HMSNs exhibit typical type IV 
curves with well-defined capillary condensation steps. This suggested that all HMSNs 
had mesoporous structure which was further confirmed by their high surface areas of 687, 
589, 760 m2g-1and pore volumes of 0.73, 0.96, 0.45 cm3g-1 for HMSNs-1, HMSNs-2 and 
HMSNs-3, respectively (Table 4.2). The pore size of HMSNs-1, HMSNs-2 and HMSNs-
3 was calculated and presented in Figure 4.17b. The appearance of sharp peaks in Figure 
4.17b indicated that HMSNs-1 and HMSNs-2 had a majority of mesopores with the size 
of 9.0nm and 5.6nm. However, for HMSNs-3, no peaks could be seen from Figure 4.17b. 
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The reason of this phenomenon may be that the average pore diameter of HMSNs-3 is 
relatively small beyond the limit of this characterization. Compared with F127 and P123, 
the molecular weight of Tweens 20 and TX100 is much smaller, which produces smaller 
micelles during fabrication process and therefore results in smaller pore size of 
nanoparticles. As pore size, surface area and pore volume of the final products highly 
depend on the kind of surfactant used for fabrication, HMSNs synthesized with 
surfactants having similar properties may have similar or even the same physicochemical 
properties, including the surface area [209, 210]. 
 
 
Table 4. 2 Physicochemical Properties of HMSNs 
 
Sample 
name 
surfactants BET 
surface 
area (m2/g) 
Pore size 
(nm) 
Pore 
volume 
(cm3/g) 
HMSNs-1 F127 589 9.0 0.96 
HMSNs-2 P123 687 5.6 0.73 
HMSNs-3 Tweens 20 760 - 0.45 
 
 
4.3.2 PALS  analysis of pore size 
 
The PALS is another technique used to identify the porosity of mesoporous materials. 
The results gained from PALS are presented in Table 4.3 which illustrates the multiple 
scales of porosity readily detectable with positrons. It is known that for mesoporous silica 
nanoparticles, τ3 is associated with micro-porosity in the amorphous silica network on 
molecular scale (D=0.2-0.4nm) while τ4 provides information on bridging micropore 
elements that connect mesopores (D≈1 nm). This information is not easily attainable from 
BET results. τ5 is related to the mesopores (D=5-20nm) [211]. Figure 4.18 depicts the 
relationship between porosity and τn. 
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Figure 4. 18 The relationship between porosity and τn [211] 
 
Table 4. 3 PALS data for HMSNs 
Sample τ3 (ns) D3 
(nm) 
I3 (%) τ4 (ns) D4 
(nm) 
I4 (%) τ5 (ns) D5 
(nm) 
I5 (%) 
HMS-1 
 
0.63 
 
0.23 
 
35.00 
 
5.19 
 
1.07 
 
1.14 
 
79.65 
 
7.8 
 
19.02 
 
HMS-2 
 
0.68 
 
0.26 
 
25.51 
 
6.46 
 
1.18 
 
1.19 
 
72.55 
 
6.6 
 
24.87 
 
HMS-3 
 
0.60 
 
0.21 
 
37.05 
 
7.18 
 
1.24 
 
13.42 
 
72.45 
 
6.5 
 
2.29 
  
τn: o-Ps lifetimes; D: average free path of corresponding pore length; I: corresponding 
intensity 
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As shown in Table 4.3, the pore size calculations were fitted to 3 other ortho-positronium 
components that are associated with the pore size (τ3, τ4 and τ5). Each of the components 
has an associated intensity value (I3, I4 and I5, relative number of pores) and a calculated 
pore size (D3, D4, and D5) using the RTE spherical model. τ3 representing very small 
micropores are very uniform between the samples, indicating that it is inherent to these 
silica products. τ4 is also very small for pores with the diameter of around 1.20nm. It was 
noticed that I4 of HMSNs-3 was much higher than that of other samples. This is a strong 
indication of the fact that there is a large proportion of micropores existing in HMSNs-3 
and this might be the reason for the absence of pore size distribution peak in Figure 4.17b. 
Given that the pore size obtained from BET is calculated by BJH method whose 
application is limited to mesopores (2 - 50nm) [212-214], micropores cannot be detected 
via this method. The largest pore size D5 (calculated from Tau 5) is related to the pore 
size from the BET data. When compared to BET results, the pore size D5 of HMSNs-1 
and HMSNs-2 fluctuated to some extent. However only a range of pore sizes rather than 
a uniform pore size can be seen from PALS [211]. In addition, it is noteworthy that I5 of 
HMSNs-3 is only 2.29, so it is not a significant proportion of pores in this range for this 
sample. 
 
In conclusion, BET technique using BJH for pore size calculation is only effective to 
evaluate the size of mesopores such as HMSNs-1 and HMSNs-2. When refers to material 
with a large proportion of micropores like HMSNs-3, other methods (PALS et al.) should 
be applied in the measurement of pore size. Further, the pore size of HMSNs can be 
controlled by changing the surfactants used for synthesis. Under the reaction conditions 
used here, Tweens 20 resulted in the formation of micropores (< 2nm), while P123 and 
F127 tend to yield mesopores. The possible reason for this phenomenon would be 
attributed to the surfactant behaviour during fabrication process.  
 
4.3.3 Controlled  and sustained release of HMSNs with different pore size 
 
 
In order to investigate the release behaviour of HMSNs with different pore size, 5-FU had 
been loaded into HMSNs-1, HMSNs-2 and HMSNs-3 to obtain 5-FU loaded HMSNs. 
The loading capacity and some physical parameters are listed in Table 4.4. Three HMSNs 
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exhibit a similar loading capacity of around 10%. However, HMSNs are expected to 
achieve a higher drug loading (20% ~ 50%) as they have the advantage of the high surface 
area and high pore volume. The low drug encapsulation ability of HMSNs might be due 
to the electrostatic repulsions between negatively charged silica nanoparticles and 
negatively charged 5-FU molecules. Therefore the surface of the HMSNs needs to be 
modified to improve 5-FU loading which will be specifically discussed in Chapter 6. 
 
Table 4. 4 Loading capacity and other physical parameters of HMSNs 
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Figure 4. 19 In vitro release profiles of HMSNs with different pore size in PBS with a 
pH of 5.0 
 
The release of 5-FU from HMSNs with three pore sizes was examined in phosphate-
buffered solution (PBS) with a pH of 7.4. As evidenced in Figure 4.19, all HMSNs 
displayed a sustained release and the release rate is related to the pore size of HMSNs. In 
the first 2 hours, three HMSNs demonstrated a similar release rate because at the first 
Samples Pore size (nm) Loading 
capacity (%) 
Zata potentials 
(mV) 
HMSNs-1 9.0 10.8 -5.32 
HMSNs-2 5.6 9.3 -18.6 
HMSNs-3 < 2 13.6 -27.1 
78 
 
stage of drug release (stage I presented in Figure 4.15), drug encapsulated on the surface 
or at the entrances of pores are released. 5-FU loaded HMSNs have been washed at the 
end of the drug loading procedure before freeze-drying. Therefore, some of the drugs 
attached on the surface of HMSNs were washed away. However, the release of the drug 
remained on the surface, in addition to those encapsulated in the pore entrance and near 
the pore entrance leads to the rapid release behavior of HMSNs. At this release stage, 
drug molecules were easily released from the HMSNs and the effect of pore size on drug 
release is not significant. In addition, the concentration difference of the drug between 
the environment (PBS solution) and inside the HMSNs is huge at this release stage, which 
could account for the rapid release as well. As the size of the pores is much bigger than 
that of the drug molecule (~0.5 nm), which provides enough room for the free 
transportation of the drug, the drug can be encapsulated into the pores and the cavity of 
HMSNs, not just attached on the surface. When the release proceeds further, drug stored 
in the cavity of HMSNs passes through the pores to get released. As a result, pore size 
becomes a more influential factor, determining the release speed of 5-FU. As expected, 
HMSNs with larger pores present a faster release rate in addition to a higher cumulative 
release rate. Within 24 hours, about 42.5%, 37.4% and 33.6% of 5-FU were released from 
HMSNs-1, HMSNs-2 and HMSNs-3, respectively.  
 
In the attempt to investigate the release kinetics of HMSNs, an empirical equation (Eq. 1) 
was used to describe their release behaviour. Eq. 1 was introduced by Ritger and Peppas 
in 1987 for description of solute release from non-swellable and swellable devices in 
controlled release systems [215, 216].  
 
ࡹ࢚
ࡹஶ ൌ ࡷ࢚࢔        (1) 
 
The nature logarithm form of Eq. 1 is: 
 
ܔܖ ቀ ࡹ࢚ࡹஶቁ ൌ ܔܖࡷ ൅ ࢔࢒࢔࢚       (2) 
 
79 
 
where Mt/MĞ is the accumulative release percentage of 5-FU at time t; k is a constant and 
n is the diffusional exponent indicating the transport mechanism of the drug from their 
carriers. Table 4.5 lists the diffusional exponent values (n) and their corresponding drug 
release mechanism based on literature [217, 218].  
 
Table 4. 5 Values of diffusional exponent and corresponding drug release mechanism 
 
 
Figure 4. 20 In vitro release kinetics of HMSNs with different pore size in PBS with a 
pH of 5.0 
2.4
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Diffusional exponent, n  
Drug release 
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Thin film Cylindrical 
samples 
Spherical samples 
 
< 0.50 
 
< 0.45 
 
< 0.43 
Quasi-Fickian 
diffusion 
0.50 0.45 0.43 Fickian diffusion 
 
0.50< n < 1.00 
 
0.45 < n < 1.00 
 
0.43 < n < 1.00 
Non-Fickian 
diffusion 
(Anomalous 
transport) 
1.00 1.00 1.00 Zero-order release 
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To obtain n values for three HMSNs, data extracted from drug release studies (Figure 
4.19) were calculated according to Eq. 2. n of HMSNs (the slope) were graphically 
determined by plotting  ቀெ௧ெஶቁ versus ln t (Figure 4.20). The linearity of the regression 
line was evaluated by the relevance coefficient (R2). As shown in Figure 4.20, the release 
data of three HMSNs fit well to the Ritger-Peppas model which was evidenced by a high 
R2 value (0.986, 0.981 and 0.943 for HMSNs-1, HMSNs-2 and HMSNs-3, respectively). 
n is under 0.43 for all three HMSNs, demonstrating that three HMSNs follow the Quasi-
Fickian diffusion mechanism in which 5-FU molecules transport through the pores of 
porous silica carriers without any relevant deformation and stresses during the whole 
release process. Further, although the pore size regulates the speed of 5-FU molecules 
passing through the pores, it shows no significant effect on their release mechanism. In 
other words, the release rate of drug loaded HMSNs can be adjusted to a certain rate for 
specific application while maintains their sustained release mechanism.  
 
4.4 Cytotoxicity and non-specific cellular uptake of HMSNs  
 
 
 
Figure 4. 21  Cytotoxicity of HMSNs on SW 480 cells at different concentrations 
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no toxic function on cancer cells. The biocompatibility of HMSNs was studied by an 
MTT assay. Colorectal cancer cells SW 480 cells were cultured with HMSNs of varying 
concentration for 24 hours. The cytotoxicity of HMSNs was expressed by the percentage 
of cell viability compared to the control group which was not exposed to HMSNs (Figure 
4.21). The viability of cells treated with HMSNs in the concentration range of 20 ~ 100 
Pg/mL was similar to cells that were not exposed to HMSNs, demonstrating that HMSNs 
are non-toxic and biocompatible with SW 480 cells. Therefore, HMSNs are a potential 
nanocarrier for drug delivery systems to colorectal cancer cells. 
 
To evaluate the natural ability of HMSNs to enter cancer cells, the cell uptake of FITC 
modified HMSNs by SW480 cancer cells was investigated in vitro by flow cytometry and 
fluorescence microscopy. After cell attachment in a 24 well culture plate at 37 qC in 5% 
CO2 for 24 hours, the SW480 cells (100000/well) were treated with FITC-HMSNs of 
different concentration (2, 5, and 10 μg/mL) for various incubation times (30 min, 2 h 
and 4 h).  
 
As shown in Figure 4.22a, with increased HMSNs concentration and incubation time, 
more particles were found to be internalised into SW480 cells, indicating that cell 
internalisation of HMSNs are concentration and time dependent. The confocal 
microscopy images and the corresponding 3D microscope projections showed in Figure 
4.22b-i proved that the FITC-HMSNs can penetrate the plasma membrane of SW480 cells 
and translocate into the cytoplasm.  However, the uptake of HMSNs by SW480 cells is 
relatively low, reaching a maximum of 50.8 % cells associated with HMSNs at 10 μg/mL 
and 4 h incubation time (Figure 4.22a). Thus it is important to develop targeted drug 
delivery systems that will improve the internalisation rate.  
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Figure 4. 22 Cell uptake of FITC-HMSNs with varying time and concentration by SW480 
cells (A), confocal laser scanning microscope (CLSM) images of SW480 cells cultivated 
with FITC-HMSNs (10 μg/mL) for 4 hours (B-G) and corresponding 3D microscope 
projections (H-I). Blue: the nucleus (B & E); green: FITC (C & F); merging of image B 
and C (D); merging of image E and F (G); Scale bars are 40 μm for images B, C and D 
and 10 μm for images E-I. 
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4.5 Conclusions 
 
Hollow mesoporous silica nanoparticles with large internal cavities were synthesized 
through a novel and facile method by using Eudragit S100 nanoparticles as both a core 
template and an assistant in the self-organization of surfactant micelles. The aggregation 
problem has been effectively depressed through this “Eugragit assisted” strategy. The 
HMSNs were found to exhibit a high drug loading and sustained release of chemotherapy 
drug 5-FU. The HMSNs followed the Quasi-Fickian diffusion mechanism in which 5-FU 
molecules transport through the pores of porous silica carriers without any relevant 
deformation and stresses during the whole release process. Further, pore size is an 
important parameter to regulate the release speed of 5-FU molecules from HMSNs. More 
importantly, the synthesized HMSNs were found to exhibit nontoxic to colorectal cancer 
cells and can enter colorectal cancer cells with a concentration and time dependent 
manner. The successful synthesis of HMSNs in addition to their excellent 
biocompatibility demonstrate the potential of HMSNs as effective drug carriers for 
building versatile cancer-targeted drug delivery systems. 
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Chapter 5   Modification of HMSNs for 
targeting delivery 
 
 
5.1 Introduction 
 
Nanoparticles have been extensively studied as drug carriers for cancer treatments [6, 20, 
219], because they can be passively accumulated in tumour tissues due to a phenomenon 
called the enhanced-permeation end-retention effect (EPR) [6, 7]. However, this effect is 
limited just to vascularized tumours and is usually not sufficient for a complete 
eradication of the cancer [8]. Numerous research groups are therefore trying to develop 
an efficient system for the active targeting of cancer cells by binding various ligands on 
the surface of the nanoparticles [9-11]. Such systems could provide a specific 
accumulation of the nanoparticles in targeted cells and thus represent a powerful tool to 
improve the efficacy of the cancer treatment.  
 
The over expression of certain receptors on the surface of tumour cells can be exploited 
for targeting by drug carriers. EGFR, as one of receptors, has shown to involve in cellular 
responses including proliferation and metastatic spread [49]. As a result, EGFR is one of 
the most heavily investigated tumour targeting biomarkers for constructing nanoparticles 
for targeted cancer therapeutic applications [7, 11, 220]. EGF, hepatin-binding EGF (HB-
EGF), betacellulin, transforming growth-factor-a (TGF-a), epiregulin and amphiregulin 
are six known endogenous ligands of EGFR. Although any of these ligands can be used 
as a targeting agent for EGFR, EGF with a good compromise between the binding affinity 
and the size of the molecule (EGF, 6.1 kDa) is one of the most commonly detected factors 
in humans [8]. It is hypothesized that EGF as a ligand to EGFR on the surface of 
nanocarriers will exhibit specific delivery of anticancer drug, 5-FU, into colorectal cancer 
cells, and thus enhance the resultant anti-cancer activity and reduce the side effects of 
anticancer drugs. 
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Several surface modification methods have been implemented to covalently couple EGF 
to the surface of nanoparticles [221] and carbodiimide chemistry has been found to be a 
preferential method for the binding of EGF to silica nanoparticles [75, 221, 222]. For a 
HMSNs based drug delivery system, the challenge lies in successfully maintaining an 
intact structure while combining the targeting ligands and drugs into nanocarriers. In 
many cases, HMSNs based targeted delivery systems end up with collapsed HMSNs 
because too many functionalization steps were applied and each of them might involve 
several times of centrifugations and re-dispersions which negatively affect the stability 
of HMSNs. Therefore, facile method with less steps for EGF immobilization is of great 
importance.  
 
In order to protect the structure of HMSNs, a facile, single step strategy for EGF grafting 
will be introduced, where EGF is covalently linked to the surface of amine functionalized 
HMSNs by using aqueous 1-(3-(dimethylamino)propyl)-3- ethylcarbodiimide 
hydrochloride (EDC) and N-Hydroxysuccinimide (NHS) as promoters. The covalent 
attachment of the EGF to the particle surface was first confirmed by time of flight 
secondary ion mass spectrometry (ToF-SIMs). Such functionalized particles are proved 
by cell experiments to be suitable candidates as drug carriers for targeting delivery due 
to the combination of the large loading capacity and the targeting function.  Importantly, 
the control of the quantity of EGF attachments on the surface of HMSNs was achieved 
by changing the EGF concentration during the grafting. An increase in EGF on HMSNs 
will increase the targeting efficiency to colorectal cancer cells. 
 
5.2 A facile, one step strategy for EGF labelling 
 
The covalent binding of proteins, such as EGF, to nanoparticles is highly challenging 
since their active conformation must be preserved during the binding process, which 
limits the choice of the reaction conditions. Several surface modification methods have 
been implemented to covalently couple EGF to the surface of nanoparticles [221] and 
carbodiimide chemistry is found to be the most effective method for the binding of EGF 
to silica nanoparticles [75, 221, 222]. 
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Carbodiimide chemistry is to generate crosslink between carboxylic groups and primary 
amines using EDC and NHS and is a versatile and powerful tool for preparing 
biomolecular probes, crosslinking peptides and proteins, and immobilizing 
macromolecules for use in numerous cell biology detection and protein analysis. EGF as 
a protein, contains both carboxylic acids and primary amines (C-and N-termini, and also 
in amino acids presenting in side-chains of EGF). Thus, HMSNs bearing either amine or 
carboxyl groups can be easily crosslinked to EGF by the utility of EDC and NHS.  
 
However, most previous research only focused on generating carboxyl functionalized 
silica nanoparticles for the binding of EGF [75, 221, 222] and the comparatively simple 
route of preparing amine functionalized ones were not reported. In particular, HMSNs 
with a hollow cavity are often obsessed with the problem of collapse when undergoing 
too many times of centrifugation or modification steps. Compared to amine group 
functionalization, carboxyl group functionalization of silica nanoparticles is relatively 
complicated as it involves more than one step [223, 224]. For example, Kralj et al 
achieved carboxyl-functionalized nanoparticles using a follow-up reaction of amine-
functionalized surfaces [225] and Yiu et al firstly modified silica nanoparticles with 
cyano groups, then oxidated them to carboxyl groups [226]. As a result, carboxyl 
functionalization of silica nanoparticles is more time consuming and might negatively 
affect the physicochemical properties (such as suspension stability) of the products. To 
overcome these shortcomings, amine modification was employed to produce HMSNs 
with functional groups while maintaining an intact structure for EGF labelling.  
 
5.2.1 Synthesis of amine functionalized HMSNs  (HMSNs-NH2) 
 
HMSNs-NH2 were synthesized by co-condensation method in which NH2 groups were 
introduced during the fabrication process. This results in a more homogeneous coverage 
of functional groups onto HMSNs. As shown in TEM and SEM images (Figure 5.1), all 
morphologic features in plain HMSNs are remained in HMSNs-NH2, such as the hollow 
structure (Figure 5.1c-f), the particle diameter (~150 nm), and a good dispersion, making 
them very suitable for targeted drug delivery systems. The deliberately broken HMSNs-
NH2 shown in Figure 5.1c and f further proved their hollow structure [102]. It is 
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noteworthy that most HMSNs-NH2 have intact structure (Figure 5.1a and d). Similar to 
HMSNs’ characterization, XRD and BET were performed to confirm the mesophase of 
HMSNs-NH2. A broad Bragg diffraction peak within the range of 2θ=0-3˚ was found in 
Figure 5.2b, illustrating that HMSNs-NH2 have a mesoporous structure [146, 186, 187]. 
BET results were collected and presented in Figure 5.2a, in addition to a classical IV type 
isotherm, a hysteresis loop at relative pressures (P/P0) of 0.45-0.9 was observed which 
further proved the mesoporous structure of HMSNs [189]. The pores of HMSNs-NH2 
have a narrower size distribution centred at 3.0 nm (Figure 5.2c). The specific surface 
area and pore volume of HMSNs-NH2 are 544m2/g and 0.57cm3/g, respectively.  
 
It is noteworthy that, compared to Figure 4.4, the Bragg diffraction peak of HMSNs-NH2 
(Figure 5.2b) shifted to a lower angle, which could be due to the grafting of –NH2 
functional groups.  According to the TEM, SEM and XRD results, the introduction of –
NH2 onto HMSNs didn’t have significant influence on the porous structure of HMSNs 
which is used for the drug loading and controlled release. However, due to the coverage 
of –NH2, slight decrease in the surface area has been identified via BET results.  
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Figure 5. 1. a, b & c) SEM images of HMSNs-NH2 and d, e & f) TEM image of HMSNs displaying hollow interior; c & f are broken HMSNs-
NH2 showing their hollow structure 
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Figure 5. 2 A) Nitrogen adsorption-desorption isotherm; B) Small angle XRD pattern of 
HMSNs-NH2; C) BJH pore size distribution.   
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NH2 groups were qualified via FTIR and quantified by thermogravimetric analysis (TGA) 
and NMR techniques. FTIR spectra of HMSNs-NH2 and the control sample (HMSNs) 
are shown in Figure 5.3. Both samples have strong bands located at around 460 cm-1 (δO–
Si–O), 1100 (ʋasym. Si–O–Si), and 3300-3500 cm-1 (ʋSi–OH), confirming the presence of the 
SiO2 inorganic phase. In particular, the bands with the highest intensity, centred at 1089 
and 1073 of HMSNs and HMSNs-NH2, respectively are associated with the SiO2 
stretching vibration [227]. The NH2 functionalization is clearly evidenced by the bands 
detected at around 1500 cm-1, which is unambiguously attributed to the NH bending 
vibration [227-230]. Results obtained by FTIR prove the effective NH2 functionalization 
of mesoporous silica nanoparticles.  
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Figure 5. 3 FTIR spectra of HMSNs-NH2 and HMSNs 
 
The TAG thermograms and 29Si single pulse excitation (SPE) spectrum were given in 
Figure 5.4  for the evaluation of NH2 quantity. A weight loss of 14.6% was found in 
HMSNs while HMSNs-NH2 presented an increased weight loss percentage of 21.5% 
(Figure 5.4a). The higher weight loss of HMSNs-NH2 is due to the degradation of grafted 
functional groups, inferring that around 5.9% (w/w) of HMSNs-NH2 was related to NH2 
immobilization. The 29Si SPE of HMSNs-NH2 spectrum is shown in Figure 5.4b in which 
Qm (m=2-4 indicating 2, 1 or 0 –OH groups are linked to Si) and T signals provide 
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information of silanol groups and grafted functional groups (-NH2), respectively [228, 
231]. The peaks at -110, -100 and -90 ppm are associated to Q4 [(SiO)4Si], Q3 
[(SiO)3SiOH] and Q2 [(SiO)2Si(OH)2], given that –OH groups of the HMSNs react with 
amine silane (APTES) for –NH2 immobilization which results in a decrease in the number 
of –OH groups on HMSNs. Thus, the presence of signals with decreased amount of –OH 
groups (Q4 & Q3) in addition to T signal can reveal the successful grafting of –NH2 [231-
235]. The relative concentration of -NH2 in HMSNs (15%) was calculated by taking the 
signal summation (T + Q2 + Q3 + Q4) as 100%.  
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Figure 5. 4 TGA thermograms of HMSNs & HMSNs-NH2 (a) and 29Si single pulse 
excitation (SPE) spectrum of HMSNs-NH2 
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5.2.2 Preparation of EGF grafted HMSNs and characterization of EGF labelling 
 
 
 
Figure 5. 5 Schematic diagram showing the process of EGF grafting onto HMSNs 
 
A facile, single-step process was developed to graft EGF onto HMSNs (Figure 5.5).   
After grafting, the characterization of EGF attachment is a crucial subsequent step. 
However, since the amount of EGF on HMSNs is very low, the determination of EGF 
immobilization emerges to be a big challenge as most characterization methods, such as 
thermo-gravimetric analysis (TGA), energy-dispersive X-ray spectroscopy (EDX), 
electron energy loss spectroscopy (ELLS) and even X-ray photoelectron spectroscopy 
(XPS) have their limit. As EGF is used as a targeting ligand to target cancer cells [75], 
cell and/or even animal experiments were carried out by researchers to evaluate the 
effectiveness of EGF and thus validate their success and effectiveness of the grafting 
[236-238]. For example, comparison between EGF and non-EGF grafted samples in 
cellular uptake by cancer cells was largely used in the illustration of effective EGF 
grafting. Even though these passive methods are useful, they cannot provide direct 
information on stability and density of targeting ligands on the surface of nanoparticles 
and thus fail to control the quantity of targeting molecules on nanoparticles for specific 
application.  
 
Time of flight secondary ion mass spectrometry (ToF-SIMS) as a highly specific 
analytical tool in the study of proteins, has been shown to be a powerful technique in the 
detection of extremely low amount of proteins which were undetectable by XPS [239]. 
Inspired by the high chemical selectivity and surface sensitivity of ToF-SIMS [239-242], 
it was hypothesized that ToF-SIMS would allow for the observation of successful EGF 
attachment to the HMSNs in addition to the quantity of the EGF immobilization. 
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In this regard, ToF-SIMS analysis was performed on HMSN surfaces before and after 
EGF grafting. Amino acids presenting in the backbone of proteins such as EGF 
are cracked into smaller immonium ions (amino acid mass fragments) during the 
measurement of TOF-SIMS. Identification of characteristic amino acid mass fragments 
by ToF-SIMS lead to its extremely high sensitivity (better than XPS) for the detection of 
proteins [240].  
 
Figure 5.6 displays the positive survey ToF-SIMS spectra (m/z 0 - 200) for the 
unmodified HMSNs, amine group grafted HMSNs (HMSNs-NH2), EGF and HMSNs 
labelled with EGF (HMSN-NH2-EGF). For the HMSN surfaces (Figure 5.6a) the intense 
ion signals at nominal m/z 28, 29 and 45 amu can be attributed mainly to Si+, SiH+ and 
SiHO+ fragments [239]. Some peaks raised by the amine groups on HMSNs-NH2 surface 
are shown in Figure 5.6b. When compared to HMSNs, HMSNs-NH2 have new peaks at 
15, 41, 43, 55, 57 and 69 amu which correspond to HN+, C3H5+, C2H5N+, C3H5N+, 
C3H7N+ and C3H3NO+ fragments, confirming the successful grafting of NH2. 
 
A control spectrum of the EGF is presented in Figure 5.6c. The main peaks at nominal 
m/z 15, 27, 41, 43 and 55 happen to overlap with those of HMSNs-NH2. However in 
addition to these peaks, intense peaks at nominal m/z 30, 70, 72, 73, 84, 86, 110 and 130 
are observed which correspond to CH4N+, C4H8N+, C4H10N+, C2H7N3+, C5H10N+, 
C5H12N+, C5H8N3+ and C9H8N+ and can be attributed to fragments from the EGF 
backbone [242].  
 
Figure 5.6d presents the ToF-SIMS spectra for EGF grafted HMSN surfaces. Ion signals 
of the major fragments for both HMSNs and EGF were detected. For example, ion signals 
of unmodified HMSNs reported above at nominal m/z 28, 29 and 45 amu can be seen. In 
addition, the ion signals at nominal m/z 30, 70, 72, 73, 84 and 86 amu which were 
assigned to fragments of EGF from the spectra of pure EGF (Figure 5.6c) are present 
thereby suggesting successful EGF attachment. Interestingly, besides these characteristic 
ion signals of HMSNs and EGF, new intense ion signals at nominal m/z 58 and 129 were 
detected which are related to C3H8N+ and C5H13N4+ fragments. After grafting onto the 
HMSNs surface, the conformation and orientation of EGF might change which can 
subsequently lead to different distributions of the amino acid fragments detected in a 
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static ToF-SIMS experiment [241]. Therefore, these new peaks could be seen as 
characteristic peaks of EGF grafting using the methods we illustrated above. These ToF-
SIMS results demonstrate the successful EGF labelling of HMSNs. 
 
 
 
 
Figure 5. 6 Positive survey mass spectra for: (A) HMSNs surface; (B) HMSNs-NH2 
surfaces; (C) EGF; (D) HMSNs-NH2-EGF. 
  
95 
 
5.2.3 The effect of EGF concentration on surface chemistries of the HMSNs 
 
The stability and density of EGF on the surface of HMSNs may play a very crucial role 
in targeting the cancer cells, though only one EGF molecule is needed to bind to the EGFR 
on the cell to initiate internalisation. However, the more EGFs grafted onto the HMSNs, 
the higher the probability of HMSNs-NH2-EGF targeting the cancer cells.  It is 
consequently important to quantify the EGF on the surface of HMSNs. In this regard, 
EGF grafting was explored by varying the concentration of EGF during the attachment 
procedure from 0.1 to 0.8 mg/ml and analysing the surfaces with ToF-SIMS (Figure 5.7). 
 
 
Figure 5. 7 Positive survey mass spectra of HMSN-NH2-EGF surface using different 
EGF concentration: 0.1,0.2,0.4 and 0.8 mg/ml. 
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Figure 5. 8 Plot of ratios of the intensities of the 28 m/z (from HMSNs) to 59 m/z, 70 
m/z and 58 m/z (from EGF) 
 
It appears that the EGF concentration has a limited effect on the resulting surface as no 
significant differences can be indentified between samples prepared with 0.1, 0.2, 0.4 and 
0.8 mg/ml of EGF (Figure 5.7). Differences, however, emerge upon close inspection of 
the ratios of 28/59, 28/70 and 28/58 mass fragments. 28 m/z is an ion signal specific for 
HMSNs while 59 m/z, 70 m/z and 58 m/z are specific for EGF, thus the ratios of 28/58, 
28/70 and 28/58 track the relative amount of EGF grafted on the surface of HMSNs. 
Figure 5.8 displays that the ratio of 28/59 decreases with an increase in EGF concentration, 
therefore suggesting that an increase in EGF concentration can lead to a greater amount 
of EGF to be attached onto the surface of HMSNs. As ToF-SIMS is a very surface specific 
technique (penetration depth < 1.5 nm) [241], an increase in EGF surface coverage would 
result in less silica but more protein being detected, thus the ratio of 28/59 decreased. 
Moreover, the same trend can be seen for the 28/70 and 28/58 ratios.  
 
The differences between the samples shown in Figure 5.7 are developed from comparing 
only a few peaks selected from ToF-SIMs spectra and the information contained in 
unselected peaks is disregarded. Although this univariate analysis is useful, it is not 
enough to properly evaluate the EGF attachment of these surfaces, because the remaining 
peaks can provide important information for fully classifying the differences of surface 
chemistries between samples. Thereby, PCA was employed to extract the most influential 
factors from the complex mass spectra and to help in data interpretation. In the attempt to 
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classify the TOF-SIMS data by PCA, 35 peaks listed in Table 5.1 were used. The selection 
of these peaks is based on the assignments taken from literature [243-246]. Only the 
characteristic nitrogen containing peaks were studied which arise from amino acid 
fragments ions so they are indicators of EGF immobilization. 
 
Table 5. 1 Positive fragment ions (immonium ions) used in PCA 
 
 
  
NO. Fragment m/z No Fragment m/z 
1 CH4N+ 30 18 C4H10N+ 72 
2 C2H4N+ 42 19 C2H7N3+ 73 
3 CH3N2+ 43 20 C3H8NO+ 74 
4 CH4N2+ 44 21 C4H6NO+ 84 
5 C2H6N+ 44 22 C5H10N+ 84 
6 C2H3S+ 47 23 C5H12N+ 86 
7 C3H4N+ 54 24 C3H7N2O+ 87 
8 C3H6N+ 56 25 C3H8NO2+ 88 
9 C2H4NO+ 58 26 C4H10N3+ 100 
10 C3H8N+ 58 27 C4H11N3+ 101 
11 CH5N3+ 59 28 C4H8NO2+ 102 
12 C2H5S+ 61 29 C7H7O+ 107 
13 C4H6N+ 68 30 C5H8N3+ 110 
14 C4H5O+ 69 31 C8H10N+ 120 
15 C3H4NO+ 70 32 C5H11N4+ 127 
16 C4H8N+ 70 33 C5H13N4+ 129 
17 C3H3O2+ 71 34 C9H8N+ 130 
   35 C9H8O+ 132 
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Figure 5.9 displays the scores plot of positive fragment ions on PC1 and PC2 for the EGF 
grafted HMSN samples and their corresponding loading plots show the influence of each 
amino acid peak on PC1 and PC2. Each sample was characterised by 35 groups of positive 
fragment ions derived from replicated positive ion mass spectra. About 91 % of the total 
variances were captured by PC1 and PC2 revealing that these two-PC’s models retain the 
most of the original information.   
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Figure 5. 9 Scores on PC1 and PC2 (a) and corresponding loading plots on PC1 (b) and 
PC2 (c) of immonium ions from static positive spectra of HMSNs-NH2-EGF prepared 
with EGF concentration of 0.1, 0.2, 0.4 and 0.8 mg/ml 
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As shown in Figure 5.9a, with an increase in EGF concentration, a decrease of PC1 scores 
was observed. The EGF concentration of 0.1 and 0.2 mg/ml groups having the highest 
PC1 scores overlaps with both PC’s, which reflects their similar surface chemistries in 
terms of nitrogen species. Marked differences are observed when the EGF concentration 
is increased further. When the concentration increases to 0.4 mg/ml, the samples have 
negative scores on both PC1 and PC2 and that are separated from low concentration ones 
(0.1 and 0.2 mg/ml). In contrast, the samples with 0.8 mg/ml EGF concentration have 
negative scores on PC1 but positive scores on PC2 and that are well separated from other 
three samples, signifying that they have quite different surfaces. This may be due to more 
EGF proteins being attached onto the HMSNs surfaces. Figure 5.9b and c indicate a high 
negative loading of C4H8N+ (at m/z 70 amu) on PC1 and C3H8N+ (at m/z 58 amu) on PC2, 
which reflects these two fragments contribute the most to the differences between samples 
with different amount of EGF attachments.  
 
In summary, PCA on the ToF-SIMS data demonstrates EGF has been attached onto the 
NH2 modified HMSNs surface and different concentration of EGF grafting leads to 
different surface chemistries of the final products.  
 
5.2.4 Analysis on immonium ions distinguishing samples with different surface 
chemistry 
 
The loadings of immonium ions on PC1 and PC2 point at the peaks (CH4N+, C2H4N+, 
C3H8N+, CH5N3+ and C4H8N+) that discriminate the groups (Figure 5.9 b and c). Therefore, 
the relative intensities of these ions, which have the most impact on distinguishing 
samples with different surface chemistry, are closely related to the amount of EGF that 
has been grafted onto the nanoparticles. The detailed effect of EGF concentration on the 
amount of EGF attachments can be observed by comparing the relative intensities of these 
main immonium ions between different samples. In order to gain an acute insight into the 
quantity of EGF on samples, Si+ and SiOH+ fragments are included in the analysis. Thus, 
each sample was characterised by 7 groups of immonium ions derived from replicated 
positive static secondary ion mass spectra.  
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Figure 5. 10 Comparison of characteristic immonium ions intensities between samples 
 
Shown in Figure 5.10, unmodified HMSNs had significantly high Si+ and SiOH+ 
intensities but low immonium ions intensities (almost zero), consistent with the fact that 
no EGF protein is present on the surface of this sample. NH2 functionalized HMSNs 
present a similar trend to unmodified HMSNs, however these samples have relatively 
high CH4N+ and C2H4N+ signals due to the presence of amine functional groups on the 
surface. On the contrary, all EGF grafted samples had enhanced immonium ion signals 
and decreased silica intensities.  Further, with the increase in EGF concentration, the Si+ 
and SiOH+ intensities decreased inferring that EGF concentration had a positive effect on 
facilitating the EGF grafting.  
 
Significant differences can be seen by close inspecting the changes of immonium ions 
signals between samples. Firstly, CH5N3+ and C4H8N+ fragments are the EGF indicators 
since HMSNs-NH2 didn’t show such fragments. The intensities of these two immonium 
ions increased along with an increase in EGF concentration revealing more EGF has been 
grafted onto the surface of HMSNs, which is consistent with the gradual decrease of silica 
signals. If the intensities of these two fragments of pure EGF were set as 100%, at the 
highest EGF concentration (0.8 mg/ml), the detected intensities of these two fragments 
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of HMSNs-NH2-EGF are 66.7 % and 78.6%, respectively revealing more than 50% of 
EGFs was grafted on HMSNs. Secondly, the CH4N+ and C2H4N+ fragments presented in 
EGF and the amine group grafted samples varied differently. Along with an increase in 
EGF concentration, although a gradually growing trend was not observed with these two 
ions signal intensities, four EGF grafted HMSNs showed improved signals compared to 
pure EGF and HMSNs-NH2 samples. These enhanced intensities were attributed to the 
synergy of joint signals of CH4N+ and C2H4N+ generated by EGF and free amine groups.  
Lastly, C3H8N+ fragment was uniquely shown in EGF grafted samples.  
 
ToF-SIMS combined with PCA were proved in this study to be able to evaluate the 
binding efficiency between EGF and silica nanoparticles. This method could be extended 
as a general approach to analyse protein biomarkers in targeted drug delivery systems. 
 
5.3 Comparison of newly developed grafting method with other  
           methods 
 
5.3.1 Superior EGF grafting efficiency by the new grafting method  
 
As mentioned before, HMSNs with a cavity inside tend to form a defect structure as too 
many functional steps or harsh experimental procedures (such as high temperature) are 
involved in the process which will cause the collapse of HMSNs, a main issue that need 
to be considered. Therefore, in order to protect HMSNs from damage, a more facile 
process with fewer steps to graft EGF onto HMSNs was developed. To compare, EGF 
grafted HMSNs were prepared via two routes and final products were named as HMSN-
COOH-EGF (produced from commonly use route) and HMSN-NH2-EGF (fabricated 
from the newly developed route) and characterized through ToF-SIMS (Figure 5.11).  As 
shown from ToF-SIMS results, ion signals of major fragments of both silica and EGF 
were detected in both HMSN-COOH-EGF and HMSN-NH2-EGF. The intense ion signals 
at nominal m/z 28 can be attributed to Si+, while peaks at nominal m/z 58, 70, 71, and 72 
amu correspond to EGF. Importantly, although EGF can be attached to HMSNs through 
either of the routes, it is worth noticing that HMSN-NH2-EGF have demonstrated 
enhanced EGF signals and decreased silica signals inferring more EGF were introduced 
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to covered the surface of HMSNs. Therefore, less silica signals were detected in this 
sample. This result proved that new EGF immobilization method has a superior EGF 
grafting efficiency when compared to the commonly used ones.  
 
 
 
Figure 5. 11 Routes of EGF lebelling based on carbodiimide chemistry: (A) A commonly 
used route; (B) Newly developed route with reduced steps to protect HMSNs from 
damage and Positive survey mass spectra for: (C) HMSN-COOH-EGF surface; Insets: 
High mass resolution of static ToF-SIMs in the 70-72 amu region. (D) HMSNs-NH2-EGF 
surfaces; 
 
Further, SEM images were taken to study the morphology of EGF grafted HMSNs 
through different routes (Figure 5.12). After EGF grafting, HMSN-NH2-EGF remain the 
intact structure while HMSN-COOH-EGF show broken particles. This is due to more 
modification steps applied and thus more centrifugation rounds were involved in route 1 
(Figure 5.11).  
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Figure 5. 12 SEM images of HMSN-COOH-EGF (a) and HMSN-NH2-EGF (b) 
 
 
5.3.2 Increase EGF labels on HMSNs for enhanced targeting efficiency 
 
The use of TOF-SIMs provides opportunities to determine relative EGF concentration on 
HMSNs. Therefore, the amount of EGF grafted onto HMSNs was compared by changing 
the EGF concentration during modification process. In 5.2.3 and 5.2.4, it was reported 
that increasing EGF concentration can result in higher EGF attachments on nanoparticles 
via route 2 illustrated in Figure 5.11.  Again, 4 different EGF concentrations for EGF 
grafting (0.1, 0.2, 0.4 and 0.8 mg/ml) were compared based on carboxyl group 
functionalized HMSNs (route 1 in Figure 5.11). Unfortunately, no differences can be 
found from these four spectra (Figure 5.13a). Moreover, as shown in Figure 5.13b, 
although different EGF concentration were employed, all samples were overlapped along 
both PC’s indicating their similar surface chemistries (a comparison to Figure 5.9). From 
Figure 5.13a and b, 4 important ion signals were selected: 28 m/z  (specific for HMSNs), 
30 m/z, 44 m/z and 58 m/z (correspond to EGF). The ratio of silica to protein: 28/30, 
28/44 and 28/58 of different EGF grafted samples was calculated and presented in Figure 
5.13c (a comparison to Figure 5.8).  When the EGF concentration was increased gradually 
from 0.1-0.8 mg/ml, rather than a regular trend, the ratio of 28/58, 28/44 and 28/30 
fluctuated. Thereby an effective control of EGF quantity on HMSNs is failed with the 
commonly used route for EGF immobilization.  
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A new grafting method was developed specific to improve the EGF grafting efficiency of 
HMSNs in 5.3.1. This new strategy for EGF labelling can tailor make HMSN-NH2-EGF 
with a certain amount of EGF attachments on HMSNs (illustrated in 5.2.3). This will 
contribute to more versatile applications of EGF grafting. A precise control of EGF on 
HMSNs could lead to an effective regulation of nanoparticles entering the cells and 
thereby controlling the drug concentration in targeted cells. It is known that the cancer 
development is a multistep process where different drug concentration and exposure time 
were required at different stages.  
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Figure 5. 13 Positive survey mass spectra  (a) and scores on PC1 and PC2 (b) of HMSN-
COOH-EGF surface using different EGF concentration: 0.1,0.2,0.4 and 0.8 mg/ml; and 
plot of ratios of the intensities of the 28 m/z (from HMSNs) to 30 m/z, 44 m/z and 58 m/z 
(from EGF) (c) 
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5.4 Effectively target colorectal cancer cells by EGF grafted HMSNs  
 
5.4.1 Effective targeting effect of HMSN-EGF to EGFR positive CRC cells 
 
 
 
 
Figure 5. 14 Cellular uptake of both EGF grafted and plain HMSNs in SW480 cells 
 
Targeting is essential for drug delivery systems as it has the potential to precisely target 
and kill cancerous cells while leaving normal cells unharmed. To configure HMSNs for 
targeted drug delivery, EGF was grafted onto HMSNs (HMSN-EGF) to target the EGFR 
positive colorectal cancer cells (SW 480 cells). HMSNs with and without EGF attachment 
were covalently linked to a fluorescent dye (FITC), making them visible by fluorescence 
microscopy and flow cytometry. SW 480 cells were treated with varying doses (1, 2, 5, 
10 and 20 μg/ml) of HMSN-EGF for 2 hours in addition to non-EGF grafted HMSNs for 
control.   
 
With increased nanoparticle concentration, more HMSNs and EGF-HMSNs are found to 
be associated with SW480 cells (Figure 5.14), indicating that the uptake of both HMSNs 
and EGF-HMSNs by the cells are concentration dependent. It was found for nanoparticle 
concentrations below 20 μg/ml, the cellular uptake of HMSN-EGF was higher than 
unmodified HMSNs (Figure 5.14).  In order for nanoparticles to internalise into > 90 % 
of cells only 5 μg/mL of EGF-HMSNs was required while for unmodified HMSNs 20 
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μg/mL was necessary to achieve the same result. This improved internalisation was due 
to the ability of the targeting molecules, EGF, to attach to their receptors, EGFR, which 
were found to be overexpressed on cancer cells. Therefore EGF attachment can facilitate 
the cellular uptake of nanoparticles and the EGF-EGFR reaction could account for this 
observation.  
 
On the other hand, at a concentration of 20 μg/mL both HMSNs and HMSN-EGF were 
found to be taken up by ~ 100% of cells. However it is more preferable to deliver a smaller 
quantity of HMSNs to minimise side effects to patients. Additionally, due to the targeting 
function of EGF it will be possible to reduce systemic elimination of HMSNs from the 
body and the problematic delivery of chemotherapeutic drugs to normal cells. 
 
Figure 5.15 a-f displays confocal microscopic images of SW480 cell incubated with FITC 
labelled HMSN-EGF and HMSNs (10 μg/mL) for 0.5, 2 and 4 hours. Green dots are 
nanoparticles and cell nucleus were visualized in blue colour. As observed in Figure 5.15 
a-f, with increased time, more HMSNs and EGF-HMSNs are taken up by SW480 cells, 
demonstrating that the uptake of both HMSNs and EGF-HMSNs by the cells are time 
dependent. Also, the uptake of HMSN-EGF into target cells was significantly higher than 
that of HMSNs when the same incubation time was applied, consistent with the fact that 
EGF attachment enhances the capacity of nanoparticle entering the targeted cells (EGFR 
positive cells).  
 
To further prove that the particles are actually penetrating into the cells, the cytoplasm of 
the cells was stained and 3D projections of the cellular uptake of EGF-HMSNs were 
presented in Figure 5.15 g-h. The cells were sliced with a slice thickness of 1 μm and all 
the slices were combined and presented as a 3D projection. Green dots were seen within 
the 3D projections indicating the EGF-HMSNs have been internalized into the cells.  
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Figure 5. 15 (a-c): the confocal laser scanning microscope (CLSM) images of SW480 
cells cultivated with 10 μg/mL FITC-HMSNs; (d-f): CLSM images of SW480 cells 
cultivated with 10 μg/mL FITC-EGF-HMSNs; and (g-h): 3D microscope projections of 
SW 480 cells cultivated with 10 μg/mL FITC-EGF-HMSNs for 4h.Green dots are 
nanoparticles while cell nucleus were visualized in blue colour.  
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5.4.2 Reduced targeting effect of HMSN-EGF by pretreating SW480 cells with 
free EGF  
 
 
 
Figure 5. 16.  The cellular uptake rate (mean fluorescence intensity) of HMSN-EGF and 
HMSNs in SW 480 cells with or without 5 μM of free EGF pretreatment 
 
As HMSN-EGF had a higher uptake in SW 480 cells, to validate that this enhanced uptake 
rate is facilitated specifically by the EGF targeting bioconjugates, SW480 cells were 
treated with 5 μM of free EGF before incubation with 5 μg/mL of HMSN-EGF and plain 
HMSNs. As seen in Figure 5.16, when cells were pretreated with free EGF, the ability to 
internalize HMSN-EGF decreased while the capacity to internalize plain HMSNs 
remained the same. After pretreating with free EGF, the mean fluorescence intensity (MFI) 
value of cells treated with HMSN-EGF decreased about 25%. However, no obvious 
differences can be seen in the uptake of plain HMSNs between cells with and without 
free EGF pretreatments. This demonstrated that part of the EGF receptors on the cell 
surface can be occupied by free EGF which may inhibit the binding between HMSN-EGF 
and EGFR. This result can be further confirmed by the confocal microscope images, as 
seen in Figure 5.17, the uptake of the nanoparticles into target cells was visualized by 
luminescence of green emitting FITC (green dots) and the cell nucleus was shown in blue 
colour. After 2 hours of treatment with HMSNs, only a few of the cells were seen 
associated with HMSNs while the uptake of HMSN-EGF was much higher. After 
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pretreating with free EGF, cells associated with HMSN-EGF decreased indicating the 
uptake of HMSN-EGF was inhibited.    
 
 
     
                             HMSNs                                    HMSN-EGF                     HMSN-EGF + free EGF 
 
Figure 5. 17. Confocal microscope images of EGF-HMSNs and HMSNs in SW 480 cells. 
 
5.4.3 Non-targeting effect of HMSN-EGF to EGFR negative cell line SW620  
 
The cellular uptake studies on the SW 480 cells have demonstrated that HMSN-EGF 
exhibited a higher uptake rate than HMSNs and the cellular uptake can be inhibited by 
pre-treating the cells with 5 μM of free EGF. To further confirm that the higher uptake 
of HMSN-EGF was mediated specifically via EGFR, cellular uptake experiments were 
conducted on SW 620 cells which do not express EGFR. 
 
 As shown in Figure 5.18, the SW 620 cells were treated with different concentrations of 
HMSNs or HMSN-EGF for 2 hours and the MFI were measured by flow cytometer. 
Similar to the cellular uptake in SW 480 cells, the cell uptake of both HMSN-EGF and 
HMSNs were concentration dependant: the mean fluorescence intensity increased as the 
concentration of nanoparticles increased. However, the difference between HMSN-EGF 
and HMSNs is not obvious in this cell line as the MFI of cells treated with HMSNs and 
HMSN-EGF on each concentration point was close to each other.  
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Figure 5. 18. The mean fluorescence intensity in the SW 620 cells treated with different 
concentrations of HMSNs or EGF-HMSNs for 2 hours. 
 
5.5 Conclusions 
 
To precisely kill colorectal cancer cells, HMSNs were successfully synthesized and 
bioconjugated with specific receptor ligand EGF. The construction of a targeting 
molecule (EGF) to the surface of HMSNs was achieved through a newly developed 
strategy, where the carboxyl groups of EGF were conjugated to an amine terminated 
mesoporous silica surface. This method to graft EGF on silica surface proved be facile 
and effective and can protect HMSNs from damage during modification. The accurate 
control of the number of EGF attachments on HMSNs was achieved via this method, 
proving its superiority to commonly used ones.  
 
The characterization of EGF attachments was carried out using ToF-SIMS. The ToF-
SIMS data revealed the successful grafting of EGF attachments. PCA was implemented 
to further extract and clarify the information from the complex ToF-SIMs data and 
illustrated that EGF concentration played a crucial role in the binding efficiency of the 
EGF to the nanoparticles. In all cases, the combination of ToF-SIMS and PCA proved 
0
200
400
600
800
1000
1200
1400
0 5 10 15 20 25
M
FI
Particle concentration
HMSNs-FITC
EGF-HMSNs-FITC
112 
 
the effectiveness of the method in classifying relative surface concentration of EGF 
attachments. 
 
In vitro experiments present direct evidences that HMSN-EGF can efficiently and 
selectively enter the EGFR positive colorectal cancer cells (SW480). However, the 
targeting function of the current drug delivery system had no effect on EGFR negative 
cancer cell lines SW620. More importantly, cellular uptake results on SW 480 and SW 
620 cells suggested that the EGF-EGFR endocytosis pathway accounted for the improved 
internalisation of HMSN-EGF. Therefore, by utilizing the EGF-EGFR interactions, the 
specific delivery of drugs in colorectal cancer cells can be achieved, which could 
guarantee a more precise killing of cancer cells without damaging the normal cells.  
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Chapter 6   Functionalization of HMSNs for 
favourite 5-FU loading and siRNA 
encapsulation 
 
 
6.1 Introduction 
 
Inadequate intracellular concentration of anti-cancer drug is always associated to the 
failure of cancer therapy as drug concentration is a key parameter for successful treatment. 
The excellent targeting function of current drug delivery system was demonstrated based 
on HMSNs in last chapter, which can boost the number of nanoparticles to be internalized 
by targeted cell population and thus increasing the amount of drug transported and 
accumulated into cancer cells. However, even though with high surface area, high volume 
and large cavity, HMSNs showed a relative low 5-FU loading capacity (~ 10%) which 
may be due to the electrostatic repulsion between the drug and the carriers. In this case, 
compared to those carriers with a higher drug loading capacity, more HMSNs was 
required to be taken up by cancer cells to achieve an effective cure concentration for 
cancer therapy. From a technical point of view, it is more preferable to deliver a smaller 
quantity of HMSNs to minimise patient side effects [247]. Therefore, increasing the drug 
loading capacity of HMSNs is essential for further optimizing the current drug delivery 
system. The encapsulation of drugs in nanoparticles can be improved by functionalization 
[248] or by optimizing the drug encapsulation conditions. Precisely controlling the 
grafting of chemical groups on HMSNs would result in an enhancement in drug loading. 
 
On the other hand, drug resistance is another issue associated with cancer therapy. Even 
though a very high 5-FU loading and excellent targeting behaviour of HMSNs could be 
achieved, the therapeutic effect of 5-FU is still limited due to the appearance of drug 
resistance in cancer cells. To overcome this problem, siRNA encapsulation appeared to 
be another potential application for HMSNs. Therefore, in this chapter, the studies focus 
on the modifications of HMSNs for enhanced 5-FU loading and effective siRNA 
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encapsulation. Different functionalizations of HMSNs are introduced in this chapter to 
make HMSNs more versatile for particular applications and ways of improving siRNA 
encapsulation of HMSNs are explored.  
 
6.2 Enhanced 5-FU loading capacity of HMSNs by precise functionalization 
 
6.2.1 Study of 5-FU partition coefficient 
 
The partition coefficient (Pow) is defined as the quotient of two concentrations of a test 
substance (like 5-FU) in a two-phase system, where two largely immiscible solvents (n-
octanol and water) were mixed with a fixed volume ratio. The logarithm of Pow between 
n-octanol and water (log Pow) has often been used as a key parameter to describe the 
lipophilicity of a molecule. In the pharmaceutic field, logP is utilized to estimate the 
biological activities of the drugs, such as solubility [249], biodegradation rate, bio-
accumulation, membrane permeability [250], and drug absorption and toxicity 
predictions. Therefore, the investigation of the Pow of 5-FU is essential to predict its 
transport and activity, thereby providing information for the subsequent modification of 
HMSNs specific for high 5-FU loading.  
 
The shake flask method is one of the common and standard experimental procedures 
adopted for logPow study. This method is applied to determine the solubility and 
hydrophobicity of compounds with logP values ranging from –2 to 4. The determination 
is based on the principle that hydrophobic substances soluble in the lipid phase show a 
positive logPow (log Pow > 0), while negative logPow values (log Pow < 0) typifies polar 
compounds soluble in the water phase. 
 
According to OECD guideline 107 [173], an effective partition coefficient study refers to 
all obtained log Pow values falling within a range of -2 ~ 4 with a offset of ± 0.3 units. As 
shown in Table 6.1, the log Pow values of 5-FU with all ratios (octanol : water) are within 
the range mentioned above and are consistently negative, indicating that 5-FU is 
hydrophilic. Specifically, when the volume of water decreased from 26.67 mL to 13.33 
mL, the 5-FU concentration in water phase increased significantly from 7.747 μg/mL to 
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13.17 μg/mL. This is due to the fact that most 5-FU molecules prefer congregating in the 
water phase, thus with a decrease in the water volume, a more concentrated 5-FU solution 
is observed. In contrast, no obvious difference was found in 5-FU concentration in the 
octanol phase. With varying octanol volume, from 26.67 mL to 13.33 mL, 5-FU 
concentration remained at around 2.2 ~ 2.6 μg/mL, which can be explained by the 
hydrophilic property of 5-FU. 
 
Table 6. 1 Partition coefficient of 5-FU and relevant parameters 
 1:2 (O:W) 
 
1:1 (O:W) 
 
2:1 (O:W) 
 
Water volume (mL) 26.67 20 13.33 
Oil volume (mL) 13.33 20 26.67 
C water (μg/mL) 
 
7.747 
 
9.925 13.17 
 
C octanol (μg/mL) 2.279 2.380 
 
2.629 
Pow 0.2942 0.2398 0.1996 
log Pow -0.5314 -0.6201 -0.6997 
 
 
As shown in Figure 6.1, even though the volume of water and octanol changes, it appears 
that in all ratios, around 75% of 5-FU are dissolved in the water phase while the other 
~25% is found in the octanol phase. Therefore, a more hydrophilic surface of HMSNs 
would increase the loading of 5-FU.  
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Figure 6. 1 percentages of 5-FU dissolved in each phase with varying octanol to water 
ratio 
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6.2.2 Preparation and characterization of functionalized HMSNs 
 
 
 
Figure 6. 2 TEM images of HMSNs (a), HMSN-NH2 (b), HMSN-COOH (c), HMSN-CN (d) and HMSN-CH3 (e) 
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Surface-functionalized HMSNs were synthesized by post grafting method where 
chemical groups were introduced to the surface of as-synthesized HMSNs using 
appropriate silanes. CPTES, APTES and TEMS were used to prepare HMSN-CN, 
HMSN-NH2 and HMSN-CH3 while HMSN-COOH was obtain by oxidizing HMSN-CN. 
In all cases, plain HMSNs without any modification was used as a control. The 
morphology of modified and plain HMSNs were characterized by TEM and BET. As 
shown in Figure 6.2, all modified HMSNs (Figure 6.2 b-e) had a similar morphology to 
that of plain HMSNs (Figure 6.2 a) revealing that the structure of these nanoparticles can 
be well preserved during all functionalization processes. In particular, the surface-
functionalized HMSNs maintained a hollow structure and a very spherical shape with a 
mean diameter of ~120 nm and a shell thickness of ~10 nm. In addition, all HMSNs 
displayed a highly uniform size, shell thickness and more importantly, a mono-dispersion 
which is one of the main requirements for drug delivery systems. 
 
The presence of mesoporous structure in all HMSNs was confirmed by BET (Figure 6.3). 
The nitrogen adsorption/desorption experiments demonstrated that both modified and 
plain HMSNs showed characteristic isotherm of mesoporous materials, a type IV 
isotherm, indicating the existence of mesopores. Well-defined steps occurred in the 
relative pressure of 0.35-0.55 and 0.9-1.0 were related to capillary condensation and 
desorption in open mesopores and interstitial pores, respectively [189]. As seen in Figure 
6.3b, narrow pore size distributions are presented in HMSNs before and after surface 
modifications. The average pore size of all HMSNs was calculated using the desorption 
branch of the isotherm by the typical Barrett-Joyner-Halenda (BJH) method, according 
to which HMSNs, HMSN-NH2, HMSN-CN, HMSN-COOH and HMSN-CH3 have a 
pore size of 2.78 nm, 2.47 nm, 2.28 nm, 2.61 nm and 2.51 nm, respectively. 
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Figure 6. 3 N2 adsorption-desorption isotherms (a) and the corresponding pore size 
distributions (b) of plain and functionalized HMSNs  
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Table 6. 2 Structure parameters of functionalized and non-functionalized HMSNs 
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Figure 6. 4 FTIR spectra of plain and functionalized HMSNs and plain HMSNs 
 
 
HMSNs HMSN-
CH3 
HMSN-
CN 
HMSN-
NH2 
HMSN-
COOH 
Plain 
HMSNs 
Pore size (nm) 2.51  2.28 2.47 2.61 2.78 
Pore volume 
(cm3/g) 
0.43 0.50 0.43 0.47 0.53 
Surface area 
(m2/g) 
434 514 413 498 820 
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Structure parameters of the HMSNs with and without modifications were summarized in 
Table 6.2. According to Table 6.2, not significant differences can be found in the pore 
size and pore volume between all kinds of nanoparticles, proving that surface 
functionalization had a limited effect on the two parameters of final products. The 
maintaining of pore size and pore volume guarantees large spaces in functionalized 
HMSNs for drug loading that ideally should be same as non-functionalized ones. 
However, due to the coverage of functional groups, the surface area of functionalized 
samples decreased when compared to plain HMSNs. On the other hand, due to being 
different batches, the surface area of the plain HMSNs is slightly different from that 
presented in Section 4.2.1 even though the same fabrication procedures were applied. 
Compared with F127 and P123, the molecular weight of Tweens 20 and TX100 is much 
smaller, which produces smaller micelles during the fabrication and therefore results in 
smaller pore size of nanoparticles. As pore size, surface area and pore volume of the final 
products highly depend on the kind of surfactant used for fabrication, HMSNs 
synthesized with surfactants having similar properties may have similar or even the same 
physicochemical properties, including the surface area. These results were consistent 
with similar studies [228].   
 
Different chemical groups of -NH2, -CN, -COOH and –CH3 were grafted onto the surface 
of HMSNs separately and the successful grafting was evidenced by FTIR technique. 
FTIR spectra of modified HMSNs and the control sample (HMSNs) were shown in Figure 
6.4. All samples have strong bands located at around 460 (δO–Si–O), 1100 (ʋasym. Si–
O–Si), and 3300-3500 cm-1 (ʋSi–OH), confirming the presence of the SiO2 inorganic phase 
[227]. The -NH2 functionalization is clearly evidenced by the bands detected at around 
1500 cm-1 and 3000 cm-1, which are unambiguously attributed to the NH bending 
vibration and C-N stretching vibration, respectively [227-230]. Similarly, -CN and –
COOH functionalizations were proved by the observation of relative characteristic peaks. 
The peak at 2200cm-1 corresponding to cyano groups (CN) was observed in the spectrum 
of HMSN-CN while HMSN-COOH was shown at a peak of 1730cm-1 relating to C=O 
vibration of COOH. The bands appeared at around 3000 cm-1 in the spectrum of HMSN-
CH3 are assigned to C-H vibration of methyl groups (–CH3) confirming the existence of 
–CH3 on the surface of HMSN-CH3. Results obtained by FTIR proved the effective 
surface functionalization of HMSNs, thereby confirming the presentence of -NH2, -CN, 
122 
 
-COOH and –CH3 on the surface of HMSN-NH2, HMSN-CN, HMSN-COOH and 
HMSN-CH3, respectively. 
 
Thermogravimetric analysis (TGA) was carried out to further confirm the effective 
surface modification of functionalized HMSNs. All samples were tested under nitrogen 
condition at the temperature ranging from room temperature up to 650 qC.  The weight 
loss of samples obtained from TGA arose from the decomposition of chemical groups 
thereby a difference in the weight loss between samples can indicate the relative amount 
of chemical groups grafted onto particles.  As seen from Figure 6.5, the total weight loss 
of plain HMSNs was ~8.0% due to the dehydroxylation of silanol groups (Si-OH). In 
contrast, all functionalized HMSNs showed a total weight loss of ~20% which was 
mainly from thermal cracking of grafted functional groups. Therefore, the success of the 
grafting has been proven by TGA results which was in accordance with the FTIR results 
illustrated above and the relative amount of functional groups of modified HMSNs was 
~12% (w/w).  
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Figure 6. 5 TGA curves of functionalized HMSNs and plain HMSNs 
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6.2.3 Regulate 5-FU loading capacity of HMSNs by modifications 
 
Table 6. 3 Loading capacity of functionalized and non-functionalized HMSNs 
 
The 5-FU loading capacity of functionalized and non-functionalized HMSNs has been 
monitored using a UV spectrophotometer. An initial drug concentration of 3 mg/ml was 
applied and the concentration change after 24 hours of loading was tracked. The loading 
capacity of all HMSNs were calculated and listed in Table 6.3. As expected, a difference 
in the amount of 5-FU loading after surface functionalization was observed, which 
resulted from the different hydrophobicity and hydrophilicity of the functional groups 
[228]. The plain HMSNs presented a loading percentage of 18.34% which increase to 
28.89% (the best) after amine functionalization. It was reported that by using amine 
functionalized mesoporous silica nanoparticles (MSNs, non-hollow structure) 
specifically for 5-FU encapsulation, a 5-FU loading of 124 mg 5-FU/g MSNs was 
achieved [251]. Therefore, by designing and fabricating MSNs with different structure 
such as the hollow MSNs,   the 5-FU loading can be significantly improved.  This 
enhanced loading capacity could be attributed to the hollow structure of HMSNs and the 
high efficiency of functionalization. 
 
Furthermore, -CH3 functionalization decreases the loading capacity of HMSNs to some 
extent (from 18.34% to 12.73%). 5-FU is a water-soluble drug therefore it is harder to 
approach HMSNs functionalized with methyl groups which is slightly more hydrophobic. 
On the other hand, -CN and -COOH functionalized HMSNs showed moderate loading 
ability with a loading percentage of 22.54% and 20.73%, respectively. Although HMSN-
COOH is hydrophilic which is similar to 5-FU, its loading capacity is inferior to HMSN-
NH2. This can be explained by the different surface charge of HMSN-NH2 and HMSN-
COOH. Given that 5-FU is negatively charged, it is much easier for 5-FU to get inside 
HMSNs HMSN
-CH3 
HMSN-
CN 
HMSN-
NH2 
HMSN-
COOH 
Plain 
HMSNs 
Loading capacity (%) 12.73 22.54 28.89 20.73 18.34 
Loading capacity  
(mg 5-FU/g HMSNs) 
127.3 225.4 288.9 207.3 183.4 
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the positively charged HMSN-NH2 via electrostatic attractions. However, the existence 
of negative charge of –COOH groups may repel 5-FU molecules and decrease the 5-FU 
loading capacity of HMSN-COOH.  
 
In summary, the loading capacity of HMSNs specific to 5-FU can be improved via 
surface functionalization. The presence of –NH2 groups on the surface of nanoparticles 
resulted in a highest 5-FU loading capacity. A combination of a similarity in 
hydrophilicity and a presence of reverse charge of the drug gives rise to this highest 
loading capacity of HMSN-NH2. This finding in addition to the higher EGF 
immobilization by HMSN-NH2 illustrated in Chapter 5 will definitely render the current 
drug delivery system more versatile for various applications.  
 
6.3 Control of 5-FU loading and release 
 
6.3.1 The effect of pH on drug loading and release 
 
The above study illustrated that HMSN-NH2 can significantly increase the amount of 5-
FU encapsulated into nanoparticles due to the similar hydrophilicity to drug and the 
existence of positive charge provided by –NH2 groups. Therefore the control of the 
intensity of electrostatic force between nanoparticles and 5-FU may further regulate 5-
FU loading capacity of particles.  
 
In this regard, the loading of 5-FU by HMSN-NH2 was carried out in 4 different pHs, 4.0, 
5.5, 7.4 and 8.5. As shown in Figure 6.6, as pH increases, the loading of 5-FU capacity 
of HMSN-NH2 increases and attains the maximum loading capacity of 27.52% at pH of 
8.5. HMSN-NH2 is positively charged at a wider pH range because of the protonation of 
the amine groups while under different pH values, the behaviour of 5-FU in terms of 
surface charge is different [252, 253]. As shown in Figure 6.7, the deprotonation of 5-FU 
can occur at N1 or N3 or both to form the monoanions AN1, AN3 and dianion under 
alkaline condision.  It is reported that at pH 7-10, AN1, AN3 and dianion of 5-FU coexist 
as a mixture in aqueous medium [252, 253]. Therefore, at acidic pHs (4.0 and 5.5), 5-FU 
becomes less deprotonated or non-deprotonated resulting in a very low surface charge of 
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5-FU. Therefore, lower drug loading capacity of HMSN-NH2 (18.56% and 19.03%) was 
observed at these two pHs. Nevertheless, when pH increased to 7.4 and 8.5, the 
deprotonation of 5-FU enhanced thereby enhancing electrostatic attractions between 
HMSN-NH2 and 5-FU. Instead of being a neutral molecule in the medium, most 5-FU 
molecules transferred to monoanions and dianion, which generated negative charges and 
led to more 5-FU being encapsulated into the nanoparticles.  
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Figure 6. 6  5-FU loading capacity of HMSNs and HMSN-NH2 at different pH values 
(a) and UV spectra of remaining 5-FU after 24 hours loading by HMSN-NH2 at 
different pH values (b) 
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Figure 6. 7 Two possible 5-FU anions (AN1 and AN3) and dianion  
 
 
 
On the other hand, no obvious differences can be seen in the loading capacity of HMSNs 
at various pHs. Due to the presence of negatively charged silanolate groups on the surface, 
the loading capacity of HMSNs was inferior to HMSN-NH2 at all pHs. The encapsulation 
of 5-FU by HMNSs might be mainly based on hydrogen bonding rather than electrostatic 
force. In addition, under alkaline pHs where 5-FU possesses more negative charges, a 
slightly decrease in drug loading capacity of HMSNs was found. This could be due to 
the repulsive interaction between carriers and the drug.  
 
6.3.2 The effect of particle size and shell thickness on drug loading and release 
 
To study the effect of particle size on 5-FU loading and release behaviours, HMSNs with 
different particle size (100, 200 and 300 nm) were synthesized and their morphology 
were shown by SEM images (Figure 6.8).  As seen from Figure 6.8, all HMSNs exhibit 
very spherical shape with different diameters. In addition, the size of each kind of 
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HMSNs is uniform and is at the target size 100, 200 and 300 nm. A mono-dispersion is 
found consistently for all particles.  
 
 
 
 
Figure 6. 8 SEM images of HMSNs with different particle size: 100 nm (a & d); 200 nm 
(b & e) and 300 nm (c & f) 
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Figure 6. 9 Loading capacities (a) and release profiles (b) at pH 5.5 of HMSNs with 
varying particle size  
 
Drug loading and release experiments were performed on HMSNs with varying particle 
size and their loading capacities and release behaviours are shown in Figure 6.9. HMSNs 
with particle size of 100, 200 and 300 nm obtained similar 5-FU loading capacities of 
~20% and cumulative release percentages of ~40% (Figure 6.9), indicating particle size 
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is not an important factor of HMSNs in determining 5-FU loading and release ability. On 
the other hand, three kinds of HMSNs displayed sustained release profiles with a 
maximum release percentage approached at 5 hours and maintained for another 20 hours.  
 
Similarly, HMSNs with a varying shell thickness were prepared for testing the effect of 
shell thickness on drug loading and release performances. As presented in Figure 6.10, 
the shell thickness of HMSNs can be changed from ~10 nm to ~30 nm while the particle 
size remains the same as ~120 nm. HMSNs with different shell thickness showed 
spherical appearance and hollow structure. Along with the increase in shell thickness, a 
decrease in cavity size was found, which resulted from the fact that the size of the 
nanoparticles used to develop cavities in HMSNs were different.  
 
 
 
Figure 6. 10 SEM images of HMSNs with different shell thickness: 10 nm (a & d); 15 
nm (b & e) and 30 nm (c & f) 
 
The loading and release performance of HMSNs with different shell thickness were 
summarized in Figure 6.11. Firstly, the drug loading capacity of HMSNs with a shell 
thickness of 10, 15 and 30 nm were 18.42%, 16.93% and 12.16%, respectively. The 
ability to encapsulate 5-FU decreases with an increase in shell thickness and HMSNs 
with the maximum shell thickness (30 nm) shows an obvious decrease in 5-FU loading 
capacity. This might be due to the reduced size of cavities in this kind of HMSNs and 
therefore less space in HMSNs available for drug storage. Secondly, the release 
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behaviour of HMSNs with shell thickness of 10 and 15 nm generates a similar release 
behaviour with a final released drug proportion of ~ 40%. However, even though a 
sustained release profile was presented for HMSNs with 30 nm shell, only ~ 15% of 
loaded drug can be release from the carriers. In addition, the release rate was slower than 
the other two samples, which could be due to the thicker shell that provides a longer way 
for drug molecules to transport. 
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Figure 6. 11 Loading capacities (a) and release profiles (b) at pH 5.5 of HMSNs with 
varying shell thickness  
 
 
6.3.3 The effect of EGF on HMSNs’ drug loading and release behaviours  
 
EGF attachment had been proved to be an excellent targeting ligand in chapter 5 which 
enables HMSNs to precisely target cancer cells. After targeting, an effective killing of 
cancer cells should be guaranteed by releasing the anti-cancer drug pre-loaded in EGF-
HMSNs. Therefore, it is important to study the drug loading and release behaviours of 
EGF-HMSNs. Figure 6.12 shows the morphology of EGF-HMSNs. After EGF grafting, 
EGF-HMSNs maintain the spherical and hollow structure as plain HMSNs in addition to 
a good dispersion. The loading and release profiles of EGF-HMSNs and HMSNs are 
given in Figure 6.13, where a decreased loading capacity is found in EGF-HMSNs. EGF 
appeared on the surface of nanoparticles, which may block some pores of HMSNs and 
hinder the drug to get inside the nanocarriers. Therefore, the 5-FU loading capacity of 
nanocarriers decreases from 20% to 12.5% after EGF conjugation. On the other hand, 
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the EGF attachments have limited effect on the final drug release percentage which was 
proved by a similar cumulative release percentage found in both HMSNs and EGF-
HMSNs. Nevertheless, the release rate of EGF-HMSNs is slowed down by the EGFs. As 
seen in Figure 6.13B, HMSNs can attain a maximum drug concentration in the first 5 
hours of the release process while EGF-HMSNs exhibit a much slower release profile 
with a highest release rate at 25 hours.   
 
 
Figure 6. 12 SEM images (a & b) and TEM image (c) of HMSN-EGF  
 
 
0 5 10 15 20 25
0
5
10
15
20
Lo
ad
in
g 
ca
pa
ci
ty
 (%
)
Loading time (h)
 EGF
 non-EGF
A
  
0 5 10 15 20 25
0
10
20
30
40
50
 
 
Release time (h)
C
ul
m
at
iv
e 
re
le
as
e 
(%
)
 non-EGF
 EGF
B
 
Figure 6. 13 Loading (a, at pH 8.0) and release (b, at pH 5.5) profiles of HMSNs with 
and without EGF attachments  
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6.4 SiRNA encapsulation based on HMSNs 
 
With targeting ligand EGF on the surface, HMSN-NH2-EGF can precisely target and kill 
cancer cells by releasing the anti-cancer drug into target cells. However, the cancer cells 
develop drug resistance after the drugs are continuously applied.  
 
Multidrug resistance (MDR) referring to the ability of cancer cells to adapt and survive 
from chemotherapy is one of the most complex and challenging problems in cancer 
treatments [14, 109, 254, 255]. Although nanopariticle based drug delivery systems are 
often used to prevent MDR in cancer treatment by sidestepping drug resistance 
mechanisms, the development of drug resistant genes by cancer cells ultimately leads to 
unsatisfied outcomes. A novel approach to address MDR is to take advantage of the 
ability of nanocarriers to deliver nucleic acids (such as siRNA) to cancer cells, which 
knock down genes associated with MDR.  
To overcome the 5-FU resistance, HMSNs were modified for siRNA delivery to silence 
the gene expression involved in MDR. As siRNA is negatively charged, HMSNs were 
pre-functionalized to be positively charged and thus offer the electrostatic force for 
siRNA loading.  
6.4.1 Increased surface charge of HMSNs for SiRNA loading   
 
HMSNs-NH2 possessing abundant amine groups on the surface thereby render HMSNs 
positive surface charge for siRNA loading. An additional advantage of HMSNs-NH2 is 
the enhanced loading capacity specifically to 5-FU. In this regard, HMSNs-NH2 were 
applied to load siRNA and could serve as carriers for co-delivery of 5-FU and siRNA.  
  
Amino-functionalized HMSNs with an average diameter of ~100 nm were obtained via 
grafting 3-aminopropyltriethoxysilane (APTES) on HMSNs (Figure 6.14a). The particles 
displayed a high surface area of 680 m2/g, a pore size of 2.5 nm and a pore volume of 
1.12 cm3/g. The corresponding values after amino-functionalization were 380 m2/g, 2.3 
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nm and 0.78 cm3/g respectively (Table 6.4). Zeta potentials of particles before and after 
functionalization are -27.1 mV and 0.936 mV respectively (Figure 6.14b). The increase 
in zeta potential and decrease in surface area is due to the introduction of –NH2 groups.  
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Figure 6. 14 SEM image (a) and zeta potential (b) of HMSN-NH2 
 
 
 
Table 6. 4 Parameters of HMSNs and HMSN-NH2 
Samples  
Pore size 
(nm) 
Pore volume 
(cm3/g) 
Surface area 
(m2/g) 
HMSNs 
 
2.5 
 
1.12 
 
680 
HMSN-NH2 
 
2.3 
 
0.78 
 
380 
 
Thereafter, various amount of HMSN-NH2 (0.5, 1, 2, 5, 10 and 20 μg) were incubated 
with 0.1 μg of siRNA to obtain particles/siRNA weight ratio from 5 to 200. The 
incubation was carried out in phosphate-buffered saline (PBS pH 7.4) for 2 h and 
encapsulation efficiency of siRNA by HMSN-NH2 were characterized by agarose gel 
electrophoresis. As shown in Figure 6.15, the loading of siRNA to HMSN-NH2 was 
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negligible (black bands at the bottom of each column indicate unloaded siRNA). With the 
highest ratio of 200, a black band with faded colour (decreased intensity) can been seen 
in the gel showing very low amount of siRNA was loaded.  This result reveals that siRNA 
can be adsorbed by HMSN-NH2 but only limited siRNA was encapsulated at a weight 
ratio of 200.  
 
 
 
Figure 6. 15 siRNA encapsulation efficiency of HMSN-NH2. Various weight ratio of 
particles/siRNA from 5 to 200 were applied. 
 
 
The poor siRNA loading capacity could be due to the low surface charge of HMSN-NH2. 
Although HMSN-NH2 presented positive charges, the potential is only 0.936 mV which 
might not be high enough to adsorb siRNA. As it is expected a high siRNA loading of 
HMSN-NH2 will guarantee an effective delivery of siRNA for the inhibition of drug 
resistant genes expression, HMSN-NH2-1, HMSN-NH2-2 and HMSN-NH2-3 with 
different surface charge were prepared and used for siRNA loading. Figure 6.16 displayed 
the potential value of plain HMSNs, HMSN-NH2-1, HMSN-NH2-2 and HMSN-NH2-3; 
the increased charge of HMSN-NH2-2 and HMSN-NH2-3 were achieved by increasing 
the amount of APTES used in functionalization stages.  
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Figure 6. 16 Zeta potential of HMSNs, HMSN-NH2-1, HMSN-NH2-2  
and HMSN-NH2-3 
The siRNA encapsulation efficiency was studied using the same method. We 
hypothesized that an enhanced loading capacity would come with the increase in surface 
charge of nanoparticles. Nevertheless, gel electrophoresis results revealed that loading of 
siRNA by particles was still negligible (Figure 6.17 and Table 6.5). These results 
suggested that the encapsulation of siRNA by HMSNs might not only associated with the 
surface charge of particles. Instead, other parameters such as pore size might also 
important for achieving an effective siRNA encapsulation.  
 
Figure 6. 17 siRNA encapsulation efficiency of HMSN-NH2-2 (a) and HMSN-NH2-3 
(b). Various weight ratio of particles/siRNA from 5 to 200 were applied. 
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Table 6. 5 siRNA encapsulation efficiency 
 
samples Pore size (nm) Potential (mv) SiRNA Loading 
HMSNs 2.3 -27 None 
HMSNs-NH2-1 2.3 0.936 limited 
HMSNs-NH2-2 2.3 11.1 limited 
HMSNs-NH2-3 2.3 40.2 limited 
 
 
6.4.2 Pore size expansion of HMSNs for efficient SiRNA encapsulation  
 
On the basis of poor siRNA loading capacity illustrated above, it is suggested that besides 
positive charged surface, larger pores might be necessary for a high siRNA loading by 
HMSNs. As the length of siRNA is about 3nm, the relative small pore size (2.3 nm) of 
current used particles would significantly reduce the adsorption of siRNA. When siRNA 
was mixed with nanoparticles, they can only attach to the surface or stay near the surface 
of nanoparticles rather than enter the pores. Similar results were found by other 
researchers when non-hollow mesoporous silica nanoparticles were employed to load 
siRNA [256]. Consequently, pore expansion of HMSNs is required before siRNA 
loading.  
 
Three HMSNs (HMSNs-S, HMSNs-M and HMSN-L) with the same particle size, shell 
thickness but different pore size (small, middle and large) were prepared and their 
structure parameters were presented in Table 6.6. As shown in Figure 6.18, all HMSNs 
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possess a large cavity inside and mesoporous shell outside, highlighting their distinctive 
hollow structure. These HMSNs with very spherical shape exhibited a good dispersion. 
Successful pore expansion of HMSNs were confirmed by scanning electron microscope 
(SEM) (Figure 6.18 a, c & e) where middle and large pores of HMSNs-M and HMSNs-
L are clearly seen from the images. Similarly, in transmission electron microscopy (TEM) 
images (Figure 6.18 b, d & f), small pores of HMSNs-S were hardly seen as white dots 
indicating pores were missing in Figure 6.18 b. In contrast, white dots appeared in Figure 
6.18 d, and become larger in Figure 6.18 f, revealing an increase in pore size of HMSNs. 
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Figure 6. 18 SEM and TEM images of HMSNs-S (a & b), HMSNs-M (c & d) and HMSNs-L (e & f) 
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The corresponding structure parameters of HMSNs-S, HMSNs-M and HMSN-L were 
listed in Table 6.6. As expected, three HMSNs achieve the same particle size of ~120 nm 
and shell thickness of ~10 nm, which is essential for investigating the effect of pore size 
on siRNA loading capacity as keeping other parameters the same are necessary for 
effective comparisons. The pore size of HMSNs-S, HMSNs-M and HMSNs-L were 2.5 
nm, 4.3 nm and 20.1nm respectively. With an increase in pore size, pore volume 
increased from 1.12 cm3/g to 1.45 cm3/g while the surface area decreased from 680 m2/g 
to 513 m2/g [113].  
 
 
Table 6. 6 Structure parameter of HMSNs-S, HMSN-M and HMSNs-L  
 
Samples HMSNs-NH2-S HMSNs-NH2-M  HMSNs-NH2-L 
Pore size (nm) 2.5 4.3 20.1 
Particle size (nm) 120 120 120 
Shell thickness 
(nm) 
10 10 10 
Pore volume 
(cm3/g) 
1.12 1.23 1.45 
Surface area 
(m2/g) 
680 604 513 
 
 
To evaluate the capacity as siRNA carriers, these three HMSNs were aminated for the 
presence of positive charges to adsorb negatively charged siRNA through electrostatic 
interaction. The degree of amination of three kinds of HMSNs were evaluated by zeta-
potential and thermogravimetric analysis (TGA). The zeta potential results (Figure 6.19a) 
demonstrate that three HMSNs possess a similar positive charge of around ~13 mV 
revealing their close amount of amine groups. This amount of grafted amine groups was 
further tracked via TGA. As shown in Figure 6.19b, the plain HMSNs have a total weight 
loss of ~12.6 wt% under nitrogen condition, which is due to the dehydroxylation of 
silanol groups.  HMSNs-S, HMSNs-M and HMSNs-L show an increased weight loss 
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proving their successful modifications. Further, a similar total weight loss percentage (~ 
18%) of HMSNs-S, HMSNs-M and HMSNs-L again illustrates the fact that they have a 
close number of functional groups.  
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Figure 6. 19 Zeta potential (a) and TGA (b) of aminated HMSNs, HMSNs-S,  
HMSNs-M and HMSNs-L 
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Results from siRNA loading (Figure 6.20) demonstrate that HMSNs-M and HMSNs-L 
have significantly higher siRNA loadings than HMSNs-S. When the pore size of HMSNs 
was expanded form 2.5 nm to 4.3 nm, an obvious increase in siRNA loading was found. 
Almost all siRNA could be encapsulated into HMSNs-M at the particle to siRNA ratio 
of 100. This can be explained that the 4.3 nm pores of HMSNs-M are large enough for 
the siRNA to pass through freely which enable HMSNs-M to encapsulate siRNA into the 
pores as well as the hollow cavity (Figure 6.21). On the other hand, when the pore size 
was further expanded to 20.1 nm, the siRNA loading of HMSNs-L remain the same as 
that of HMSNs-M. This could be due to that both HMSNs-M and HMSNs-L had reached 
their loading limit. In other words, the maximum loading capacities of both HMSNs-M 
and HMSNs-L were similar and all their active space for siRNA loading had already been 
occupied by siRNA at a weight ratio of 100. Therefore, for siRNA loading, pore size is 
a significant parameter only when the pore size of the carriers is under 4.3 nm. When 
HMSNs have a pore size larger than 4.3 nm, further expansion of the pore size will not 
affect the siRNA loading anymore.  
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Figure 6. 20 siRNA encapsulation efficiency of HMSNs-S, HMSNs-M and HMSNs-L. Various weight ratio of particles/siRNA from 5 to 200 
were applied. 
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Figure 6. 21 Proposed siRNA encapsulation of HMSNs with different pore sizes (on the 
surface VS inside the pores and hollow cavity) 
 
6.5 Conclusions 
 
The presence of functional groups with different hydrophobicity and hydrophilicity on 
HMSNs led to the variation of 5-FU loading. As 5-FU is more hydrophilic, HMSNs-NH2 
showed the highest 5-FU loading capacity of 28.89%, while the presence of the more 
hydrophobic group –CH3 on HMSNs have decreased the HMSNs’ loading capacity from 
18.34% to 12.73%. In addition, due to the electrostatic attraction between nanoparticles 
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and 5-FU, the presence of positive charge on HMSN-NH2 contributed to its highest 
loading capacity. The loading and release behaviours of HMSNs can also be well 
controlled via adjusting the structure parameters of HMSNs: particle size, pore size and 
shell thickness. For siRNA encapsulation, pore size, rather than the intensity of positive 
charge existing on HMSNs, turned out to be a crucial parameter in determining the 
siRNA encapsulation efficiency of HMSNs. Almost all siRNA can be encapsulated into 
HMSNs with a pore size of 4.3 nm at the particle to siRNA ratio of 100.  
 
144 
 
Chapter 7 Conclusions and future works  
 
 
7.1  Overview of current work 
 
Nanoparticle based drug delivery systems have the potential to revolutionize cancer 
therapy, because nanoparticles maintain a prolonged effective drug concentration which 
allows cancer cells to be exposed sustainedly to the drug. Owning to their small size and 
the characteristic features of tumour biology, like the leaky vasculature and the impair 
lymphatic system, nanoparticles can reach certain solid tumours and release biologically 
active cargos into the tumour cells. Several therapeutic nanocarriers including carbon 
nanotubes, dendrimers, polymeric nanoparticles and inorganic nanoparticles, have been 
reviewed in Chapter 2 and it was found that HMSNs possess the ability to maintain 
optimum therapeutic efficacy with nontoxicity due to their large surface area, high 
volume for drug loading and excellent biocompatibility. However, the non-ionic 
surfactant templated HMSNs often have a broad size distribution or a defective 
mesoporous structure because of the difficulties involved in controlling the formation 
and organization of micelles for the growth of silica framework.   
 
In Chapter 4, a novel “Eudragit assisted” strategy has been developed to fabricate hollow 
mesoporous silica nanoparticles (HMSNs) by utilising the Eudrgit nanoparticles as cores 
and to assist in the self-assembly of micelle organization. The significant achievements 
of this newly developed synthesis route include: 
 
1. Uniform, dispersible hollow mesoporous silica nanoparticles with large internal 
cavities were achieved with this newly developed strategy. The method using 
Eudragit S100 nanoparticles as both a core template and an assistant in the self-
organization of surfactant micelles proved an excellent method for HMSNs synthesis. 
The mesoporous structure, a high surface area and a small pore size of HMSNs were 
suggested by BET results, where IV type N2 adsorption- desorption isotherm, a 
surface area of 760m2/g and a pore size of 2.5 nm were presented.  
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2. Eudragit S-100 is a widely used pharmaceutical polymer for preparing enteric 
formulations [257, 258] and as carriers for pH dependent drug delivery systems [192-
194] due to its pH dependent solubility [190, 191].  The utilisation of Eudragit S100 
nanoparticles as a core template for the fabrication of HMSNs affords the advantage 
of non-toxicity [259], potential sites (carboxyl groups) for hydrogen bonding [260], 
and most importantly easier core removal. Eudragit core can be easily removed by 
soaking the as-synthesized HMSNs (HMSNs with Eudragit cores) in base solution 
or in Acetone under room temperature. This solvent extraction process to clean the 
Eudragit cores is facile and gentle, which remarkably preserved HMSNs form further 
damage or aggregation caused by calcination, where HMSNs subjected to a very high 
temperate.  To our knowledge, this is the first time to report the use of Eudragit S100 
nanoparticle as a core template for HMSNs synthesis.  
 
3. The synthesized HMSNs were found to exhibit great sustained release of anti-cancer 
drug 5-FU and nontoxic to colorectal cancer cells. The successful synthesis of 
HMSNs in addition to their excellent biocompatibility demonstrate the potential of 
HMSNs as effective drug carriers for building versatile cancer-targeted drug delivery 
systems. 
 
Many chemotherapeutic drugs for cancer treatments with low specificity often kill 
healthy cells as well and thereby causing immense toxicity to the patient. Therefore, 
targeting functions are essential for drug delivery systems as they have the potential to 
precisely target and kill cancerous cells while leaving normal cells unharmed. To 
configure HMSNs for targeted drug delivery, HMSNs were bioconjugated with specific 
receptor ligand EGF in Chapter 5. The construction of a targeting molecule (EGF) to the 
surface of HMSNs was achieved through a new method, where the carboxyl groups of 
EGF conjugated to an amine terminated mesoporous silica surface. This method proved 
to be facile and effective to graft EGF on silica surface and can protect HMSNs from 
damage during modification. Three principal conclusions have been reached on the 
preparation of EGF-HMSNs and their bioactivity in Chapter 5: 
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1. The current EGF grafting method can tune the quantity of EGF attachments on the 
surface of HMSNs by changing the EGF concentration during the grafting stages, 
which have not been previously reported in the open literature. A small change in 
the properties of targeting ligand in terms of effective immobilization, stability, 
concentration and binding efficiency can have a great influence on the subsequent 
performance of nanoparticulate targeted drug delivery systems in the biological 
environment. Although the utilisation of EGF for targeting delivery is well 
established, a precise control of the density of EGF attachments on nanoparticles is 
very limited. Therefore, the successful controlled grafting of EGF onto HMSNs by 
the strategy illustrated in Chapter 5 proved the superiority of this method to 
commonly used ones.  
 
2. Characterization of EGF attachments was first carried out using ToF-SIMS. The 
ToF-SIMS data revealed the successful grafting of EGF attachments. PCA was 
implemented to further extract and clarify the information from the complex ToF-
SIMs data and illustrated that EGF concentration played a crucial role in the binding 
efficiency of the EGF to the nanoparticles. In all cases, the combination of ToF-
SIMS and PCA proved to be very effective in classifying relative surface 
concentration of EGF attachments. 
 
3. In vitro experiments present direct evidences that HMSN-EGF can efficiently and 
selectively enter the EGFR positive colorectal cancer cells (SW480) and they had no 
effect on EGFR negative cancer cell line SW620. More importantly, cellular uptake 
results on SW 480 cells and SW 620 cells suggested that the EGF-EGFR endocytosis 
pathway accounted for the improved internalisation of HMSN-EGF. Therefore, by 
utilizing the EGF-EGFR interactions, the specific delivery of drugs in colorectal 
cancer cells can be achieved. This guarantees a more precisely killing of cancer cells 
without killing the normal cells.  
 
For drug delivery system, a high drug loading is always being pursued to guarantee an 
adequate intracellular concentration of anti-cancer drug in tumour area. The capacity of 
nanoparticles to include drugs can be improved by functionalization [248] or by 
optimizing the drug encapsulation conditions. In Chapter 6, the focus was on the 
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modifications of HMSNs for enhanced 5-FU loading. Different functionalization of 
HMSNs is introduced in this chapter to make HMSNs more versatile for particular 
application. The significant achievements include: 
 
1. The presence of different functional groups on HMSNs led to the variation of 5-FU 
loading, which resulted from the different hydrophobicity and hydrophilicity of the 
functional groups. As 5-FU is more hydrophilic, the presence of –NH2 groups on the 
surface of nanoparticles resulted in the highest 5-FU loading capacity of 28.89%, 
while the more hydrophobic group –CH3 decreased the HMSNs’ loading capacity 
from 18.34% to 12.73%. In addition, the presence of positive charge on HMSN-NH2 
contributed to its highest loading capacity. This is because of the electrostatic 
attraction between nanoparticles and 5-FU.   
 
2. The loading and release behaviours of HMSNs can also be controlled via adjusting 
the structure parameters of HMSNs: particle size, pore size and shell thickness. 
Studies in Chapter 6 revealed that HMSNs with particle size of 100, 200 and 300 nm 
achieved similar 5-FU loading capacities of ~20% and cumulative release 
percentages of ~40%, indicating particle size is not an important factor of HMSNs 
in determining 5-FU loading and release ability. However, the capacity of HMSNs 
to encapsulate 5-FU decreased with an increase in shell thickness and HMSNs with 
the maximum shell thickness (30 nm) shown an obvious decrease in 5-FU loading 
and release.  Similarly, pore size is another significant factor for release, with an 
increase in pore size, the release rate is accelerated (data was shown in Chapter 4).  
 
3. To overcome the 5-FU resistance, HMSNs were modified for the delivery of siRNA 
to silence the genes expression involved in multidrug resistance (MDR). Rather than 
the intensity of positive charge existing on HMSNs, pore size turned out to be a 
crucial parameter in determining the siRNA encapsulation efficiency of HMSNs. 
Poor siRNA encapsulation was observed with HMSNs having a pore size of 2.3 nm, 
which was due to the fact that siRNA was only adsorbed on the surface of HMSNs 
and cannot pass through the pores to get into the cavity. When the pore size of 
HMSNs was expanded to >4 nm, siRNA encapsulation was boosted. Almost all 
siRNA can be encapsulated into HMSNs with a pore size of 4.3 nm at the particle to 
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siRNA ratio of 100. This can be explained that the 4.3 nm pores are large enough for 
the siRNA to pass through freely which enables HMSNs to encapsulate siRNA into 
the pores as well as the hollow cavity. 
 
7.2 Limitations and future work 
 
Although achievements have been made as outlined in the previous sections, there are 
various limitations in the current project mainly due to the shortage of experimental and 
characterization equipment. Animal experiments are highly desirable to this work even 
though cell experiments were carried out for testing the biological behaviour of 
investigated drug delivery system. However, the limitations do not reduce the 
significance of the results which have been achieved as the cell experiments are as 
important as animal ones in assessing the performances of current targeted drug delivery 
system based on HMSNs.  
 
7.2.1 Targeting efficiency of EGF-HMSNs  
 
It is demonstrated in Chapter 5 that HMSNs bioconjugated with EGF can selectively and 
efficiently target cancer cells with an overexpression of EGFR. Given that most cancer 
cells overexpressed EGFR, these results in addition to the great biocompatibility of 
HMSNs suggested the feasibility of future applications of HMSNs in targeted drug 
delivery systems for cancer treatment.  More importantly, the use of TOF-SIMs provides 
opportunities to determine relative EGF concentration on HMSNs. Therefore, the amount 
of EGF grafted onto HMSNs can be compared by changing EGF concentration during 
modification process. Nevertheless, the subsequent targeting efficiency of EGF-HMSNs 
with a varying amount of EGF attachments on the surface in cancer cells have not been 
investigated in the current study. It is noteworthy that a precise control of EGF on HMSNs 
could lead to an effective regulation of nanoparticles entering the cells and thereby 
controlling the drug concentration in targeted cells. Therefore, a further investigation of 
targeting efficiency of EGF-HMSNs with different EGF concentration on the surface is 
of great importance to control drug concentration in cancer cells. It is known that the 
cancer development is a multistep process where different drug concentration and drug 
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exposure time were required for different stages. Thus, looking at the effect of the number 
of EGF ligands on the targeting behaviour of EGF-HMSNs would help engineer a 
versatile drug delivery system with controlled targeting efficiency. 
 
7.2.2 siRNA release and knockdown efficiency  
 
In Chapter 6, siRNA delivery has been highlighted as an essential task for HMSNs to 
overcome multidrug resistance. Although an effective siRNA loading by functionalized 
HMSNs was clearly illustrated in this chapter, the release profile and gene knockdown 
efficiency of siRNA loaded HMSNs were not studied, where further study associated with 
siRNA delivery in vitro and in vivo is necessary to fully assess the potential of HMSNs 
as siRNA carriers.  
 
Drug resistance at the tumour level is complex, often involving multiple and dynamically 
acquired multidrug resistance (MDR) mechanisms as a result of the expression of drug 
eƫux pumps, anti-apoptotic proteins, oncogenes, and regulators of drug metabolism. 
Therefore, further study, including how to enhance the cellular uptake efficiency of 
siRNA loaded HMSNs and effectively silence the targeted gene in vivo, needs to be 
carried out in the near future. Also, how to control the release of siRNA from HMSNs 
and protect siRNA from enzymatic degradation in vitro and in vivo should be addressed 
to guarantee the most optimal siRNA knocking down. 
 
7.2.3 Preparation multi-anticancer drug loaded HMSNs 
 
 
As a drug carrier, high drug-loading capacity is being pursued. In Chapter 6, the structure 
parameters of HMSNs can be controlled to load as many drug molecules as possible. In 
addition, the surface potential and hydrophilicity of HMSNs can also be altered for 
attracting drug molecules to enter the pores by precise surface modifications. However, 
all the studies mentioned above is designed specifically for only one drug, 5-FU. As 
pointed out by preclinical studies, a combination of chemotherapy drugs have led to 
improved anti-cancer effects and the use of combination therapy for colon cancer is well 
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established worldwide. For instance, irinotecan is commonly used with 5-FU, and have 
shown superior survival benefits to regimen of 5-FU only. In Australia, most frequently 
used first line chemotherapy regimens involve the combination of 5-FU, oxaliplation and 
leucovorin, becacizumab or irinotecan. Therefore, there exists a need to further explore 
HMSNs as a useful platform for multidrug-combined therapy. 
       
To enable the encapsulation of more than one drug in HMSNs more functionalizations 
need to be introduced on the surface or in the pores of HMSNs. However, for a 
nanoparticle based drug delivery system, the challenge lies in successfully combining 
several functions into one system. For example, an ideal drug delivery system refers to 
one that with targeting actions, sufficient therapeutic concentration of drug, nontoxicity 
and adequate biological activity. In many cases, it is difficult to couple several functional 
groups of sufficient concentration, since the number of attachment sites on the particle 
surface is limited. Moreover, each functionalization step might negatively affect the 
suspension stability of the particulate system, depending on the physicochemical 
properties of the added function. Keep this in mind, further study would focus on the 
structure optimisation of HMSNs rather than introducing functional groups. A novel kind 
of core–shell dual-mesoporous structure with smaller mesopores in the shells and ordered 
larger mesopores in the core has been constructed by Niu [261], which have exhibited the 
capacity to simultaneously loaded two kinds of drugs with different molecular sizes and 
different hydrophobicity. These core/shell hierarchical structures provide an inspiration 
for future investigation into HMSNs. In Chapters 4 and 6, it has been demonstrated that 
the pore size, shell thickness as well as particle size of HMSNs can be easily controlled, 
which would open up opportunities to build up more versatile HMSNs with tailed 
structure for multidrug encapsulation.  
 
Another method proposed for the future co-delivery based on HMSNs is that HMSNs 
would be divided into separate groups and each group will undergo respective specific 
functionalization and drug loading. Finally, all the groups would mixed up with certain 
ratio to achieve a multidrug loaded HMSNs mixture. This method takes the advantage of 
high flexibility, specificity and more importantly, avoiding multi-functionalization on one 
HMSNs and thereby increasing the efficiency while reducing toxicity. 
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7.2.4 Animal experiences  
 
In this study, HMSNs have been demonstrated as a vehicle for successful intracellular 
delivery of anticancer drug 5-FU. The current HMSNs based targeted drug delivery 
system has shown sustained release behaviour, negligible toxicity and specifically 
targeting and killing of colorectal cancer cells in vitro, which suggests that this system is 
promising in the application for colorectal cancer therapy. However, in vitro study is not 
enough for fully evaluate the biological behaviours of a drug delivery system as results 
got form cell experiments could be quite different from outcomes obtained from 
experiments performed on  live mammals. Therefore, further validation of this targeted 
drug delivery system in vivo is essential for its clinical translation.  
 
Specifically, even though EGF-HMSNs have been selectively taken up by colorectal 
cancer cells, it cannot guarantee a high selective accumulation of these nanoparticles in 
solid tumours of live animal models, because the bio-distribution of nanoparticles in vivo 
can be further influenced by biological environments [262]. In addition, there are findings 
[263] that provide strong evidence that nanoparticles not only actively interact with 
cancer cells, but also engage in and mediate in vivo behaviours. Thus, the interplay 
between biological eơects and particles will undoubtedly be an important aspect that 
needs to be further investigated so as to identify the full potential of the current delivery 
system.  
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